

<110> FarmHannong Co., Ltd.

<120> Métodos y composiciones para conferir y/o mejorar la tolerancia a los herbicidas utilizando protoporfirinógeno oxidasa o variantes de la misma

<130> OPP20173139KR

<150> KR 10-2016-0075358

<151> 2016-06-16

<160> 131

<170> Kopatent In 2.0

<210> 1

<211> 1404

<212> ADN

<213> secuencia artificial

<220>

<223> polinucleótido que codifica CyPP010

<400> 1

atgattgaag tggatgtggc tattgttggg ggtggctcta gtggattgtc agtggcttgg	60
agattacaga ggagtgtccc tcattattct ggagtctctc ttgaggcttc tgatagactt	120
ggaggtaata tcactacaca agctgtgaa ggatttgtgt gggagcttgg tccaaacagt	180
ttcgctccta ctccagcact cttacagttg attgtcgaag ttggactcca ttctgagtta	240
atcagaggag ataggcacct tccaagatat atatactgga ggggagaact ttatcctttg	300
gagccaacta ggctctttgc tttggcaaca tcaaactttt tgagtccttg gggaaagggt	360
agagctgcac tcggagcttt aggtttttgtg cctccatattc ttggatctgg agatgaaagt	420
gttgattctt tctttagaag gcatcttga caagaagttg ctgagagatt ggtggcacca	480
tttgtttcag gagtgtacgc tggagatcct caacagcttt ctgctgctgc tgcttttaga	540
aggattgtc aacttgagaa gttgggaggt tcattgatcg ctggagcact cagattaaga	600
aggcaacagc ctccacagcc aaaacctcca gctcaagtgc agatgagacc tggagaactc	660
ggtagtttta gggagggtct cgctgcatta cctagagcta tcgcacaaca gttgaaggca	720
ccacttcatt tgcaaacacc tgttgaagct attaccctg agccaaaagg aggttatctc	780
ttaaggagtg gtgaacagac ttggcacgct agatcagttg tgttggttac tccagatac	840
caaactgtg aacttgttc accattccag cctgctatcg ctagagcttt ggtaccata	900
ccttatccaa ctgttgcttg tgttgtgctt gcttacctg ctggattggg tagatcagtt	960

agacctggat ttggtgtttt ggtgcctaga ggacaaggta taaggacact cggaaccatt 1020
 tggcttccat gcttattccc acaagaact cctgctgggt ggcagggttt tacctcttc 1080
 ataggaggtg ctactgatcc tgatcttgca tcattgagag aagaggctat tgttgaacaa 1140
 gtgcaacagg atctcacaag gcttcttgat cttcctgctg caaaggcaag actcttgggt 1200
 atgaagggtt ggagaagggc tattccacaa tatacgttg gttaccctca acagtggcaa 1260
 caggtgacac acgctcttac ccagactcct ggtctcttct tatgttcaaa ctacgtgag 1320
 ggagttgcat tgggagatag agtggaacac ggaaatagga ctgctgctgc tgtggctgct 1380
 tacctcgtg gtggacaatc ataa 1404

<210> 2
 <211> 467
 <212> PRT
 <213> secuencia artificial

<220>
 <223> CyPP010

<400> 2
 Met Ile Glu Val Asp Val Ala Ile Val Gly Gly Gly Leu Ser Gly Leu
 1 5 10 15
 Ser Val Ala Trp Arg Leu Gln Arg Ser Ala Pro His Tyr Ser Gly Val
 20 25 30
 Leu Leu Glu Ala Ser Asp Arg Leu Gly Gly Asn Ile Thr Thr Gln Ala
 35 40 45
 Ala Glu Gly Phe Val Trp Glu Leu Gly Pro Asn Ser Phe Ala Pro Thr
 50 55 60
 Pro Ala Leu Leu Gln Leu Ile Ala Glu Val Gly Leu His Ser Glu Leu
 65 70 75 80
 Ile Arg Gly Asp Arg His Leu Pro Arg Tyr Ile Tyr Trp Arg Gly Glu
 85 90 95
 Leu Tyr Pro Leu Glu Pro Thr Arg Pro Leu Ala Leu Ala Thr Ser Asn
 100 105 110
 Leu Leu Ser Pro Trp Gly Lys Val Arg Ala Ala Leu Gly Ala Leu Gly
 115 120 125
 Phe Val Pro Pro Tyr Leu Gly Ser Gly Asp Glu Ser Val Asp Ser Phe
 130 135 140

Phe Arg Arg His Leu Gly Gln Glu Val Ala Glu Arg Leu Val Ala Pro
145 150 155 160
Phe Val Ser Gly Val Tyr Ala Gly Asp Pro Gln Gln Leu Ser Ala Ala
165 170 175
Ala Ala Phe Arg Arg Ile Ala Gln Leu Glu Lys Leu Gly Gly Ser Leu
180 185 190
Ile Ala Gly Ala Leu Arg Leu Arg Arg Gln Gln Pro Pro Gln Pro Lys
195 200 205
Pro Pro Ala Gln Val Gln Met Arg Pro Gly Glu Leu Gly Ser Phe Arg
210 215 220
Glu Gly Leu Ala Ala Leu Pro Arg Ala Ile Ala Gln Gln Leu Lys Ala
225 230 235 240
Pro Leu His Leu Gln Thr Pro Val Glu Ala Ile Thr Pro Glu Pro Lys
245 250 255
Gly Gly Tyr Leu Leu Arg Ser Gly Glu Gln Thr Trp His Ala Arg Ser
260 265 270
Val Val Leu Ala Thr Pro Ala Tyr Gln Thr Ala Glu Leu Val Ala Pro
275 280 285
Phe Gln Pro Ala Ile Ala Arg Ala Leu Ala Thr Ile Pro Tyr Pro Thr
290 295 300
Val Ala Cys Val Val Leu Ala Tyr Pro Ala Gly Leu Gly Arg Ser Val
305 310 315 320
Arg Pro Gly Phe Gly Val Leu Val Pro Arg Gly Gln Gly Ile Arg Thr
325 330 335
Leu Gly Thr Ile Trp Ser Ser Cys Leu Phe Pro Gln Arg Thr Pro Ala
340 345 350
Gly Trp Gln Val Phe Thr Ser Phe Ile Gly Gly Ala Thr Asp Pro Asp
355 360 365
Leu Ala Ser Leu Arg Glu Glu Ala Ile Val Glu Gln Val Gln Gln Asp
370 375 380
Leu Thr Arg Leu Leu Asp Leu Pro Ala Ala Lys Ala Arg Leu Leu Gly
385 390 395 400
Met Lys Val Trp Arg Arg Ala Ile Pro Gln Tyr Ile Val Gly Tyr Pro
405 410 415
Gln Gln Trp Gln Gln Val Thr His Ala Leu Thr Gln Thr Pro Gly Leu
420 425 430

Phe Leu Cys Ser Asn Tyr Ala Glu Gly Val Ala Leu Gly Asp Arg Val
435 440 445

Glu His Gly Asn Arg Thr Ala Ala Ala Val Ala Ala Tyr Leu Ala Gly
450 455 460

Gly Gln Ser
465

<210> 3
<211> 1458
<212> ADN
<213> secuencia artificial

<220>
<223> polinucleótido que codifica CyPP013

<400> 3
atgaaccctg ctaccctga acccttgaat gctgaagttg ttgtgattgg tgctggaatt 60
tctggattga ccttggcttg gagactccaa cagggctcta gtgctagagg aggttctcca 120
caagcagttc ttttggctga agcatcttca aggggtggag gttgtattag taccagctc 180
aaggatggat atagatggga agagggtcct aatagtttta ctccaacacc tgctctctta 240
aacctcattg cagaagttgg attactgat caacttgtgt tggctgatgc aaagttgcca 300
agatatatct actgggaggg tgctcttttg ccagttcctc ttccacctgc tgctgctttg 360
ggatctaggc tcttatcagt tggaggtaaa cttagagctt tgcagggact tttgggtttt 420
gttcctccac ctccaggtca tgaagagact gtgagacaat ttttcagaag gcagcttgga 480
tctgaagttg ctgagagatt ggtggagcct ttacatcag gagtttatgc tggagatcct 540
gatcaactta gtgcagttgc agcttttcct aggggtggctg gtctcgaaga gagatacga 600
tcattattcg ctggtgctct tcaagctctt aggcaaagac cacagcctag tccagcagct 660
atccagcctc cacctaaaag gggacaactt ggtaatttga gacagggact ccaacagtta 720
cctgaagctc ttgcacaaaa gttgggagat tctctcagat taggttggag agctttgcaa 780
ttgaaaagag caggagagct ttattgggtt ggtttcgaaa ctccagaggg atcaaggtgg 840
gttgctgcta gacaagttgt gctcgcttta cctgcatacg aagcagctgc actcttaca 900
gagttgaacc cacctgcttc tcagcttttg gcagaaatac tctatccacc tgttgctgtt 960
gtggctcttg cataccaca agaggctctc cctcagccat taagaggatt tggctatctc 1020

atccctaggt ctcaaggact tagaaccttg ggtactatat gggcttcatg tttgttcct 1080
gaaagagcac ctcaaggta tcaactatct ctcagtttct taggaggtgc tacagatgct 1140
gcattggcaa gaaggagagg tattcctcct atccctgctc tcagtccaga agagagagca 1200
caaatagctc acgcagagct ttctcaggtt ctcttaacca ggagagctga accagtgtat 1260
cttggagaga ggttgtggcc tagagctata ccacaatata cacttggaca taggcagaga 1320
attgctcaag ttcaggctca cttggcatct caaacccctg gtatttgggt ttgcgctaata 1380
tacttggatg gagtggcact cggagattgc gttagaaggg cagaggcact cgctcagcag 1440
ttgttatcac aggtgtaa 1458

<210> 4
<211> 485
<212> PRT
<213> Secuencia artificial

<220>
<223> CyPP013

<400> 4
Met Asn Pro Ala Thr Pro Glu Pro Leu Asn Ala Glu Val Val Val Ile
1 5 10 15
Gly Ala Gly Ile Ser Gly Leu Thr Leu Ala Trp Arg Leu Gln Gln Gly
20 25 30
Leu Ser Ala Arg Gly Gly Ser Pro Gln Ala Val Leu Leu Ala Glu Ala
35 40 45
Ser Ser Arg Val Gly Gly Cys Ile Ser Thr Gln Ser Lys Asp Gly Tyr
50 55 60
Arg Trp Glu Glu Gly Pro Asn Ser Phe Thr Pro Thr Pro Ala Leu Leu
65 70 75 80
Asn Leu Ile Ala Glu Val Gly Leu Thr Asp Gln Leu Val Leu Ala Asp
85 90 95
Ala Lys Leu Pro Arg Tyr Ile Tyr Trp Glu Gly Ala Leu Leu Pro Val
100 105 110
Pro Leu Ser Pro Ala Ala Ala Leu Gly Ser Arg Leu Leu Ser Val Gly
115 120 125
Gly Lys Leu Arg Ala Leu Gln Gly Leu Leu Gly Phe Val Pro Pro Pro
130 135 140
Pro Gly His Glu Glu Thr Val Arg Gln Phe Phe Arg Arg Gln Leu Gly

145		150		155		160									
Ser	Glu	Val	Ala	Glu	Arg	Leu	Val	Glu	Pro	Phe	Thr	Ser	Gly	Val	Tyr
				165					170					175	
Ala	Gly	Asp	Pro	Asp	Gln	Leu	Ser	Ala	Val	Ala	Ala	Phe	Pro	Arg	Val
			180					185					190		
Ala	Gly	Leu	Glu	Glu	Arg	Tyr	Gly	Ser	Leu	Phe	Ala	Gly	Ala	Leu	Gln
		195					200					205			
Ala	Leu	Arg	Gln	Arg	Pro	Gln	Pro	Ser	Pro	Ala	Ala	Ile	Gln	Pro	Pro
	210					215					220				
Pro	Lys	Arg	Gly	Gln	Leu	Gly	Asn	Leu	Arg	Gln	Gly	Leu	Gln	Gln	Leu
225					230					235					240
Pro	Glu	Ala	Leu	Ala	Gln	Lys	Leu	Gly	Asp	Ser	Leu	Arg	Leu	Gly	Trp
			245						250					255	
Arg	Ala	Leu	Gln	Leu	Lys	Arg	Ala	Gly	Glu	Leu	Tyr	Trp	Val	Gly	Phe
		260						265					270		
Glu	Thr	Pro	Glu	Gly	Ser	Arg	Trp	Val	Ala	Ala	Arg	Gln	Val	Val	Leu
	275						280					285			
Ala	Leu	Pro	Ala	Tyr	Glu	Ala	Ala	Ala	Leu	Leu	Gln	Glu	Leu	Asn	Pro
	290					295					300				
Pro	Ala	Ser	Gln	Leu	Leu	Ala	Glu	Ile	Leu	Tyr	Pro	Pro	Val	Ala	Val
305					310					315					320
Val	Ala	Leu	Ala	Tyr	Pro	Gln	Glu	Ala	Leu	Pro	Gln	Pro	Leu	Arg	Gly
			325						330					335	
Phe	Gly	His	Leu	Ile	Pro	Arg	Ser	Gln	Gly	Leu	Arg	Thr	Leu	Gly	Thr
		340						345					350		
Ile	Trp	Ala	Ser	Cys	Leu	Phe	Pro	Glu	Arg	Ala	Pro	Gln	Gly	Tyr	His
	355						360					365			
Ser	Phe	Leu	Ser	Phe	Leu	Gly	Gly	Ala	Thr	Asp	Ala	Ala	Leu	Ala	Arg
	370					375					380				
Arg	Arg	Gly	Ile	Pro	Pro	Ile	Pro	Ala	Leu	Ser	Pro	Glu	Glu	Arg	Ala
385					390					395					400
Gln	Ile	Ala	His	Ala	Glu	Leu	Ser	Gln	Val	Leu	Leu	Thr	Arg	Arg	Ala
			405						410					415	
Glu	Pro	Val	Tyr	Leu	Gly	Glu	Arg	Leu	Trp	Pro	Arg	Ala	Ile	Pro	Gln
		420						425					430		
Tyr	Thr	Leu	Gly	His	Arg	Gln	Arg	Ile	Ala	Gln	Val	Gln	Ala	His	Leu
		435					440					445			

Ala Ser Gln Thr Pro Gly Ile Trp Val Cys Ala Asn Tyr Leu Asp Gly
 450 455 460

Val Ala Leu Gly Asp Cys Val Arg Arg Ala Glu Ala Leu Ala Gln Gln
 465 470 475 480

Leu Leu Ser Gln Val
 485

<210> 5
 <211> 537
 <212> PRT
 <213> Arabidopsis thaliana

<220>
 <221> PÉPTIDO
 <222> (1)..(537)
 <223> AtPP01 sivestre

<400> 5
 Met Glu Leu Ser Leu Leu Arg Pro Thr Thr Gln Ser Leu Leu Pro Ser
 1 5 10 15

Phe Ser Lys Pro Asn Leu Arg Leu Asn Val Tyr Lys Pro Leu Arg Leu
 20 25 30

Arg Cys Ser Val Ala Gly Gly Pro Thr Val Gly Ser Ser Lys Ile Glu
 35 40 45

Gly Gly Gly Gly Thr Thr Ile Thr Thr Asp Cys Val Ile Val Gly Gly
 50 55 60

Gly Ile Ser Gly Leu Cys Ile Ala Gln Ala Leu Ala Thr Lys His Pro
 65 70 75 80

Asp Ala Ala Pro Asn Leu Ile Val Thr Glu Ala Lys Asp Arg Val Gly
 85 90 95

Gly Asn Ile Ile Thr Arg Glu Glu Asn Gly Phe Leu Trp Glu Glu Gly
 100 105 110

Pro Asn Ser Phe Gln Pro Ser Asp Pro Met Leu Thr Met Val Val Asp
 115 120 125

Ser Gly Leu Lys Asp Asp Leu Val Leu Gly Asp Pro Thr Ala Pro Arg
 130 135 140

Phe Val Leu Trp Asn Gly Lys Leu Arg Pro Val Pro Ser Lys Leu Thr
 145 150 155 160

Asp Leu Pro Phe Phe Asp Leu Met Ser Ile Gly Gly Lys Ile Arg Ala
 165 170 175

Gly Phe Gly Ala Leu Gly Ile Arg Pro Ser Pro Pro Gly Arg Glu Glu
 180 185 190
 Ser Val Glu Glu Phe Val Arg Arg Asn Leu Gly Asp Glu Val Phe Glu
 195 200 205
 Arg Leu Ile Glu Pro Phe Cys Ser Gly Val Tyr Ala Gly Asp Pro Ser
 210 215 220
 Lys Leu Ser Met Lys Ala Ala Phe Gly Lys Val Trp Lys Leu Glu Gln
 225 230 235 240
 Asn Gly Gly Ser Ile Ile Gly Gly Thr Phe Lys Ala Ile Gln Glu Arg
 245 250 255
 Lys Asn Ala Pro Lys Ala Glu Arg Asp Pro Arg Leu Pro Lys Pro Gln
 260 265 270
 Gly Gln Thr Val Gly Ser Phe Arg Lys Gly Leu Arg Met Leu Pro Glu
 275 280 285
 Ala Ile Ser Ala Arg Leu Gly Ser Lys Val Lys Leu Ser Trp Lys Leu
 290 295 300
 Ser Gly Ile Thr Lys Leu Glu Ser Gly Gly Tyr Asn Leu Thr Tyr Glu
 305 310 315 320
 Thr Pro Asp Gly Leu Val Ser Val Gln Ser Lys Ser Val Val Met Thr
 325 330 335
 Val Pro Ser His Val Ala Ser Gly Leu Leu Arg Pro Leu Ser Glu Ser
 340 345 350
 Ala Ala Asn Ala Leu Ser Lys Leu Tyr Tyr Pro Pro Val Ala Ala Val
 355 360 365
 Ser Ile Ser Tyr Pro Lys Glu Ala Ile Arg Thr Glu Cys Leu Ile Asp
 370 375 380
 Gly Glu Leu Lys Gly Phe Gly Gln Leu His Pro Arg Thr Gln Gly Val
 385 390 395 400
 Glu Thr Leu Gly Thr Ile Tyr Ser Ser Ser Leu Phe Pro Asn Arg Ala
 405 410 415
 Pro Pro Gly Arg Ile Leu Leu Leu Asn Tyr Ile Gly Gly Ser Thr Asn
 420 425 430
 Thr Gly Ile Leu Ser Lys Ser Glu Gly Glu Leu Val Glu Ala Val Asp
 435 440 445
 Arg Asp Leu Arg Lys Met Leu Ile Lys Pro Asn Ser Thr Asp Pro Leu
 450 455 460

Lys Leu Gly Val Arg Val Trp Pro Gln Ala Ile Pro Gln Phe Leu Val
 465 470 475 480

Gly His Phe Asp Ile Leu Asp Thr Ala Lys Ser Ser Leu Thr Ser Ser
 485 490 495

Gly Tyr Glu Gly Leu Phe Leu Gly Gly Asn Tyr Val Ala Gly Val Ala
 500 505 510

Leu Gly Arg Cys Val Glu Gly Ala Tyr Glu Thr Ala Ile Glu Val Asn
 515 520 525

Asn Phe Met Ser Arg Tyr Ala Tyr Lys
 530 535

<210> 6
 <211> 1614
 <212> ADN
 <213> Arabidopsis thaliana

<220>
 <221> gene
 <222> (1)..(1614)
 <223> AtPP01 sivestre

<400> 6
 atggagtat cttctctccg tccgacgact caatcgcttc ttccgtcggt ttcgaagccc 60
 aatctccgat taaatgttta taagcctctt agactccgtt gttcagtggc cggtaggacca 120
 accgtcggat cttcaaaaat cgaaggcggg ggaggcacca ccatcacgac ggatttgtgtg 180
 attgtcggcg gaggtattag tggctcttgc atcgctcagg cgcttgctac taagcatcct 240
 gatgctgctc cgaatttaat tgtgaccgag gctaaggatc gtgttggagg caacattatc 300
 actcgtgaag agaatggttt tctctgggaa gaaggtccca atagttttca accgtctgat 360
 cctatgctca ctatggtggt agatagtgtt ttgaaggatg atttggtgtt gggagatcct 420
 actgcgcca ggtttgtgtt gtggaatggg aaattgaggc cggttccatc gaagctaaca 480
 gacttacgtt tctttgattt gatgagtatt ggtgggaaga ttagagctgg ttttggtgca 540
 cttggcattc gaccgtcacc tccaggtcgt gaagaatctg tggaggagt tgtacggcgt 600
 aacctcgggt atgaggtttt tgagcgcctg attgaaccgt tttgttcagg tgtttatgct 660
 ggtgatcctt caaaactgag catgaaagca gcgtttggga aggtttggaa actagagcaa 720
 aatggtggaa gcataatagg tggactttt aaggcaattc aggagaggaa aaacgctccc 780
 aaggcagaac gagaccgcg cctgccaaaa ccacagggcc aaacagttgg ttctttcagg 840

aagggacttc gaatgttgcc agaagcaata tctgcaagat taggtagcaa agttaagttg 900
tcttgggaagc tctcaggtat cactaagctg gagagcggag gatacaactt aacatatgag 960
actccagatg gtttagtttc cgtgcagagc aaaagtgttg taatgacggg gccatctcat 1020
gttgcaagtg gtctcttgcg cctcttttct gaatctgctg caaatgcact ctcaaaacta 1080
tattaccac cagttgcagc agtatctatc tegtaccga aagaagcaat ccgaacagaa 1140
tgtttgatag atggtgaact aaagggtttt gggcaattgc atccacgcac gcaaggagtt 1200
gaaacattag gaactatcta cagctcctca ctctttccaa atcgcgcacc gcccggaaga 1260
atittgctgt tgaactacat tggcgggtct acaaacaccg gaattctgtc caagtctgaa 1320
ggtagagtag tggaagcagt tgacagagat ttgaggaaaa tgctaattaa gcctaattcg 1380
accgatccac ttaaattagg agttagggtg tggcctcaag ccattcctca gtttctagtt 1440
ggtcactttg atatccttga cagggctaaa tcattcttaa cgtcttcggg ctacgaaggg 1500
ctatTTTTGG gtggcaatta cgtcgttggt gtagccttag gccggtgtgt agaaggcgca 1560
tatgaaaccg cgattgaggt caacaacttc atgtcacggt acgcttaca gtaa 1614

<210> 7
<211> 537
<212> PRT
<213> Secuencia artificial

<220>
<223> AtPP01 mutante

<400> 7
Met Glu Leu Ser Leu Leu Arg Pro Thr Thr Gln Ser Leu Leu Pro Ser
1 5 10 15
Phe Ser Lys Pro Asn Leu Arg Leu Asn Val Tyr Lys Pro Leu Arg Leu
20 25 30
Arg Cys Ser Val Ala Gly Gly Pro Thr Val Gly Ser Ser Lys Ile Glu
35 40 45
Gly Gly Gly Gly Thr Thr Ile Thr Thr Asp Cys Val Ile Val Gly Gly
50 55 60
Gly Ile Ser Gly Leu Cys Ile Ala Gln Ala Leu Ala Thr Lys His Pro
65 70 75 80
Asp Ala Ala Pro Asn Leu Ile Val Thr Glu Ala Lys Asp Arg Val Gly
85 90 95

Gly Asn Ile Ile Thr Arg Glu Glu Asn Gly Phe Leu Trp Glu Glu Gly
 100 105 110
 Pro Asn Ser Phe Gln Pro Ser Asp Pro Met Leu Thr Met Val Val Asp
 115 120 125
 Ser Gly Leu Lys Asp Asp Leu Val Leu Gly Asp Pro Thr Ala Pro Arg
 130 135 140
 Phe Val Leu Trp Asn Gly Lys Leu Arg Pro Val Pro Ser Lys Leu Thr
 145 150 155 160
 Asp Leu Pro Phe Phe Asp Leu Met Ser Ile Gly Gly Lys Ile Arg Ala
 165 170 175
 Gly Phe Gly Ala Leu Gly Ile Arg Pro Ser Pro Pro Gly Arg Glu Glu
 180 185 190
 Ser Val Glu Glu Phe Val Arg Arg Asn Leu Gly Asp Glu Val Phe Glu
 195 200 205
 Arg Leu Ile Glu Pro Phe Cys Ser Gly Val Tyr Ala Gly Asp Pro Ser
 210 215 220
 Lys Leu Ser Met Lys Ala Ala Phe Gly Lys Val Trp Lys Leu Glu Gln
 225 230 235 240
 Asn Gly Gly Ser Ile Ile Gly Gly Thr Phe Lys Ala Ile Gln Glu Arg
 245 250 255
 Lys Asn Ala Pro Lys Ala Glu Arg Asp Pro Arg Leu Pro Lys Pro Gln
 260 265 270
 Gly Gln Thr Val Gly Ser Phe Arg Lys Gly Leu Arg Met Leu Pro Glu
 275 280 285
 Ala Ile Ser Ala Arg Leu Gly Ser Lys Val Lys Leu Ser Trp Lys Leu
 290 295 300
 Leu Gly Ile Thr Lys Leu Glu Ser Gly Gly Tyr Asn Leu Thr Tyr Glu
 305 310 315 320
 Thr Pro Asp Gly Leu Val Ser Val Gln Ser Lys Ser Val Val Met Thr
 325 330 335
 Val Pro Ser His Val Ala Ser Gly Leu Leu Arg Pro Leu Ser Glu Ser
 340 345 350
 Ala Ala Asn Ala Leu Ser Lys Leu Tyr Tyr Pro Pro Val Ala Ala Val
 355 360 365
 Ser Ile Ser Tyr Pro Lys Glu Ala Ile Arg Thr Glu Cys Leu Ile Asp
 370 375 380

Gly Glu Leu Lys Gly Phe Gly Gln Leu His Pro Arg Thr Gln Gly Val
385 390 395 400

Glu Thr Leu Gly Thr Ile Tyr Ser Ser Ser Leu Phe Pro Asn Arg Ala
405 410 415

Pro Pro Gly Arg Ile Leu Leu Leu Asn Met Ile Gly Gly Ser Thr Asn
420 425 430

Thr Gly Ile Leu Ser Lys Ser Glu Gly Glu Leu Val Glu Ala Val Asp
435 440 445

Arg Asp Leu Arg Lys Met Leu Ile Lys Pro Asn Ser Thr Asp Pro Leu
450 455 460

Lys Leu Gly Val Arg Val Trp Pro Gln Ala Ile Pro Gln Phe Leu Val
465 470 475 480

Gly His Phe Asp Ile Leu Asp Thr Ala Lys Ser Ser Leu Thr Ser Ser
485 490 495

Gly Tyr Glu Gly Leu Phe Leu Gly Gly Asn Tyr Val Ala Gly Val Ala
500 505 510

Leu Gly Arg Cys Val Glu Gly Ala Tyr Glu Thr Ala Ile Glu Val Asn
515 520 525

Asn Phe Met Ser Arg Tyr Ala Tyr Lys
530 535

<210> 8
<211> 30
<212> ADN
<213> Secuencia artificial

<220>
<223> cebador CyPP010co_BamHI F

<400> 8
ccccggatcc atgattgaag tggatgtggc

30

<210> 9
<211> 30
<212> ADN
<213> Secuencia artificial

<220>
<223> cebador CyPP010co_XhoI R

<400> 9
ccccctcgag tgattgtcca ccagcgaggt

30

<210> 10
 <211> 30
 <212> ADN
 <213> Secuencia artificial

 <220>
 <223> cebador CyPP013co_BamHI F

<400> 10
 ccccgatcc atgaacctg ctaccctga 30

<210> 11
 <211> 30
 <212> ADN
 <213> Secuencia artificial

 <220>
 <223> cebador CyPP013co_XhoI R

<400> 11
 cccctcgag cacctgtgat aacaactgct 30

<210> 12
 <211> 30
 <212> ADN
 <213> Secuencia artificial

 <220>
 <223> cebador CyPP010co_XbaI F

<400> 12
 cccctctaga atgattgaag tggatgtggc 30

<210> 13
 <211> 30
 <212> ADN
 <213> Secuencia artificial

 <220>
 <223> cebador CyPP010co_XhoI R

<400> 13
 cccctcgag tgattgtcca ccagcgaggt 30

<210> 14

<211>	29	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	cebador CyPP013co_XbaI F	
<400>	14	
	ccctctagaa tgaaccctgc taccctga	29
<210>	15	
<211>	30	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	cebador CyPP013co_XhoI R	
<400>	15	
	ccccctcgag cacctgtgat aacaactgct	30
<210>	16	
<211>	30	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	cebador F para CyPP010_F360M	
<400>	16	
	gtttttacct ctatgatagg aggtgctact	30
<210>	17	
<211>	30	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	cebador R para CyPP010_F360M	
<400>	17	
	agcacctcct atcatagagg taaaaacctg	30
<210>	18	
<211>	30	
<212>	ADN	
<213>	Secuencia artificial	

<220>
 <223> cebador F para CyPP010_F360V

<400> 18
 gtttttacct ctgttatagg aggtgctact 30

<210> 19
 <211> 30
 <212> ADN
 <213> Secuencia artificial

<220>
 <223> Cebador R para CyPP010_F360V

<400> 19
 agcacctcct ataacagagg taaaaacctg 30

<210> 20
 <211> 30
 <212> ADN
 <213> Secuencia artificial

<220>
 <223> Cebador F para CyPP010_F360I

<400> 20
 gtttttacct ctattatagg aggtgctact 30

<210> 21
 <211> 30
 <212> ADN
 <213> Secuencia artificial

<220>
 <223> Cebador R para CyPP010_F360I

<400> 21
 agcacctcct ataatagagg taaaaacctg 30

<210> 22
 <211> 30
 <212> ADN
 <213> Secuencia artificial

<220>
 <223> Cebador F para CyPP010_F360T

<400> 22
gtttttacct ctactatagg aggtgctact 30

<210> 23
<211> 30
<212> ADN
<213> Secuencia artificial

<220>
<223> Cebador R para CyPP010_F360T

<400> 23
agctccacca atagtagagg taaaaacctg 30

<210> 24
<211> 30
<212> ADN
<213> Secuencia artificial

<220>
<223> Cebador F para CyPP010_F360L

<400> 24
gtttttacct ctcttatagg aggtgctact 30

<210> 25
<211> 30
<212> ADN
<213> Secuencia artificial

<220>
<223> Cebador R para CyPP010_F360L

<400> 25
agctccacca ataagagagg taaaaacctg 30

<210> 26
<211> 30
<212> ADN
<213> Secuencia artificial

<220>
<223> Cebador F para CyPP010_F360C

<400> 26

gtttttacct cttgtatagg aggtgctact 30

<210> 27

<211> 30

<212> ADN

<213> Secuencia artificial

<220>

<223> Cebador R para CyPP010_F360C

<400> 27

agctccacca atacaagagg taaaaacctg 30

<210> 28

<211> 30

<212> ADN

<213> Secuencia artificial

<220>

<223> Cebador F para CyPP010_A167C

<400> 28

tcaggagtgt actgtggaga tcctcaacag 30

<210> 29

<211> 30

<212> ADN

<213> Secuencia artificial

<220>

<223> Cebador R para CyPP010_A167C

<400> 29

ttgaggatct ccacagtaca ctctgaaac 30

<210> 30

<211> 30

<212> ADN

<213> Secuencia artificial

<220>

<223> Cebador F para CyPP010_A167L

<400> 30

tcaggagtgt accttggaga tcctcaacag 30

<210>	31	
<211>	30	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador R para CyPP010_A167L	
<400>	31	
	ttgaggatct ccaaggtaca ctctgaaac	30
<210>	32	
<211>	30	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador F para CyPP010_P303L+V305L	
<400>	32	
	ataccttatac ttactcttgc ttgtgttg	30
<210>	33	
<211>	27	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador R para CyPP010_P303L+V305L	
<400>	33	
	aacacaagca agagtaagat aaggtat	27
<210>	34	
<211>	30	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador F para CyPP010_V305M	
<400>	34	
	ccttatccaa ctatggcttg tgtgtgctt	30
<210>	35	
<211>	30	
<212>	ADN	

<213>	Secuencia artificial	
<220>		
<223>	Cebador R para CyPP010_V305M	
<400>	35	
	cacaacacaa gccatagttg gataaggtat	30
<210>	36	
<211>	25	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador F para CyPP010_N59T	
<400>	36	
	gagcttggtc caactagttt cgctc	25
<210>	37	
<211>	27	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador R para CyPP010_N59T	
<400>	37	
	agcgaaacta gttggaccaa gctccca	27
<210>	38	
<211>	30	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador F para CyPP010_R89A	
<400>	38	
	caccttcag cttatatata ctggagggga	30
<210>	39	
<211>	30	
<212>	ADN	
<213>	Secuencia artificial	
<220>		

<223> Cebador R para CyPP010_R89A

<400> 39

gtatatataa gctggaaggt gcctatctcc

30

<210> 40

<211> 33

<212> ADN

<213> Secuencia artificial

<220>

<223> Cebador F para CyPP010_V165S

<400> 40

gtttcaggat catacgctgg agatcctcaa cag

33

<210> 41

<211> 33

<212> ADN

<213> Secuencia artificial

<220>

<223> Cebador R para CyPP010_V165S

<400> 41

tccagcgtat gatcctgaaa caaatggtgc cac

33

<210> 42

<211> 30

<212> ADN

<213> Secuencia artificial

<220>

<223> Cebador F para CyPP010_V305T

<400> 42

ccttatccaa ctactgcttg tgttgctt

30

<210> 43

<211> 30

<212> ADN

<213> Secuencia artificial

<220>

<223> Cebador R para CyPP010_V305T

<400>	43		
cacaacacaa	gcagtagttg	gataaggtat	30
<210>	44		
<211>	33		
<212>	ADN		
<213>	Secuencia artificial		
<220>			
<223>	Cebador F para CyPP010_S60T		
<400>	44		
ggtccaaaca	ctttcgctcc	tactccagca	etc
			33
<210>	45		
<211>	33		
<212>	ADN		
<213>	Secuencia artificial		
<220>			
<223>	Cebador R para CyPP010_S60T		
<400>	45		
aggagcgaaa	gtgtttggac	caagctccca	cac
			33
<210>	46		
<211>	33		
<212>	ADN		
<213>	Secuencia artificial		
<220>			
<223>	Cebador F para CyPP010_I340T		
<400>	46		
ctcggaaacca	cctggtcttc	atgcttattc	cca
			33
<210>	47		
<211>	33		
<212>	ADN		
<213>	Secuencia artificial		
<220>			
<223>	Cebador R para CyPP010_I340T		
<400>	47		
tgaagaccag	gtggttccga	gtgtccttat	acc
			33

<210> 48
 <211> 30
 <212> ADN
 <213> Secuencia artificial

<220>
 <223> Cebador F para CyPP010_R89L

<400> 48
 caccttcac tttatatata ctggagggga

30

<210> 49
 <211> 30
 <212> ADN
 <213> Secuencia artificial

<220>
 <223> Cebador R para CyPP010_R89L

<400> 49
 gtatatataa agtggaaggt gcctatctcc

30

<210> 50
 <211> 30
 <212> ADN
 <213> Secuencia artificial

<220>
 <223> Cebador F para CyPP010_R89V

<400> 50
 caccttcag tttatatata ctggagggga

30

<210> 51
 <211> 30
 <212> ADN
 <213> Secuencia artificial

<220>
 <223> Cebador R para CyPP010_R89V

<400> 51
 gtatatataa actggaaggt gcctatctcc

30

<210> 52
 <211> 33

<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador F para CyPP010_F161A	
<400>	52	
	agattggtgg caccagcagt ttcaggagtg tac	33
<210>	53	
<211>	33	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador R para CyPP010_F161A	
<400>	53	
	gtacactcct gaaactgctg gtgccaccaa tct	33
<210>	54	
<211>	33	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador F para CyPP010_V165C	
<400>	54	
	ccatttggtt caggatgcta cgctggagat cct	33
<210>	55	
<211>	33	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador R para CyPP010_V165C	
<400>	55	
	aggatctcca gcgtagcatc ctgaaacaaa tgg	33
<210>	56	
<211>	33	
<212>	ADN	
<213>	Secuencia artificial	

<220>
 <223> Cebador F para CyPP010_Q184G

<400> 56
 tttagaagga ttgctggact tgagaagttg gga 33

<210> 57
 <211> 33
 <212> ADN
 <213> Secuencia artificial

<220>
 <223> Cebador R para CyPP010_Q184G

<400> 57
 tcccaacttc tcaagtcag caatccttct aaa 33

<210> 58
 <211> 33
 <212> ADN
 <213> Secuencia artificial

<220>
 <223> Cebador F para CyPP010_F324V

<400> 58
 tcagttagac ctggagttgg tgttttggtg cct 33

<210> 59
 <211> 33
 <212> ADN
 <213> Secuencia artificial

<220>
 <223> Cebador R para CyPP010_F324V

<400> 59
 aggcacaaaa acaccaactc caggtctaac tga 33

<210> 60
 <211> 33
 <212> ADN
 <213> Secuencia artificial

<220>
 <223> Cebador F para CyPP010_L327T

<400>	60	
cctggatttg gtgttaccgt gcctagagga caa		33
<210>	61	
<211>	33	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador R para CyPP010_L327T	
<400>	61	
ttgtcctcta ggcacggtaa caccaaatcc agg		33
<210>	62	
<211>	30	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador F para CyPP010_A167I	
<400>	62	
tcaggagtgt acattggaga tcctcaacag		30
<210>	63	
<211>	30	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador R para CyPP010_A167I	
<400>	63	
ttgaggatct ccaatgtaca ctctgaaac		30
<210>	64	
<211>	33	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador F para CyPP010_I408R	
<400>	64	
agaagggtc gtccacaata tatcgttggt tac		33

<210> 65
<211> 30
<212> ADN
<213> Secuencia artificial

<220>
<223> Cebador R para CyPP010_I408R

<400> 65
tattgtggac gagcccttct ccaaacccttc 30

<210> 66
<211> 36
<212> ADN
<213> Secuencia artificial

<220>
<223> Cebador F para CyPP010_I408W

<400> 66
ggtttggaga agggcttggc cacaatatat cgttgg 36

<210> 67
<211> 36
<212> ADN
<213> Secuencia artificial

<220>
<223> Cebador R para CyPP010_I408W

<400> 67
ccaacgatat attgtggcca agcccttctc caaacc 36

<210> 68
<211> 30
<212> ADN
<213> Secuencia artificial

<220>
<223> Cebador F para CyPP013_F373M

<400> 68
tcattttctca gtatgttagg aggtgctaca 30

<210> 69

<211>	30	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador R para CyPP013_F373M	
<400>	69	
	agcacctcct aacatactga gaaatgagtg	30
<210>	70	
<211>	30	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador F para CyPP013_F373V	
<400>	70	
	tcattttctca gtgttttagg aggtgctaca	30
<210>	71	
<211>	30	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador R para CyPP013_F373V	
<400>	71	
	agcacctcct aaaacactga gaaatgagtg	30
<210>	72	
<211>	30	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador F para CyPP013_F373I	
<400>	72	
	tcattttctca gtatttttagg aggtgctaca	30
<210>	73	
<211>	30	
<212>	ADN	
<213>	Secuencia artificial	

<220>
 <223> Cebador R para CyPP013_F373I

<400> 73
 agcacctcct aaaatactga gaaatgagtg 30

<210> 74
 <211> 30
 <212> ADN
 <213> Secuencia artificial

<220>
 <223> Cebador F para CyPP013_F373T

<400> 74
 tcattttctca gtacttttagg aggtgctaca 30

<210> 75
 <211> 30
 <212> ADN
 <213> Secuencia artificial

<220>
 <223> Cebador R para CyPP013_F373T

<400> 75
 agcacctcct aaagtactga gaaatgagtg 30

<210> 76
 <211> 30
 <212> ADN
 <213> Secuencia artificial

<220>
 <223> Cebador F para CyPP013_F373L

<400> 76
 tcattttctca gtcttttagg aggtgctaca 30

<210> 77
 <211> 30
 <212> ADN
 <213> Secuencia artificial

<220>
 <223> Cebador R para CyPP013_F373L

<400> 77
agcacctcct aaaagactga gaaatgagtg 30

<210> 78
<211> 30
<212> ADN
<213> Secuencia artificial

<220>
<223> Cebador F para CyPP013_F373C

<400> 78
tcatttctca gttgtttagg aggtgctaca 30

<210> 79
<211> 30
<212> ADN
<213> Secuencia artificial

<220>
<223> Cebador R para CyPP013_F373C

<400> 79
agcacctcct aaacaactga gaaatgagtg 30

<210> 80
<211> 32
<212> ADN
<213> Secuencia artificial

<220>
<223> Cebador F para CyPP013_R101A

<400> 80
aagttgccag catatatcta ctgggagggt gc 32

<210> 81
<211> 32
<212> ADN
<213> Secuencia artificial

<220>
<223> Cebador R para CyPP013_R101A

<400> 81

agtagatata tgctggcaac tttgcatcag cc 32

<210> 82
<211> 30
<212> ADN
<213> Secuencia artificial

<220>
<223> Cebador F para CyPP013_A177C

<400> 82
tcaggagttt attgtggaga tcctgatcaa 30

<210> 83
<211> 30
<212> ADN
<213> Secuencia artificial

<220>
<223> Cebador R para CyPP013_A177C

<400> 83
atcaggatct ccacaataaa ctctgatgt 30

<210> 84
<211> 30
<212> ADN
<213> Secuencia artificial

<220>
<223> Cebador F para CyPP013_A177L

<400> 84
tcaggagttt atcttggaga tcctgatcaa 30

<210> 85
<211> 30
<212> ADN
<213> Secuencia artificial

<220>
<223> Cebador R para CyPP013_A177L

<400> 85
atcaggatct ccaagataaa ctctgatgt 30

<210> 86
<211> 32
<212> ADN
<213> Secuencia artificial

<220>
<223> Cebador F para CyPP013_A177I

<400> 86
ggagtttata ttggagatcc tgatcaactt ag

32

<210> 87
<211> 32
<212> ADN
<213> Secuencia artificial

<220>
<223> Cebador R para CyPP013_A177I

<400> 87
aggatctcca atataaactc ctgatgtgaa ag

32

<210> 88
<211> 30
<212> ADN
<213> Secuencia artificial

<220>
<223> Cebador F para CyPP013_P316L+V318L

<400> 88
atactctatc ttctctttgc tgttgtggct

30

<210> 89
<211> 30
<212> ADN
<213> Secuencia artificial

<220>
<223> Cebador R para CyPP013_P316L+V318L

<400> 89
cacaacagca agaggaagat agagtatttc

30

<210> 90
<211> 33
<212> ADN

<213> Secuencia artificial
 <220>
 <223> Cebador F para CyPP013_V318L

 <400> 90
 tatccacctc ttgctgttgt ggctcttgca tac 33

 <210> 91
 <211> 32
 <212> ADN
 <213> Secuencia artificial

 <220>
 <223> Cebador R para CyPP013_V318L

 <400> 91
 caacagcaag aggtggatag agtatttctg cc 32

 <210> 92
 <211> 30
 <212> ADN
 <213> Secuencia artificial

 <220>
 <223> Cebador F para CyPP013_V318M

 <400> 92
 ctctatccac ctatggctgt tgtggctctt 30

 <210> 93
 <211> 30
 <212> ADN
 <213> Secuencia artificial

 <220>
 <223> Cebador R para CyPP013_V318M

 <400> 93
 agccacaaca gccataggtg gatagagtat 30

 <210> 94
 <211> 30
 <212> ADN
 <213> Secuencia artificial

 <220>

<223> Cebador F para CyPP013_P316A+V318L

<400> 94

atactctatg ctctctttgc tgttgtggct

30

<210> 95

<211> 30

<212> ADN

<213> Secuencia artificial

<220>

<223> Cebador R para CyPP013_P316A+V318L

<400> 95

cacaacagca gcaggaagat agagtatttc

30

<210> 96

<211> 32

<212> ADN

<213> Secuencia artificial

<220>

<223> Cebador F para CyPP013_F373N

<400> 96

tttctcagta acttaggagg tgctacagat gc

32

<210> 97

<211> 31

<212> ADN

<213> Secuencia artificial

<220>

<223> Cebador R para CyPP013_F373N

<400> 97

cctcctaagt tactgagaaa tgagtgataa c

31

<210> 98

<211> 32

<212> ADN

<213> Secuencia artificial

<220>

<223> Cebador F para CyPP013_F373H

<400>	98	
tttctcagtc acttaggagg tgctacagat gc		32
<210>	99	
<211>	31	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador R para CyPP013_F373H	
<400>	99	
cctcctaagt gactgagaaa tgagtataa c		31
<210>	100	
<211>	38	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador F para CyPP013_G194Q	
<400>	100	
gcttttccta ggtggctca gctcgaagag agatacgg		38
<210>	101	
<211>	38	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador R para CyPP013_G194Q	
<400>	101	
ccgtatctct cttcgagctg agccacccta ggaaaagc		38
<210>	102	
<211>	38	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador F para CyPP013_G194K	
<400>	102	
gcttttccta ggtggctaa actcgaagag agatacgg		38

<210> 103
 <211> 38
 <212> ADN
 <213> Secuencia artificial

 <220>
 <223> Cebador R para CyPP013_G194K

 <400> 103
 ccgtatctct cttcgagttt agccacccta ggaaaagc 38

 <210> 104
 <211> 38
 <212> ADN
 <213> Secuencia artificial

 <220>
 <223> Cebador F para CyPP013_G194R

 <400> 104
 gcttttccta ggtggctcg tctcgaagag agatacgg 38

 <210> 105
 <211> 38
 <212> ADN
 <213> Secuencia artificial

 <220>
 <223> Cebador R para CyPP013_G194R

 <400> 105
 ccgtatctct cttcgagacg agccacccta ggaaaagc 38

 <210> 106
 <211> 38
 <212> ADN
 <213> Secuencia artificial

 <220>
 <223> Cebador F para CyPP013_G194E

 <400> 106
 gcttttccta ggtggctga actcgaagag agatacgg 38

 <210> 107
 <211> 38

<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador R para CyPP013_G194E	
<400>	107	
	ccgtatctct cttcgagttc agccacccta ggaaaagc	38
<210>	108	
<211>	38	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador F para CyPP013_G194M	
<400>	108	
	gcttttccta gggtagctat gctcgaagag agatacgg	38
<210>	109	
<211>	38	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador R para CyPP013_G194M	
<400>	109	
	ccgtatctct cttcgagcat agccacccta ggaaaagc	38
<210>	110	
<211>	32	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador F para CyPP013_F337V	
<400>	110	
	cagccattaa gaggagtggg tcattctatc cc	32
<210>	111	
<211>	32	
<212>	ADN	
<213>	Secuencia artificial	

<220>
 <223> Cebador R para CyPP013_F337V

<400> 111
 gggatgagat gaccactcc tcttaatggc tg 32

<210> 112
 <211> 33
 <212> ADN
 <213> Secuencia artificial

<220>
 <223> Cebador F para CyPP013_L340T

<400> 112
 gaggatttgg tcataccatc cctaggtctc aag 33

<210> 113
 <211> 33
 <212> ADN
 <213> Secuencia artificial

<220>
 <223> Cebador R para CyPP013_L340T

<400> 113
 cttgagacct agggatggta tgaccaaadc ctc 33

<210> 114
 <211> 32
 <212> ADN
 <213> Secuencia artificial

<220>
 <223> Cebador F para CyPP013_I353T

<400> 114
 gaaccttggg tactacctgg gcttcattgt tg 32

<210> 115
 <211> 32
 <212> ADN
 <213> Secuencia artificial

<220>
 <223> Cebador R para CyPP013_I353T

<400>	115	
caaacatgaa gcccgagtag tacccaaggt tc		32
<210>	116	
<211>	33	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador F para CyPP013_F171A	
<400>	116	
agattggtgg agcctgctac atcaggagtt tat		33
<210>	117	
<211>	33	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador R para CyPP013_F171A	
<400>	117	
ataaactcct gatgtagcag gctccaccaa tct		33
<210>	118	
<211>	33	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador F para CyPP013_R101A	
<400>	118	
gatgcaaagt tgccagctta tatctactgg gag		33
<210>	119	
<211>	33	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador R para CyPP013_R101A	
<400>	119	
ctcccgtag atataagctg gcaactttgc atc		33

<210>	120	
<211>	33	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador F para CyPP013_V175C	
<400>	120	
	cctttcacat caggatgtta tgctggagat cct	33
<210>	121	
<211>	33	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador R para CyPP013_V175C	
<400>	121	
	aggatctcca gcataacatc ctgatgtgaa agg	33
<210>	122	
<211>	31	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador F para CyPP013_V175L	
<400>	122	
	acatcaggat tgtatgctgg agatcctgat c	31
<210>	123	
<211>	33	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Cebador R para CyPP013_V175L	
<400>	123	
	tccagcatac aatcctgatg tgaaaggctc cac	33
<210>	124	

<211>	20	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Forward cebador for bar probe	
<400>	124	
	ttccgtaccg agccgcagga	20
<210>	125	
<211>	20	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Reverse cebador for bar probe	
<400>	125	
	cgttgggcag cccgatgaca	20
<210>	126	
<211>	32	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Sitio de restricción de CyPP010_BamHIF	
<400>	126	
	ccccgatcc atgattgaag tggatgtggc ta	32
<210>	127	
<211>	33	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Sitio de restricción de CyPP010_XhoIR	
<400>	127	
	ccccctcgag tgattgtcca ccagcgaggt aag	33
<210>	128	
<211>	32	
<212>	ADN	
<213>	Secuencia artificial	

<220>		
<223>	Sitio de restricción de CyPP013_BamHIF	
<400>	128	
	ccccgatcc atgaaccctg ctaccctga ac	32
<210>	129	
<211>	33	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	Sitio de restricción de CyPP013_XhoIR	
<400>	129	
	ccccctcgag cacctgtgat aacaactgct gag	33
<210>	130	
<211>	1404	
<212>	ADN	
<213>	Secuencia artificial	
<220>		
<223>	secuenciua de ácido nucleico de CyPP010m-6	
<400>	130	
	atgattgaag tggatgtggc tattgttggg ggtggcttta gtggattgtc agtggcttgg	60
	agattacaga ggagtgtccc tcattattct ggagttcttc ttgaggcttc tgatagactt	120
	ggaggtaata tcactacaca agctgtgaa ggatttgtgt gggagcttgg tccaaacagt	180
	ttcgctccta ctccagcact cttacagttg attgtgaag ttggactcca ttctgagtta	240
	atcagaggag ataggcacct tccaagatat atatactgga ggggagaact ttatcctttg	300
	gagccaacta ggctctttgc ttggcaaca tcaaactttt tgagtccttg gggaaaggtt	360
	agagctgcac tcggagcttt aggtttttgtg cctccatata ttggatctgg agatgaaagt	420
	gttgattctt tctttagaag gcatcttggg caagaagttg ctgagagatt ggtggcacca	480
	tttgtttcag gagtgtacgc tggagatcct caacagcttt ctgctgctgc tgcttttaga	540
	aggattgtc aacttgagaa gttgggaggt tcattgatcg ctggagcact cagattaaga	600
	aggcaacagc ctccacagcc aaaacctcca gctcaagtgc agatgagacc tggagaactc	660
	ggtagtttta gggggggtct cgctgcatta cctagagcca tcgcacaaca gttgaaggca	720

ccacttcatt tgcaaacacc tgttgaagct attaccctg agccaaaagg aagttatctc 780
ttaaggagtg gtgaactgac ttggcacgct agatcagttg tgttggctac tccagcatac 840
caaactgctg aacttgttgc accattccag cctgctatcg ctagagcttt ggctaccata 900
ccttatccaa ctgttgcttg tgttgtgctt gcttaccctg ctggattggg tagatcagtt 960
agacctggat ttggtgtttt ggtgcctaga ggacaaggta taaggatact cggaaccatt 1020
tggctcttcat gcttattccc acaaaggact cctgctggtt ggcaggcttt tacctctatg 1080
ataggaggtg atactgatcc tgatcttgca tcattgagag aagaggccat tgttgaacaa 1140
gtgcaacagg atctcacaag gcttcttgat cttcctgctg caaaggcaag actcttgggt 1200
atgaaggttt ggagaggggc tattccacaa tatacgttg gttaccctca acagaggcaa 1260
caggtgacac acgctcttac ccagactcct ggtctcttct tatgttcaaa ctacgcagag 1320
ggagttgcat tgggggatag agtgaacac ggaaatagga ctgctgctgc tgtggctgct 1380
tacctcgctg gtggacaatc atga 1404

<210> 131
<211> 467
<212> PRT
<213> Secuencia artificial

<220>
<223> CyPP010m-6

<400> 131
Met Ile Glu Val Asp Val Ala Ile Val Gly Gly Gly Leu Ser Gly Leu
1 5 10 15
Ser Val Ala Trp Arg Leu Gln Arg Ser Ala Pro His Tyr Ser Gly Val
20 25 30
Leu Leu Glu Ala Ser Asp Arg Leu Gly Gly Asn Ile Thr Thr Gln Ala
35 40 45
Ala Glu Gly Phe Val Trp Glu Leu Gly Pro Asn Ser Phe Ala Pro Thr
50 55 60
Pro Ala Leu Leu Gln Leu Ile Ala Glu Val Gly Leu His Ser Glu Leu
65 70 75 80
Ile Arg Gly Asp Arg His Leu Pro Arg Tyr Ile Tyr Trp Arg Gly Glu
85 90 95
Leu Tyr Pro Leu Glu Pro Thr Arg Pro Leu Ala Leu Ala Thr Ser Asn

100	105	110
Leu Leu Ser Pro Trp Gly Lys Val Arg Ala Ala Leu Gly Ala Leu Gly		
115	120	125
Phe Val Pro Pro Tyr Leu Gly Ser Gly Asp Glu Ser Val Asp Ser Phe		
130	135	140
Phe Arg Arg His Leu Gly Gln Glu Val Ala Glu Arg Leu Val Ala Pro		
145	150	155
Phe Val Ser Gly Val Tyr Ala Gly Asp Pro Gln Gln Leu Ser Ala Ala		
165	170	175
Ala Ala Phe Arg Arg Ile Ala Gln Leu Glu Lys Leu Gly Gly Ser Leu		
180	185	190
Ile Ala Gly Ala Leu Arg Leu Arg Arg Gln Gln Pro Pro Gln Pro Lys		
195	200	205
Pro Pro Ala Gln Val Gln Met Arg Pro Gly Glu Leu Gly Ser Phe Arg		
210	215	220
Gly Gly Leu Ala Ala Leu Pro Arg Ala Ile Ala Gln Gln Leu Lys Ala		
225	230	235
Pro Leu His Leu Gln Thr Pro Val Glu Ala Ile Thr Pro Glu Pro Lys		
245	250	255
Gly Ser Tyr Leu Leu Arg Ser Gly Glu Leu Thr Trp His Ala Arg Ser		
260	265	270
Val Val Leu Ala Thr Pro Ala Tyr Gln Thr Ala Glu Leu Val Ala Pro		
275	280	285
Phe Gln Pro Ala Ile Ala Arg Ala Leu Ala Thr Ile Pro Tyr Pro Thr		
290	295	300
Val Ala Cys Val Val Leu Ala Tyr Pro Ala Gly Leu Gly Arg Ser Val		
305	310	315
Arg Pro Gly Phe Gly Val Leu Val Pro Arg Gly Gln Gly Ile Arg Ile		
325	330	335
Leu Gly Thr Ile Trp Ser Ser Cys Leu Phe Pro Gln Arg Thr Pro Ala		
340	345	350
Gly Trp Gln Ala Phe Thr Ser Met Ile Gly Gly Asp Thr Asp Pro Asp		
355	360	365
Leu Ala Ser Leu Arg Glu Glu Ala Ile Val Glu Gln Val Gln Gln Asp		
370	375	380
Leu Thr Arg Leu Leu Asp Leu Pro Ala Ala Lys Ala Arg Leu Leu Gly		
385	390	395
		400

Met Lys Val Trp Arg Gly Ala Ile Pro Gln Tyr Ile Val Gly Tyr Pro
405 410 415

Gln Gln Arg Gln Gln Val Thr His Ala Leu Thr Gln Thr Pro Gly Leu
420 425 430

Phe Leu Cys Ser Asn Tyr Ala Glu Gly Val Ala Leu Gly Asp Arg Val
435 440 445

Glu His Gly Asn Arg Thr Ala Ala Ala Val Ala Ala Tyr Leu Ala Gly
450 455 460

Gly Gln Ser
465

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference OPP173139KR	FOR FURTHER ACTION	See item 4 below
International application No. PCT/KR2017/006275	International filing date (<i>day/month/year</i>) 15 June 2017 (15.06.2017)	Priority date (<i>day/month/year</i>) 16 June 2016 (16.06.2016)
International Patent Classification (8th edition unless older edition indicated) See relevant information in Form PCT/ISA/237		
Applicant FARMHANNONG CO., LTD.		

1.	This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 bis.1(a).																								
2.	This REPORT consists of a total of 11 sheets, including this cover sheet.																								
In the attached sheets, any reference to the written opinion of the International Searching Authority should be read as a reference to the international preliminary report on patentability (Chapter I) instead.																									
3.	This report contains indications relating to the following items: <table style="width: 100%;"> <tr> <td style="width: 5%; text-align: center;">☒</td> <td style="width: 25%;">Box No. I</td> <td style="width: 70%;">Basis of the report</td> </tr> <tr> <td style="text-align: center;">☐</td> <td>Box No. II</td> <td>Priority</td> </tr> <tr> <td style="text-align: center;">☐</td> <td>Box No. III</td> <td>Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</td> </tr> <tr> <td style="text-align: center;">☐</td> <td>Box No. IV</td> <td>Lack of unity of invention</td> </tr> <tr> <td style="text-align: center;">☒</td> <td>Box No. V</td> <td>Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</td> </tr> <tr> <td style="text-align: center;">☐</td> <td>Box No. VI</td> <td>Certain documents cited</td> </tr> <tr> <td style="text-align: center;">☐</td> <td>Box No. VII</td> <td>Certain defects in the international application</td> </tr> <tr> <td style="text-align: center;">☒</td> <td>Box No. VIII</td> <td>Certain observations on the international application</td> </tr> </table>	☒	Box No. I	Basis of the report	☐	Box No. II	Priority	☐	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability	☐	Box No. IV	Lack of unity of invention	☒	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement	☐	Box No. VI	Certain documents cited	☐	Box No. VII	Certain defects in the international application	☒	Box No. VIII	Certain observations on the international application
☒	Box No. I	Basis of the report																							
☐	Box No. II	Priority																							
☐	Box No. III	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability																							
☐	Box No. IV	Lack of unity of invention																							
☒	Box No. V	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement																							
☐	Box No. VI	Certain documents cited																							
☐	Box No. VII	Certain defects in the international application																							
☒	Box No. VIII	Certain observations on the international application																							
4.	The International Bureau will communicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but not, except where the applicant makes an express request under Article 23(2), before the expiration of 30 months from the priority date (Rule 44bis .2).																								

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No. +41 22 338 82 70	Date of issuance of this report 18 December 2018 (18.12.2018) Authorized officer Kihwan Moon e-mail: pct.team1@wipo.int
--	---

PATENT COOPERATION TREATY

From the
INTERNATIONAL SEARCHING AUTHORITY

To:
YOU ME PATENT AND LAW FIRM

115 Teheran-ro Gangnam-gu Seoul 06134 Republic of Korea

PCT

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

Date of mailing
(day/month/year) **20 September 2017 (20.09.2017)**

Applicant's or agent's file reference
OPP173139KR

FOR FURTHER ACTION

See paragraph 2 below

International application No.
PCT/KR2017/006275

International filing date (day/month/year)
15 June 2017 (15.06.2017)

Priority date(day/month/year)
16 June 2016 (16.06.2016)

International Patent Classification (IPC) or both national classification and IPC

C07K 14/195(2006.01)i, C12N 1/12(2006.01)i, C12N 15/63(2006.01)i, C12N 15/82(2006.01)i

Applicant
FARMHANNONG CO., LTD.

1. This opinion contains indications relating to the following items:

- ☒ Box No. I Basis of the opinion
- ☐ Box No. II Priority
- ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- ☐ Box No. IV Lack of unity of invention
- ☒ Box No. V Reasoned statement under Rule 43bis. I(a)(i) with regard to novelty, inventive step and industrial applicability; citations and explanations supporting such statement
- ☐ Box No. VI Certain documents cited
- ☐ Box No. VII Certain defects in the international application
- ☒ Box No. VIII Certain observations on the international application

2. FURTHER ACTION

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

Name and mailing address of the ISA/KR
International Application Division
Korean Intellectual Property Office
189 Cheongsa-ro, Seo-gu, Daejeon,
35208, Republic of Korea
Facsimile No. +82-42-481-8578



Date of completion of this opinion

18 September 2017 (18.09.2017)

Authorized officer

LEE GYONG CHEOL

Telephone No. +82-42-481-8611



**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.

PCT/KR2017/006275

Box No. 1 Basis of this opinion

1. With regard to the **language**, this opinion has been established on the basis of :

- ☒ the international application in the language in which it was filed
- ☐ a translation of the international application into _____ which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b))

2. ☐ This opinion has been established taking into account the **rectification of an obvious mistake** authorized by or notified to this Authority under Rule 91 (Rule 43*bis*.I(a))

3. ☒ With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, this opinion has been established on the basis of a sequence listing:

- a. ☒ forming part of the international application as filed:
☒ in the form of an Annex C/ST.25 text file.
☐ on paper or in the form of an image file.
- b. ☐ furnished together with the international application under PCT Rule 13*ter*.I(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
- c. ☐ furnished subsequent to the international filing date for the purposes of international search only:
☐ in the form of an Annex C/ST.25 text file (Rule 13*ter*.I(a)).
☐ on paper or in the form of an image file (Rule 13*ter*.I(b) and Administrative Instructions, Section 713).

4. ☐ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

5. Additional comments:

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.

PCT/KR2017/006275

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	8-15,21,23	YES
	Claims	1-7,16-20,22	NO
Inventive step (IS)	Claims	NONE	YES
	Claims	1-23	NO
Industrial applicability (IA)	Claims	1-23	YES
	Claims	NONE	NO

2. Citations and explanations :

Reference is made to the following document:

D1: WO 2015-092706 A1 (BASF AGRO B.V.) 25 June 2015

1. Novelty and Inventive Step

1.1. Claims 1-7

1.1.1. Claims 1-4

D1, which is considered to present the most relevant state of art, discloses a mutated protoporphyrinogen oxidase (PPO) comprising a sequence of SEQ ID NO: 84 identical to SEQ ID NO: 4 of the present invention, the SEQ ID NO: 84 having mutated site 1 corresponding to R101 and mutated site 5 corresponding to F373 and in which the amino acid at mutated site 1 is Ala, and the amino acid at mutated site 5 is Met, wherein the Ala and Met respectively corresponds to R101A and F373M of the present invention (see page 77, lines 27-34; table 2a).

As all of the features of claims 1-4 are disclosed in D1, these claims are anticipated by D1. Therefore, claims 1-4 lack novelty under PCT Article 33(2).

1.1.2. Claim 5

Claim 5 relates to a polynucleotide encoding the polypeptide of any one of claims 1-4. As disclosed above in section 1.1.1, claims 1-4 are anticipated by D1, and D1 discloses a polynucleotide encoding a mutated PPO polypeptide (see page 6, lines 22-24).

Continued on Supplemental Box

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.

PCT/KR2017/006275

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

The phrase 'ALS(acetolactate synthase)-nhibiting herbicide' in claim 13 is considered to be a typographical error for 'ALS(acetolactate synthase)-inhibiting herbicide'. Therefore, claim 13 does not meet the requirement of PCT Article 6.

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of : Box No. V

As all of the features of claim 5 are disclosed in D1, this claim is anticipated by D1. Therefore, claim 5 lacks novelty under PCT Article 33(2).

1.1.3. Claims 6-7

Claims 6-7 relate to a recombinant vector comprising the polynucleotide of claim 5 (claim 6) and recombinant cell comprising the recombinant vector of claim 6 (claim 7). As disclosed above in section 1.1.2, claim 5 is anticipated by D1, and D1 discloses an isolated recombinant expression vector comprising an expression cassette containing a mutated PPO nucleic acid with expression of a vector in a host cell (see page 188, lines 10-13).

As all of the features of claims 6-7 are disclosed in D1, these claims are anticipated by D1. Therefore, claims 6-7 lack novelty under PCT Article 33(2).

1.2. Claims 8-15

1.2.1. Claim 8

Claim 8 relates to a composition for conferring or enhancing herbicide tolerance of a plant or algae, comprising the polypeptide of any one of claims 1-4. As disclosed above in section 1.1.1, claims 1-4 are anticipated by D1, and the additional features of claim 8 comprising the composition comprising the polypeptide of any one of claims 1-4 can be easily derived by a person skilled in the art from the features of D1 considering that a nucleotide sequence encoding a wild-type or a mutated PPO is resistant or tolerant to PPO-inhibiting herbicides (see abstract).

Accordingly, claim 8 would have been obvious over D1. Therefore, claim 8 lacks an inventive step under PCT Article 33(3).

1.2.2 Claims 9-15

The additional feature of claim 9 dependent on claim 8 would be easily conceived by a person skilled in the art from the feature of D1 considering that a nucleotide sequence encoding a wild-type or a mutated PPO is resistant or tolerant to PPO-inhibiting herbicides

Continued on The Next Page

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of : Previous Page

(see abstract).

The additional features of claims 10-11 directly or indirectly dependent on claim 9 are corresponding to examples of PPO inhibiting herbicides including profluzol in D1 (see page 13, lines 14-37).

The additional feature of claim 12 depending on claim 8 relating to a second herbicide-tolerant polypeptide or a gene encoding thereof, and tolerance to the second herbicide which is conferred or enhanced, is not disclosed in D1. However, this feature can be easily derived by a person skilled in the art considering that the plant comprises at least one additional heterologous nucleic acid comprising a nucleotide sequence encoding a herbicide tolerance enzyme in D1 (see page 11, lines 11-16).

The additional features of claims 13-14 depending on claim 12 relating to types of the second herbicide, are not disclosed in D1. However, these features can be easily derived by a person skilled in the art considering that the plant comprises at least one additional heterologous nucleic acid comprising a nucleotide sequence encoding a herbicide tolerance enzyme including acetohydroxyacid synthase (AHAS; EC 4.1.3.18, also known as acetolactate synthase or ALS) in D1 (see page 11, lines 11-16).

The additional feature of claim 15 depending on claim 12 relating to types of the the gene encoding the second herbicide-tolerant polypeptide, is not disclosed in D1. However, this feature can be easily derived by a person skilled in the art considering that the plant comprises at least one additional heterologous nucleic acid comprising a nucleotide sequence encoding a herbicide tolerance enzyme including acetohydroxyacid synthase (AHAS; EC 4.1.3.18, also known as acetolactate synthase or ALS) in D1 (see page 11, lines 11-16).

Accordingly, claims 9-15 would have been obvious over D1. Therefore, claims 9-15 lack an inventive step under PCT Article 33(3).

1.3. Claims 16-17

1.3.1. Claim 16

Continued on The Next Page

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of : Previous Page

Claim 16 relates to a transformant of a plant or algae having herbicide tolerance, or a clone or progeny thereof, comprising the polypeptide of any one of claims 1-4. As disclosed above in section 1.1.1, claims 1-4 are anticipated by D1, and D1 discloses a transgenic plant cell comprising a nucleic acid encoding a mutated-PPO polypeptide (see claim 5).

As all of the features of claim 16 are disclosed in D1, this claim is anticipated by D1. Therefore, claim 16 lacks novelty under PCT Article 33(2).

1.3.2. Claim 17

The additional feature of claim 17 dependent on claim 16 is corresponding to a transgenic plant cell in D1 (see claim 5).

As all of the features of claim 17 are disclosed in D1, this claim is anticipated by D1. Therefore, claim 17 lacks novelty under PCT Article 33(2).

1.4. Claims 18-23

1.4.1. Claim 18

Claim 18 relates to a method of preparing plants or algae having herbicide tolerance, the method comprising transforming algae, or plant cell, protoplast, callus, hypocotyl, seed, cotyledon, shoot, or whole plant, with the polypeptide of any one of claims 1-4. As disclosed above in section 1.1.1, claims 1-4 are anticipated by D1, and D1 discloses a method of producing a transgenic plant cell with an increased resistance to a PPO inhibiting herbicide as compared to a wild type variety of the plant cell comprising, transforming the plant cell with an expression cassette comprising a nucleic acid encoding a mutated-PPO polypeptide (see claim 9).

As all of the features of claim 18 are disclosed in D1, this claim is anticipated by D1. Therefore, claim 18 lacks novelty under PCT Article 33(2).

1.4.2. Claim 19

Continued on The Next Page

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of : Previous Page

Claim 19 relates to a method of conferring or enhancing herbicide tolerance of plants or algae, the method comprising transforming algae, or plant cell, protoplast, callus, hypoeotyl, seed, cotyledon, shoot, or whole plant, with the polypeptide of any one of claims 1-4. As disclosed above in section 1.1.1, claims 1-4 are anticipated by D1, and D1 discloses a method of producing a transgenic plant cell with an increased resistance to a PPO inhibiting herbicide as compared to a wild type variety of the plant cell comprising, transforming the plant cell with an expression cassette comprising a nucleic acid encoding a mutated-PPO polypeptide (see claim 9).

As all of the features of claim 19 are disclosed in D1, this claim is anticipated by D1. Therefore, claim 19 lacks novelty under PCT Article 33(2).

1.4.3. Claim 20

Claim 20 relates to a method of controlling weeds in a cropland, the method comprising, providing the cropland with a plant comprising the polypeptide of any one of claims 1-4, and applying an effective dosage of protoporphyrinogen oxidase-inhibiting herbicide to the cropland. As disclosed above in section 1.1.1, claims 1-4 are anticipated by D1, and D1 discloses a method for controlling undesired vegetation at a plant cultivation site, the method comprising the steps of: a) providing, at a site, a plant that comprises a mutated-PPO which is resistant or tolerant to a "PPO inhibiting herbicide"; and b) applying to the site an effective amount of the herbicide (see claim 1).

As all of the features of claim 20 are disclosed in D1, this claim is anticipated by D1. Therefore, claim 20 lacks novelty under PCT Article 33(2).

1.4.4. Claims 21-22

The additional feature of claim 21 depending on claim 20 relating to applying an effective dosage of two or more kinds of protoporphyrinogen oxidase-inhibiting herbicides sequentially or simultaneously, is not disclosed in D1. However, this feature can be easily derived by a person skilled in the art considering that a PPO inhibiting herbicide is applied in conjunction with one or more additional herbicides in D1 (see claim 4).

Continued on The Next Page

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of : Previous Page

Accordingly, claim 21 would have been obvious over D1. Therefore, claim 21 lacks an inventive step under PCT Article 33(3).

The additional feature of claim 22 depending on claim 20 corresponding to the plant comprising at least one additional heterologous nucleic acid comprising a nucleotide sequence encoding a herbicide tolerance enzyme, and applying the PPO inhibiting herbicide is applied in conjunction with one or more additional herbicides in D1 (see page 11, lines 11-16; claim 4).

As all of the features of claim 22 are disclosed in D1, this claim is anticipated by D1. Therefore, claim 22 lacks novelty under PCT Article 33(2).

1.4.5. Claim 23

Claim 23 relates to a method of removing an undesired aquatic organism from a culture medium, the method comprising: providing a culture medium with algae comprising the polypeptide of any one of claims 1-4, and applying an effective dosage of protoporphyrinogen oxidase-inhibiting herbicide to the culture medium. As disclosed above in section 1.1.1, claims 1-4 are anticipated by D1, and D1 discloses a method for controlling undesired vegetation at a plant cultivation site, the method comprising the steps of: a) providing, at a site, a plant that comprises a mutated protoporphyrinogen oxidase (mutated-PPO) which is resistant or tolerant to a "PPO inhibiting herbicide"; and b) applying to the site an effective amount of the herbicide (see claim 1).

Claim 23 differs from that of D1 in providing the culture medium with algae. However, this feature is merely one of several straightforward possibilities from which the skilled person would select in accordance with circumstances without the exercise of inventive skill, considering that "plant" is used in its broadest sense as it pertains to organic material and includes algae in D1 (see page 8, lines 15-18).

Accordingly, claim 23 would have been obvious over D1. Therefore, claim 23 lacks an inventive step under PCT Article 33(3).

2. Industrial Applicability

Continued on The Next Page

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.

PCT/KR2017/006275

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of : Previous Page

Claims 1-23 are industrially applicable under PCT Article 33(4).

PATENT COOPERATION TREATY

From the
INTERNATIONAL SEARCHING AUTHORITY

To:
YOU ME PATENT AND LAW FIRM

115 Teheran-ro Gangnam-gu Seoul 06134 Republic of Korea

PCT

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

Date of mailing
(day/month/year) **20 September 2017 (20.09.2017)**

Applicant's or agent's file reference
OPP173139KR

FOR FURTHER ACTION

See paragraph 2 below

International application No.
PCT/KR2017/006275

International filing date (day/month/year)
15 June 2017 (15.06.2017)

Priority date(day/month/year)
16 June 2016 (16.06.2016)

International Patent Classification (IPC) or both national classification and IPC

C07K 14/195(2006.01)i, C12N 1/12(2006.01)i, C12N 15/63(2006.01)i, C12N 15/82(2006.01)i

Applicant
FARMHANNONG CO., LTD.

1. This opinion contains indications relating to the following items:

- ☒ Box No. I Basis of the opinion
- ☐ Box No. II Priority
- ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- ☐ Box No. IV Lack of unity of invention
- ☒ Box No. V Reasoned statement under Rule 43bis. I(a)(i) with regard to novelty, inventive step and industrial applicability; citations and explanations supporting such statement
- ☐ Box No. VI Certain documents cited
- ☐ Box No. VII Certain defects in the international application
- ☒ Box No. VIII Certain observations on the international application

2. FURTHER ACTION

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

Name and mailing address of the ISA/KR
International Application Division
Korean Intellectual Property Office
189 Cheongsa-ro, Seo-gu, Daejeon,
35208, Republic of Korea
Facsimile No. +82-42-481-8578



Date of completion of this opinion

18 September 2017 (18.09.2017)

Authorized officer

LEE GYONG CHEOL

Telephone No. +82-42-481-8611



**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.

PCT/KR2017/006275

Box No. 1 Basis of this opinion

1. With regard to the **language**, this opinion has been established on the basis of :

- ☒ the international application in the language in which it was filed
- ☐ a translation of the international application into _____ which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b))

2. ☐ This opinion has been established taking into account the **rectification of an obvious mistake** authorized by or notified to this Authority under Rule 91 (Rule 43*bis*.I(a))

3. ☒ With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, this opinion has been established on the basis of a sequence listing:

- a. ☒ forming part of the international application as filed:
- ☒ in the form of an Annex C/ST.25 text file.
- ☐ on paper or in the form of an image file.
- b. ☐ furnished together with the international application under PCT Rule 13*ter*.I(a) for the purposes of international search only in the form of an Annex C/ST.25 text file.
- c. ☐ furnished subsequent to the international filing date for the purposes of international search only:
- ☐ in the form of an Annex C/ST.25 text file (Rule 13*ter*.I(a)).
- ☐ on paper or in the form of an image file (Rule 13*ter*.I(b) and Administrative Instructions, Section 713).

4. ☐ In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that forming part of the application as filed or does not go beyond the application as filed, as appropriate, were furnished.

5. Additional comments:

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.

PCT/KR2017/006275

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Claims	8-15,21,23	YES
	Claims	1-7,16-20,22	NO
Inventive step (IS)	Claims	NONE	YES
	Claims	1-23	NO
Industrial applicability (IA)	Claims	1-23	YES
	Claims	NONE	NO

2. Citations and explanations :

Reference is made to the following document:

D1: WO 2015-092706 A1 (BASF AGRO B.V.) 25 June 2015

1. Novelty and Inventive Step

1.1. Claims 1-7

1.1.1. Claims 1-4

D1, which is considered to present the most relevant state of art, discloses a mutated protoporphyrinogen oxidase (PPO) comprising a sequence of SEQ ID NO: 84 identical to SEQ ID NO: 4 of the present invention, the SEQ ID NO: 84 having mutated site 1 corresponding to R101 and mutated site 5 corresponding to F373 and in which the amino acid at mutated site 1 is Ala, and the amino acid at mutated site 5 is Met, wherein the Ala and Met respectively corresponds to R101A and F373M of the present invention (see page 77, lines 27-34; table 2a).

As all of the features of claims 1-4 are disclosed in D1, these claims are anticipated by D1. Therefore, claims 1-4 lack novelty under PCT Article 33(2).

1.1.2. Claim 5

Claim 5 relates to a polynucleotide encoding the polypeptide of any one of claims 1-4. As disclosed above in section 1.1.1, claims 1-4 are anticipated by D1, and D1 discloses a polynucleotide encoding a mutated PPO polypeptide (see page 6, lines 22-24).

Continued on Supplemental Box

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.

PCT/KR2017/006275

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

The phrase 'ALS(acetolactate synthase)-nhibiting herbicide' in claim 13 is considered to be a typographical error for 'ALS(acetolactate synthase)-inhibiting herbicide'. Therefore, claim 13 does not meet the requirement of PCT Article 6.

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of : Box No. V

As all of the features of claim 5 are disclosed in D1, this claim is anticipated by D1. Therefore, claim 5 lacks novelty under PCT Article 33(2).

1.1.3. Claims 6-7

Claims 6-7 relate to a recombinant vector comprising the polynucleotide of claim 5 (claim 6) and recombinant cell comprising the recombinant vector of claim 6 (claim 7). As disclosed above in section 1.1.2, claim 5 is anticipated by D1, and D1 discloses an isolated recombinant expression vector comprising an expression cassette containing a mutated PPO nucleic acid with expression of a vector in a host cell (see page 188, lines 10-13).

As all of the features of claims 6-7 are disclosed in D1, these claims are anticipated by D1. Therefore, claims 6-7 lack novelty under PCT Article 33(2).

1.2. Claims 8-15

1.2.1. Claim 8

Claim 8 relates to a composition for conferring or enhancing herbicide tolerance of a plant or algae, comprising the polypeptide of any one of claims 1-4. As disclosed above in section 1.1.1, claims 1-4 are anticipated by D1, and the additional features of claim 8 comprising the composition comprising the polypeptide of any one of claims 1-4 can be easily derived by a person skilled in the art from the features of D1 considering that a nucleotide sequence encoding a wild-type or a mutated PPO is resistant or tolerant to PPO-inhibiting herbicides (see abstract).

Accordingly, claim 8 would have been obvious over D1. Therefore, claim 8 lacks an inventive step under PCT Article 33(3).

1.2.2 Claims 9-15

The additional feature of claim 9 dependent on claim 8 would be easily conceived by a person skilled in the art from the feature of D1 considering that a nucleotide sequence encoding a wild-type or a mutated PPO is resistant or tolerant to PPO-inhibiting herbicides

Continued on The Next Page

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of : Previous Page

(see abstract).

The additional features of claims 10-11 directly or indirectly dependent on claim 9 are corresponding to examples of PPO inhibiting herbicides including profluzol in D1 (see page 13, lines 14-37).

The additional feature of claim 12 depending on claim 8 relating to a second herbicide-tolerant polypeptide or a gene encoding thereof, and tolerance to the second herbicide which is conferred or enhanced, is not disclosed in D1. However, this feature can be easily derived by a person skilled in the art considering that the plant comprises at least one additional heterologous nucleic acid comprising a nucleotide sequence encoding a herbicide tolerance enzyme in D1 (see page 11, lines 11-16).

The additional features of claims 13-14 depending on claim 12 relating to types of the second herbicide, are not disclosed in D1. However, these features can be easily derived by a person skilled in the art considering that the plant comprises at least one additional heterologous nucleic acid comprising a nucleotide sequence encoding a herbicide tolerance enzyme including acetohydroxyacid synthase (AHAS; EC 4.1.3.18, also known as acetolactate synthase or ALS) in D1 (see page 11, lines 11-16).

The additional feature of claim 15 depending on claim 12 relating to types of the the gene encoding the second herbicide-tolerant polypeptide, is not disclosed in D1. However, this feature can be easily derived by a person skilled in the art considering that the plant comprises at least one additional heterologous nucleic acid comprising a nucleotide sequence encoding a herbicide tolerance enzyme including acetohydroxyacid synthase (AHAS; EC 4.1.3.18, also known as acetolactate synthase or ALS) in D1 (see page 11, lines 11-16).

Accordingly, claims 9-15 would have been obvious over D1. Therefore, claims 9-15 lack an inventive step under PCT Article 33(3).

1.3. Claims 16-17

1.3.1. Claim 16

Continued on The Next Page

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of : Previous Page

Claim 16 relates to a transformant of a plant or algae having herbicide tolerance, or a clone or progeny thereof, comprising the polypeptide of any one of claims 1-4. As disclosed above in section 1.1.1, claims 1-4 are anticipated by D1, and D1 discloses a transgenic plant cell comprising a nucleic acid encoding a mutated-PPO polypeptide (see claim 5).

As all of the features of claim 16 are disclosed in D1, this claim is anticipated by D1. Therefore, claim 16 lacks novelty under PCT Article 33(2).

1.3.2. Claim 17

The additional feature of claim 17 dependent on claim 16 is corresponding to a transgenic plant cell in D1 (see claim 5).

As all of the features of claim 17 are disclosed in D1, this claim is anticipated by D1. Therefore, claim 17 lacks novelty under PCT Article 33(2).

1.4. Claims 18-23

1.4.1. Claim 18

Claim 18 relates to a method of preparing plants or algae having herbicide tolerance, the method comprising transforming algae, or plant cell, protoplast, callus, hypocotyl, seed, cotyledon, shoot, or whole plant, with the polypeptide of any one of claims 1-4. As disclosed above in section 1.1.1, claims 1-4 are anticipated by D1, and D1 discloses a method of producing a transgenic plant cell with an increased resistance to a PPO inhibiting herbicide as compared to a wild type variety of the plant cell comprising, transforming the plant cell with an expression cassette comprising a nucleic acid encoding a mutated-PPO polypeptide (see claim 9).

As all of the features of claim 18 are disclosed in D1, this claim is anticipated by D1. Therefore, claim 18 lacks novelty under PCT Article 33(2).

1.4.2. Claim 19

Continued on The Next Page

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of : Previous Page

Claim 19 relates to a method of conferring or enhancing herbicide tolerance of plants or algae, the method comprising transforming algae, or plant cell, protoplast, callus, hypoeotyl, seed, cotyledon, shoot, or whole plant, with the polypeptide of any one of claims 1-4. As disclosed above in section 1.1.1, claims 1-4 are anticipated by D1, and D1 discloses a method of producing a transgenic plant cell with an increased resistance to a PPO inhibiting herbicide as compared to a wild type variety of the plant cell comprising, transforming the plant cell with an expression cassette comprising a nucleic acid encoding a mutated-PPO polypeptide (see claim 9).

As all of the features of claim 19 are disclosed in D1, this claim is anticipated by D1. Therefore, claim 19 lacks novelty under PCT Article 33(2).

1.4.3. Claim 20

Claim 20 relates to a method of controlling weeds in a cropland, the method comprising, providing the cropland with a plant comprising the polypeptide of any one of claims 1-4, and applying an effective dosage of protoporphyrinogen oxidase-inhibiting herbicide to the cropland. As disclosed above in section 1.1.1, claims 1-4 are anticipated by D1, and D1 discloses a method for controlling undesired vegetation at a plant cultivation site, the method comprising the steps of: a) providing, at a site, a plant that comprises a mutated-PPO which is resistant or tolerant to a "PPO inhibiting herbicide"; and b) applying to the site an effective amount of the herbicide (see claim 1).

As all of the features of claim 20 are disclosed in D1, this claim is anticipated by D1. Therefore, claim 20 lacks novelty under PCT Article 33(2).

1.4.4. Claims 21-22

The additional feature of claim 21 depending on claim 20 relating to applying an effective dosage of two or more kinds of protoporphyrinogen oxidase-inhibiting herbicides sequentially or simultaneously, is not disclosed in D1. However, this feature can be easily derived by a person skilled in the art considering that a PPO inhibiting herbicide is applied in conjunction with one or more additional herbicides in D1 (see claim 4).

Continued on The Next Page

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of : Previous Page

Accordingly, claim 21 would have been obvious over D1. Therefore, claim 21 lacks an inventive step under PCT Article 33(3).

The additional feature of claim 22 depending on claim 20 corresponding to the plant comprising at least one additional heterologous nucleic acid comprising a nucleotide sequence encoding a herbicide tolerance enzyme, and applying the PPO inhibiting herbicide is applied in conjunction with one or more additional herbicides in D1 (see page 11, lines 11-16; claim 4).

As all of the features of claim 22 are disclosed in D1, this claim is anticipated by D1. Therefore, claim 22 lacks novelty under PCT Article 33(2).

1.4.5. Claim 23

Claim 23 relates to a method of removing an undesired aquatic organism from a culture medium, the method comprising: providing a culture medium with algae comprising the polypeptide of any one of claims 1-4, and applying an effective dosage of protoporphyrinogen oxidase-inhibiting herbicide to the culture medium. As disclosed above in section 1.1.1, claims 1-4 are anticipated by D1, and D1 discloses a method for controlling undesired vegetation at a plant cultivation site, the method comprising the steps of: a) providing, at a site, a plant that comprises a mutated protoporphyrinogen oxidase (mutated-PPO) which is resistant or tolerant to a "PPO inhibiting herbicide"; and b) applying to the site an effective amount of the herbicide (see claim 1).

Claim 23 differs from that of D1 in providing the culture medium with algae. However, this feature is merely one of several straightforward possibilities from which the skilled person would select in accordance with circumstances without the exercise of inventive skill, considering that "plant" is used in its broadest sense as it pertains to organic material and includes algae in D1 (see page 8, lines 15-18).

Accordingly, claim 23 would have been obvious over D1. Therefore, claim 23 lacks an inventive step under PCT Article 33(3).

2. Industrial Applicability

Continued on The Next Page

**WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY**

International application No.

PCT/KR2017/006275

Supplemental Box

In case the space in any of the preceding boxes is not sufficient.

Continuation of : Previous Page

Claims 1-23 are industrially applicable under PCT Article 33(4).



(51) International Patent Classification:

C07K 14/195 (2006.01) *C12N 15/63* (2006.01)
C12N 1/12 (2006.01) *C12N 15/82* (2006.01)

(21) International Application Number:

PCT/KR2017/006275

(22) International Filing Date:

15 June 2017 (15.06.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10-2016-0075358 16 June 2016 (16.06.2016) KR

(71) Applicant: FARMHANNONG CO., LTD. [KR/KR]; 24,
Yeoui-daero, Yeongdeungpo-gu, Seoul 07320 (KR).

(72) Inventors: SUNG, Soon-Kee; 99, Gajeong-ro, Yuseong-gu, Daejeon 34115 (KR). YOON, Joonseon; 99, Gajeong-ro, Yuseong-gu, Daejeon 34115 (KR). HAN, Yunjung; 99, Gajeong-ro, Yuseong-gu, Daejeon 34115 (KR). AHN, Young Ock; 99, Gajeong-ro, Yuseong-gu, Daejeon 34115 (KR). PARK, Joonghyuk; 99, Gajeong-ro, Yuseong-gu, Daejeon 34115 (KR). HONG, Myoung-Ki; 99, Gajeong-ro, Yuseong-gu, Daejeon 34115 (KR).

(74) Agent: YOU ME PATENT AND LAW FIRM; 115
Teheran-ro, Gangnam-gu, Seoul 06134 (KR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: METHODS AND COMPOSITIONS FOR CONFERRING AND/OR ENHANCING HERBICIDE TOLERANCE USING PROTOPORPHYRINOGEN OXIDASE OR VARIANT THEREOF

[Fig. 33a]



(57) Abstract: Provided is technology for conferring enhanced herbicide tolerance and/or enhancing herbicide tolerance of plants and/or algae using a protoporphyrinogen oxidase derived from prokaryotes or its amino acid variants.



【DESCRIPTION】**【Invention Title】**

METHODS AND COMPOSITIONS FOR CONFERRING AND/OR
ENHANCING HERBICIDE TOLERANCE USING PROTOPORPHYRINOGEN
5 OXIDASE OR VARIANT THEREOF

【Technical Field】

Provided are protoporphyrinogen oxidases derived from prokaryotes or its
variants, and technology for conferring and/or enhancing herbicide tolerance of plants
10 and/or algae using the same.

【Background Art】

A porphyrin biosynthetic pathway serves for the synthesis of chlorophyll and
heme which play vital roles in plant metabolism, and it takes place in the chloroplast.
15 In this pathway, protoporphyrinogen IX oxidase (hereinafter, referred to as PPO;
EC:1.3.3.4) catalyzes the oxidation of protoporphyrinogen IX to protoporphyrin IX.
After the oxidation of protoporphyrinogen IX to protoporphyrin IX, protoporphyrin IX
binds with magnesium by Mg-chelatase to synthesize chlorophyll, or it binds with iron
by Fe-chelatase to synthesize heme.

20 Therefore, when PPO activity is inhibited, synthesis of chlorophylls and heme
is inhibited and the substrate protoporphyrinogen IX leaves the normal porphyrin
biosynthetic pathway, resulting in the rapid export of protoporphyrinogen IX from the
chloroplast to the cytoplasm, and cytoplasmic protoporphyrin IX accumulation caused
by the oxidation. Accumulated protoporphyrin IX generates highly reactive singlet
25 oxygen ($^1\text{O}_2$) in the presence of light and oxygen molecules which destroy cell
membrane and rapidly lead to plant cell death. Based on this principle, herbicides
inhibiting PPO activity have been developed. Until now, there have been 9 families of
PPO inhibiting herbicides, including pyrimidinediones, diphenyl-ethers,
phenylpyrazoles, N-phenylphthalimides, thiadiazoles, oxadiazoles, triazolinones,
30 oxazolidinediones, and others herbicides, which are classified according to their

chemical structures.

Further, in order to prevent effects of these herbicides on the growth of crops while using the herbicides, there is a need to provide herbicide tolerance for the crops.

Meanwhile, algae are photosynthetic organisms that can convert light energy
5 into chemical energy which can be used to synthesize various useful compounds. For example, algae can fix carbon by photosynthesis and convert carbon dioxide into sugar, starch, lipids, fats, or other biomolecules, thereby removing greenhouse gases from the atmosphere. In addition, large-scale cultivation of algae can produce a variety of substances such as industrial enzymes, therapeutic compounds and proteins, nutrients,
10 commercial materials and fuel materials.

However, in case of large-scale cultivation of algae in a bioreactor or in an open or enclosed pond, contamination may occur by undesired competitive organisms, for example, undesired algae, fungi, rotifer, or zooplankton.

Thus, a technology is needed to harvest desired plants and/or algae on a large
15 scale by treating herbicides at a concentration that would inhibits the growth of competitive organisms without herbicide tolerance, after conferring herbicide tolerance to desired plants and/or algae.

【References】

20 (Patent document 1) U.S. patent application registration publication US 6,308,458 (2001.10.30)

(Patent document 2) U.S. patent application registration publication US 6,808,904 (2004.10.26)

(Patent document 3) U.S. patent application registration publication US
25 7,563,950 (2009.07.21)

(Patent document 4) International patent application laid-open publication WO2011/085221 (2011.07.14)

(Non-patent document 1) Li X, Volrath SL, Chilcott CE, Johnson MA, Ward ER, Law MD, Development of protoporphyrinogen oxidase as an efficient selection
30 marker for agrobacterium tumefaciens- mediated transformation of maize. Plant

physiology 133:736-747, 2003

【Disclosure】

【Technical Problem】

5 In this specification, it is found that hemY-type PPO genes derived from prokaryotes and mutants thereof show a wide herbicide tolerance to protoporphyrinogen oxidase (PPO)-inhibiting herbicides, and thereby it is proposed if providing plants and/or algae with the same, herbicide tolerance can be conferred and/or enhanced.

One embodiment provides a polypeptide variant comprising, consisting
10 essentially of, or consisting of:

(1) an amino acid sequence wherein one or more selected from the group consisting of amino acids affecting to the interaction between a PPO inhibiting herbicide and the polypeptide of PPO, SEQ ID NO: 2 (e.g., amino acids positioned on binding sites of SEQ ID NO: 2 interacting with PPO inhibiting herbicide) are
15 respectively and independently deleted or substituted with an amino acid which is different from original amino acid in the corresponding position, or

(2) an amino acid sequence having 95% or higher, 98% or higher, or 99% or higher sequence homology with the amino acid sequence (1).

The one or more selected from the group consisting of amino acids affecting to
20 the interaction between PPO inhibiting herbicides and the polypeptide of PPO, SEQ ID NO: 2, may be one or more selected from the group consisting of N59, S60, R89, F161, V165, A167, Q184, P303, V305, F324, L327, I340, F360, and I408, of the amino acid sequence of SEQ ID NO: 2.

Another embodiment provides a polypeptide variant comprising, consisting
25 essentially of, or consisting of:

(1) an amino acid sequence wherein one or more selected from the group consisting of amino acids affecting to the interaction between PPO inhibiting herbicides and the polypeptide of PPO, SEQ ID NO: 4 (e.g., amino acids positioned on binding sites of SEQ ID NO: 4 interacting with PPO inhibiting herbicide) are respectively and
30 independently deleted or substituted with an amino acid which is different from original

amino acid in the corresponding position, or

(2) an amino acid sequence having 95% or higher, 98% or higher, or 99% or higher sequence homology with the amino acid sequence (1).

The one or more selected from the group consisting of amino acids affecting to the interaction between PPO inhibiting herbicides and the polypeptide of PPO, SEQ ID NO: 4, may be one or more selected from the group consisting of R101, F171, V175, A177, G194, P316, V318, F337, L340, I353, and F373, of the amino acid sequence of SEQ ID NO: 4.

Other embodiment provides a polynucleotide encoding the polypeptide or the polypeptide variant.

Other embodiment provides a recombinant vector comprising the polynucleotide.

Other embodiment provides a recombinant cell comprising the recombinant vector.

Other embodiment provides a composition for conferring or enhancing herbicide tolerance of plants or algae, comprising one or more selected from the group consisting of:

the polypeptide of SEQ ID NO: 2, the polypeptide of SEQ ID NO: 4, a polypeptide variant thereof as described above, and a polypeptide with an amino acid sequence having 95% or higher, 98% or higher, or 99% or higher sequence homology with the polypeptide or polypeptide variants;

a polynucleotide encoding the polypeptide, the polypeptide variants, and a polypeptide with an amino acid sequence having 95% or higher, 98% or higher, or 99% or higher sequence homology with the polypeptide or variants;

a recombinant vector comprising the polynucleotide; and
a recombinant cell comprising the recombinant vector.

For example, the polynucleotide encoding the polypeptide of SEQ ID NO: 2 may comprise the polynucleotide sequence of SEQ ID NO: 1, and the polypeptide of SEQ ID NO: 4 may comprise the polynucleotide sequence of SEQ ID NO: 3, but not limited thereto.

The herbicide may be an herbicide inhibiting protoporphyrinogen oxidase.

As a specific embodiment, the herbicide may be one or more selected from the group consisting of pyrimidinediones, diphenyl-ethers, phenylpyrazoles, N-phenylphthalimides, phenylesters, thiadiazoles, oxadiazoles, triazolinones, oxazolidinediones and other herbicides, but not limited thereto.

As a specific embodiment, the herbicide may be one or more selected from the group consisting of butafenacil, saflufenacil, benzfendizone, tiafenacil, fomesafen, oxyfluorfen, aclonifen, acifluorfen, bifenox, ethoxyfen, lactofen, chlomethoxyfen, chlorintofen, fluoroglycofen-ethyl, halosafen, pyraflufen-ethyl, fluazolate, flumioxazin, cinidon-ethyl, flumiclorac-pentyl, fluthiacet, thidiazimin, oxadiargyl; oxadiazon, carfentrazone, sulfentrazone, azafenidin, pentoxazone, pyraclonil, flufenpyr-ethyl, profluazol, phenopylate (2,4-dichlorophenyl 1-pyrrolidinecarboxylate), carbamate analogues of phenopylate (for example, O-phenylpyrrolidino- and piperidinocarbamate analogues (refer to "Ujjana B. Nandihalli, Mary V. Duke, Stephen O. Duke, Relationships between molecular properties and biological activities of O-phenyl pyrrolidino- and piperidinocarbamate herbicides., J. Agric. Food Chem., 1992, 40(10) 1993-2000")), agriculturally acceptable salts thereof, and combinations thereof, but not limited thereto.

The plant means a multicellular eukaryote having photosynthetic capability, which may be a monocotyledonous plant or a dicotyledonous plant, and may be an herbaceous plant or a woody plant. The algae mean unicellular organism having photosynthetic capability, which may be a prokaryotic alga or a eukaryotic alga.

In one embodiment, the plants and algae are genetically manipulated in order to further comprise a second herbicide tolerance polypeptide or a gene encoding thereof, and broader range of herbicide tolerance to the second herbicide may be conferred and/or enhanced. The plants and algae genetically manipulated in order to comprise the second herbicide tolerance polypeptide or a gene encoding thereof more may be prepared using a composition for conferring and/or enhancing tolerance to the herbicide wherein the second herbicide tolerance polypeptide or a gene encoding thereof is further comprised. Thus, a composition for conferring and/or enhancing tolerance to the herbicide may further comprise the second herbicide tolerance polypeptide or a gene

encoding thereof.

As a specific embodiment, the second herbicide may include cell division-inhibiting herbicides, photosynthesis-inhibiting herbicides, amino acid synthesis-inhibiting herbicides, plastid-inhibiting herbicides, and cell membrane-inhibiting herbicides, but not limited thereto.

As a specific embodiment, the second herbicide may be exemplified by glyphosate, glufosinate, dicamba, 2,4-D(2,4-dichlorophenoxyacetic acid), isoxaflutole, ALS(acetolactate synthase)-inhibiting herbicide, photosystem II-inhibiting herbicide, phenylurea-based herbicide, bromoxynil-based herbicide, and combinations thereof, but not limited thereto.

As a specific embodiment, the second herbicide may be exemplified by one or more selected from the group consisting of glyphosate herbicide-tolerant EPSPS(glyphosate tolerant 5-enolpyruvylshikimate-3-phosphate synthase), GOX(glyphosate oxidase), GAT (glyphosate-N-acetyltransferase) or glyphosate decarboxylase); glufosinate herbicide-tolerant PAT(phosphinothricin-N-acetyltransferase); dicamba herbicide-tolerant DMO(dicamba monooxygenase); 2,4-D herbicide-tolerant 2,4-D monooxygenase or AAD(aryloxyalkanoate dioxygenase); ALS-inhibiting sulfonylurea-based herbicide-tolerant ALS(acetolactate Synthase), AHAS(acetohydroxyacid synthase), or Athahasl (acetohydroxyacid synthase Large Subunit); photosystem II-inhibiting herbicide-tolerant photosystem II protein D1; phenylurea-based herbicide-tolerant cytochrome P450; plastid-inhibiting herbicide-tolerant HPPD(hydorxylphenylpyruvate dioxygenase); bromoxynil herbicide-tolerant nitrilase; and combinations thereof, but not limited thereto.

Further, the gene encoding the second herbicide-tolerant polypeptide may be exemplified by one or more selected from the group consisting of glyphosate herbicide-tolerant cp4 epsps, epsps (AG), mepsps, 2mepsps, goxv247, gat4601 or gat4621 gene; glufosinate herbicide-tolerant bar, pat or pat (SYN) gene; dicamba herbicide-tolerant dmo gene; 2,4-D herbicide-tolerant AAD-1, AAD-12 gene; ALS-inhibiting sulfonylurea-based herbicide-tolerant ALS, GM-HRA, S4-HRA, ZM-HRA, Csr1, Csr1-1, Csr1-2, SurA or SurB; photosystem II-inhibiting herbicide-tolerant psbA gene;

phenylurea herbicide-tolerant CYP76B1 gene; isoxaflutole herbicide-tolerant HPPDPF W336 gene and bromoxynil herbicide-tolerant bxn gene; and combinations thereof, but not limited thereto.

Other embodiment provides a transformant of a plant and/or algae having
5 herbicide tolerance, which are transformed with the polynucleotide, or a clone or progeny thereof.

Other embodiment provides a method of preparing plants or algae having herbicide tolerance, comprising a step of transforming plants and/or algae with the polynucleotide.

10 Other embodiment provides a method of conferring or enhancing herbicide tolerance of plants and/or algae, comprising a step of transforming plants and/or algae with the polynucleotide.

The transformation may be performed on algae, and/or plant cell, protoplast, callus, hypocotyl, seed, cotyledon, shoot, or whole plant.

15 The transformant may be algae, and/or plant cell, protoplast, callus, hypocotyl, seed, cotyledon, shoot, or whole plant.

Other embodiment provides a method of controlling weeds in a cropland comprising:

a step of providing the cropland with a plant comprising one or more selected
20 from the group comprising of the polypeptide of SEQ ID NO: 2 or 4, the polypeptide variant, a polynucleotide encoding thereof, a recombinant vector comprising the polynucleotide, and a recombinant cell comprising the recombinant vector; and

a step of applying an effective dosage of a protoporphyrinogen oxidase-inhibiting herbicide to the cropland (or to the plant).

25 As a specific embodiment, the step of applying an effective dosage of protoporphyrinogen oxidase-inhibiting herbicide to the cropland may be performed by applying an effective dosage of two or more protoporphyrinogen oxidase-inhibiting herbicides sequentially or simultaneously.

As other embodiment, the plant may be genetically manipulated in order to
30 further comprise a second herbicide-tolerant polypeptide or a gene encoding the same,

and an effective dosage of the protoporphyrinogen oxidase-inhibiting herbicide and the second herbicide may be applied sequentially or simultaneously.

Other embodiment provides a method of removing an undesired aquatic organism from a culture medium, comprising a step of providing a culture medium with
5 algae comprising one or more selected from the group consisting of the polypeptide, the polypeptide variant, a polynucleotide encoding the polypeptide or the polypeptide variant, a recombinant vector comprising the polynucleotide, and a recombinant cell comprising the recombinant vector, and a step of applying an effective dosage of protoporphyrinogen oxidase-inhibiting herbicide to the culture medium.

10

【Technical Solution】

Provided is a technology of conferring and/or enhancing herbicide tolerance of plants or algae.

Herein, ‘conferring and/or enhancing herbicide tolerance of plants or algae’ or
15 ‘enhancing herbicide tolerance of plants or algae’ is interpreted as conferring tolerance on plants or algae which do not have herbicide tolerance, or enhancing tolerance of plants or algae which have herbicide tolerance, or broad meaning of covering both.

As used herein, ‘consisting of a sequence,’ ‘consisting essentially of a sequence,’ or ‘comprising a sequence’ is used in order to mean both cases of comprising
20 described sequence, or necessarily comprising the sequence, and may be interpreted as meaning of comprising a sequence other than described sequence and/or comprising mutation (addition, deletion, and/or substitution of an amino acid or nucleic acid), as long as maintaining an intrinsic activity of protein, polypeptide, or nucleic acid molecule and exhibiting intended function.

25 In one embodiment, provided are one or more polypeptide variants selected from the group consisting of:

a polypeptide variant comprising, consisting essentially of, or consisting of an amino acid sequence wherein one or more selected from the group consisting of amino acids affecting to the interaction between PPO inhibiting herbicides and polypeptide of
30 PPO, SEQ ID NO: 2 (e.g., amino acids positioned on binding sites of SEQ ID NO: 2

interacting with PPO inhibiting herbicide), are respectively and independently deleted or substituted with other amino acid which is different from the original amino acid, or an amino acid sequence having 95% or higher, 98% or higher, or 99% or higher homology thereto; and

- 5 a polypeptide variant comprising, consisting essentially of, or consisting of amino acids affecting to the interaction between PPO inhibiting herbicides and polypeptide of PPO, SEQ ID NO: 4 (e.g., amino acids positioned on binding sites of SEQ ID NO: 4 interacting with PPO inhibiting herbicide), are respectively and independently deleted or substituted with other amino acid which is different from
10 original amino acid in the corresponding position, or an amino acid sequence having 95% or higher, 98% or higher, or 99% or higher homology thereto.

In other embodiment, provided is a polynucleotide encoding the polypeptide or the polypeptide variant, a recombinant vector comprising the polynucleotide, and a recombinant cell comprising the recombinant vector. The polynucleotide may be
15 designed in order that an optimized codon is comprised in a cell to be transformed among codons encoding each amino acid. The optimized codon may be easily known to a person skilled in the art (for example, refer to "<http://www.genscript.com/codon-opt.html>", "<http://sg.idtdna.com/CodonOpt>" etc.).

In other embodiment, provided a composition for conferring or enhancing
20 herbicide tolerance of plants or algae, comprising one or more selected from the group consisting of:

- the polypeptide of SEQ ID NO: 2, the polypeptide of SEQ ID NO: 4, the polypeptide variants thereof, and a polypeptide with an amino acid sequence having 95% or higher, 98% or higher, or 99% or higher sequence homology thereto;
- 25 a polynucleotide encoding the polypeptide or the polypeptide variants;
a recombinant vector comprising the polynucleotide; and
a recombinant cell comprising the recombinant vector.

For example, the polynucleotide encoding the polypeptide of SEQ ID NO: 2 may comprise the polynucleotide sequence of SEQ ID NO: 1, and the polypeptide of
30 SEQ ID NO: 4 may comprise the polynucleotide sequence of SEQ ID NO: 3, but not

limited thereto.

Another embodiment provides a transformant of a plant or algae having herbicide tolerance, which is transformed with the polynucleotide encoding the polypeptide or the polypeptide variant. The polynucleotide may be designed in order
5 that an optimized codon is comprised in a cell to be transformed among codons encoding each amino acid. The optimized codon may be easily known to a person skilled in the art (for example, refer to "<http://www.genscript.com/codon-opt.html>", "<http://sg.idtdna.com/CodonOpt>" etc.).

In other embodiment, provided is a method of preparing plants or algae having
10 herbicide tolerance, comprising a step of transforming algae, or plant cell, protoplast, callus, hypocotyl, seed, cotyledon, shoot, or whole plant with the polynucleotide.

In other embodiment, provided is a method of conferring or enhancing herbicide tolerance of plants or algae, comprising a step of transforming algae, or plant cell, protoplast, callus, hypocotyl, seed, cotyledon, shoot, or whole plant with the
15 polynucleotide.

Hereinafter, the present invention will be described in more detail.

The polypeptide having amino acid sequences of SEQ ID NO: 2 or 4, or an amino acid sequence having 95% or higher, 98% or higher, or 99% or higher sequence homology with thereof and its variant provided herein is a PPO protein derived from a
20 prokaryote (for example, cyanobacteria), and is an herbicide-tolerant PPO protein having tolerance to PPO inhibiting herbicides. Specifically, a PPO protein which is derived from *Thermosynechococcus elongatus* BP-1 is provided, and it is designated as CyPPO10, and its amino acid sequence is represented by SEQ ID NO: 2, and a nucleotide sequence of a gene encoding thereof is represented by SEQ ID NO: 1. In
25 addition, a PPO derived from *Synechococcus* sp. JA-3-3Ab strain is provided, and it is designated as CyPPO13, and its amino acid sequence is represented by SEQ ID NO: 4, and a nucleotide sequence of a gene encoding thereof is represented by SEQ ID NO: 3.

Herein, the polypeptide and variants of the polypeptide described above may be expressed respectively as herbicide-tolerant PPO protein or herbicide-tolerant PPO
30 protein variant having tolerance to PPO inhibiting herbicides. In addition, as used herein,

“herbicide-tolerant PPO or its variant” may be used in order to mean the above herbicide-tolerant PPO protein or herbicide-tolerant PPO protein variant, herbicide-tolerant PPO protein-encoding gene or herbicide-tolerant PPO protein variant-encoding gene, or all of them.

- 5 Cyanobacteria-derived PPO proteins have more excellent enzyme activity themselves than plant PPOs, and these PPO proteins can confer tolerance to PPO-inhibiting herbicides and intensify herbicide tolerance by comprising amino acid mutation in a range of overall maintaining intrinsic enzyme activity than wild type PPO proteins. Such amino acid mutation may be comprise substitution, deletion, addition
10 and/or introduction of one or more of amino acids selected from amino acid residues of interaction sites between PPO proteins and herbicides.

The PPO protein variant will be described in more detail as follows.

One embodiment provides a polypeptide variant comprising, consisting essentially of, or consisting of:

- 15 an amino acid sequence wherein one or more selected from the group consisting of amino acids affecting to the interaction between PPO inhibiting herbicides and the polypeptide of PPO, SEQ ID NO: 2 (CyPPO10) (e.g., amino acids positioned on binding sites to PPO inhibiting herbicides of polypeptide of SEQ ID NO: 2), are respectively and independently deleted or substituted with other amino acid which is
20 different from the original amino acid (namely, an amino acid in the corresponding position of the wild type) or

an amino acid sequence having 95% or higher, 98% or higher, or 99% or higher homology thereto.

- The amino acid residue of polypeptide of SEQ ID NO: 2 which is deleted or
25 substituted with other amino acid that is different from the original amino acid (namely, one or more selected from the group consisting of amino acids positioned in binding sites to PPO inhibiting herbicides of polypeptide of SEQ ID NO: 2) may be one or more selected from the group consisting of N59 (meaning of “N(Asn) in the 59th position”; the expression of the following amino acid residues is interpreted in the same manner),
30 S60, R89, F161, V165, A167, Q184, P303, V305, F324, L327, I340, F360, and I408 of

the amino acid sequence of SEQ ID NO: 2.

In one specific embodiment, the variant of polypeptide may comprise, consist essentially of, or consist of:

an amino acid sequence wherein one or more selected from the group consisting of N59, S60, R89, F161, V165, A167, Q184, P303, V305, F324, L327, I340, F360, and I408 of the amino acid sequence of SEQ ID NO: 2 are respectively and independently deleted or substituted with an amino acid which is selected from the group consisting of M(Met), V(Val), I(Ile), T(Thr), L(Leu), C(Cys), A(Ala), S(Ser), F(Phe), P(Pro), W(Trp), N(Asn), Q(Gln), G(Gly), Y(Tyr), D(Asp), E(Glu), R(Arg), H(His), K(Lys), etc. and is different from the original amino acid at the corresponding position (for example, substituted with an amino acid which is selected from the group consisting of M(Met), V(Val), I(Ile), T(Thr), L(Leu), C(Cys), A(Ala), S(Ser), R(Arg), W(Trp), G(Gly) etc. and is different from the original amino acid at the corresponding position in the wild type), or

an amino acid sequence having 95% or higher, 98% or higher, or 99% or higher homology thereto.

For example, the variant of polypeptide may comprise, consist essentially of, or consist of:

an amino acid sequence comprising one or more amino acid mutations selected from the group consisting of F360M (meaning of “the amino acid residue in the 360th position is substituted from F(Phe) to M(Met)”); the expression of the following amino acid mutations is interpreted in the same manner), F360V, F360I, F360T, F360L, F360C, A167C, A167L, A167I, P303L, V305L, V305M, V305T, N59T, S60T, R89A, R89L, R89V, F161A, V165S, V165C, Q184G, F324V, L327T, I340T, I408R, and I408W, in the amino acid sequence of SEQ ID NO: 2 or

an amino acid sequence having 95% or higher, 98% or higher, or 99% or higher homology thereto.

More specifically, the variant of polypeptide may comprise, consist essentially of, or consist of:

an amino acid sequence comprising one or more amino acid mutations selected

from the group consisting of amino acid mutations of F360M, F360V, F360I, F360T, F360L, F360C, A167C, A167L, A167I, P303L, N59T, S60T, R89A, R89L, R89V, F161A, V165S, V165C, Q184G, V305L, V305M, V305T, F324V, L327T, I340T, I408R, I408W, P303L+V305L (meaning of a mutant or mutation comprising all of substitution of the 303rd residue from P to L and substitution of the 305th residue from V to L; the expression of the following two or more amino acid mutations is interpreted in the same manner), N59T+F360V, S60T+V165S+F360M, S60T+V165S+F360I, S60T+I340T+F360I, R89A+F360M, R89A+F360I, R89A+F360L, R89L+F360I, R89V+F360I, R89A+A167L+F360M, R89A+V305T+F360M, V165S+F360M, V165S+F360I, V165S+F360L, V165S+F360V, V165C+F360M, V165C+A167C+F360M, V165C+A167I+F360M, V165C+A167L+F360M, A167L+F360M, A167L+F360I, A167C+F360M, A167C+F360I, A167I+F360M, V305M+F360M, V305T+F360I, V305L+F360M, I408R+F360M, or I408W+F360M, in the amino acid sequence of SEQ ID NO: 2 or

an amino acid sequence having 95% or higher, 98% or higher, or 99% or higher homology thereto.

Other embodiment provides a polypeptide variant comprise, consist essentially of, or consist of:

an amino acid sequence wherein one or more selected from the group consisting of amino acids affecting to the interaction between PPO inhibiting herbicides and the polypeptide of PPO, SEQ ID NO: 4 (CyPPO13) (e.g., amino acids positioned on binding sites to PPO inhibiting herbicides of polypeptide of SEQ ID NO: 4), are respectively and independently deleted or substituted with other amino acid which is different from the original amino acid at the corresponding position (namely, an amino acid in the corresponding position of the wild type), or

an amino acid sequence having 95% or higher, 98% or higher, or 99% or higher homology thereto.

The amino acid residue of polypeptide of SEQ ID NO: 4 which is deleted or substituted with other amino acid that is different from the original amino acid at the corresponding position (e.g., one or more selected from the group consisting of amino

acids positioned in binding sites to PPO inhibiting herbicides of polypeptide of SEQ ID NO: 3) may be one or more selected from the group consisting of R101, F171, V175, A177, G194, P316, V318, F337, L340, I353, and F373, of the amino acid sequence of SEQ ID NO: 4.

5 In one specific embodiment, the variant of polypeptide may comprise, consist essentially of, or consist of:

an amino acid sequence wherein one or more selected from the group consisting of R101, F171, V175, A177, G194, P316, V318, F337, L340, I353, and F373, of the amino acid sequence of SEQ ID NO: 4 are respectively and independently deleted or substituted with an amino acid which is selected from the group consisting of M(Met), V(Val), I(Ile), T(Thr), L(Leu), C(Cys), A(Ala), S(Ser), F(Phe), P(Pro), W(Trp), N(Asn), Q(Gln), G(Gly), Y(Tyr), D(Asp), E(Glu), R(Arg), H(His), K(Lys), etc. and is different from the original amino acid at the corresponding position in the wild type (for example, substituted with an amino acid which is selected from the group consisting of M(Met), V(Val), I(Ile), T(Thr), L(Leu), C(Cys), A(Ala), E(Glu), Q(Gln), K(Lys), R(Arg), H(His), N(Asn), etc. and is different from the amino acid at the corresponding position in the wild type), or

an amino acid sequence having 95% or higher, 98% or higher, or 99% or higher homology thereto.

20 For example, the variant of polypeptide may comprise, consist essentially of, or consist of:

an amino acid sequence comprising one or more amino acid mutations selected from the group consisting of F373M, F373V, F373I, F373T, F373L, F373C, F373N, F373H, A177C, A177L, A177I, P316A, P316L, V318L, V318M, R101A, F171A, V175C, V175L, G194E, G194Q, G194M, G194K, G194R, F337V, L340T, and I353T, in the amino acid sequence of SEQ ID NO: 4 or an amino acid sequence having 95% or higher, 98% or higher, or 99% or higher homology thereto. More specifically, the variant of polypeptide may comprise an amino acid sequence comprising one or more amino acid mutations selected from the group consisting of amino acid mutations of F373M, F373V, F373I, F373T, F373L, F373C, F373N, F373H, A177C, A177L, A177I,

P316A, P316L, V318L, V318M, R101A, F171A, V175C, V175L, G194E, G194Q, G194M, G194K, G194R, F337V, L340T, I353T, P316L+V318L, P316A+V318L, R101A+F373M, A177C+F373M, A177I+F373M, A177L+F373M, A177L+F373I, A177L+F373L, A177L+F373T, A177L+F373V, A177C+F373T, A177C+F373V, 5 V175L+F373M, G194E+F373M, G194Q+F373M, G194M+F373M, G194K+F373M, G194R+F373M, or V318M+F373M, in the amino acid sequence of SEQ ID NO: 4 or

an amino acid sequence having 95% or higher, 98% or higher, or 99% or higher homology thereto.

The polypeptide variant comprising an amino acid sequence having sequence 10 homology (for example, 95% or higher, 98% or higher, or 99% or higher sequence homology) described herein may maintain enzyme activity equivalent to that of a polypeptide having an amino acid sequence which is a standard of identification of sequence homology (for example, the PPO protein having amino acid mutation described above), for example, 5% or higher, 10% or higher, 20% or higher, 30% or 15 higher, 40% or higher, 50% or higher, 60% or higher, 70% or higher, 80% or higher, 90% or higher, or 95% or higher enzyme activity to a polypeptide having an amino acid sequence which is a standard in plants (in a whole plant, in a plant cell or cell culture, in a plant tissue, etc.), in algae, and/or in vitro, and having function to confer herbicide tolerance. The sequence homology description is used in order to clarify that the 20 herbicide-tolerance PPO protein variant or polypeptide variant described herein may comprise all sequence mutations in the range of satisfying the above condition (maintain enzyme activity and having function to confer herbicide tolerance).

The names of amino acids used in the description are arranged as follows:

Amino acid	3-letter code	1-letter code
Alanine	Ala	A
Isoleucine	Ile	I
Leucine	Leu	L
Methionine	Met	M
Phenylalanine	Phe	F
Proline	Pro	P
Tryptophan	Trp	W
Valine	Val	V
Asparagine	Asn	N
Cysteine	Cys	C
Glutamine	Gln	Q
Glycine	Gly	G
Serine	Ser	S
Threonine	Thr	T
Tyrosine	Tyr	Y
Aspartic acid	Asp	D
Glutamic acid	Glu	E
Arginine	Arg	R
Histidine	His	H
Lysine	Lys	K

The herbicide-tolerant PPO protein variant may maintain enzyme activity of PPO protein, and exhibit enhanced herbicide tolerance compared to the wild type.

In addition, the herbicide-tolerant PPO protein variant may comprise further mutation exhibiting biologically equal activity to a polypeptide consisting of SEQ ID NO: 2 or SEQ ID NO: 4, or an amino acid sequence having amino acid mutation described above. For example, the additional mutation may be amino acid substitution which does not overall alter molecular activity, and such amino acid substitution is publicly known in the art. In one example, the additional substitution may be substitution of amino acid residues Ala/Ser, Val/Ile, Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Ser/Gly, Thr/Phe, Ala/Pro, Lys/Arg, Asp/Asn, Leu/Ile, Leu/Val, Ala/Glu, or Asp/Gly, but not limited thereto. In some cases, the herbicide-tolerant PPO protein variant may be under modification by one or more selected from the group consisting of phosphorylation, sulfation, acylation, glycosylation, methylation, farnesylation, etc. In addition, the herbicide-tolerant PPO protein variant may comprise a protein variant wherein structural stability to heat, pH, etc. of the protein is increased or protein activity is increased by amino acid mutation and/or modification.

The term “sequence homology” refers to the degree of similarity to the wild

type or reference amino acid sequence or nucleotide sequence, and any protein may be included in the scope of the present invention, as long as it includes amino acid residues having 60% or higher, 65% or higher, 70% or higher, 75% or higher, 80% or higher, 85% or higher, 90% or higher, 95% or higher, 98% or higher, or 99% or higher identity to the amino acid sequence of the herbicide-tolerant PPO protein and retains a biological activity equivalent to the herbicide-tolerant PPO protein variant. Such protein homologues may comprise an active site equivalent to that of a targeted protein. Such homology comparison may be conducted or with the aid of readily available comparison programs. The homology between two or more sequences can be calculated as a percentage (%) using an online available analysis program. The sequence alignment for sequence comparison may be conducted by any conventional method known in the relevant art, and for example, the conventional method may include, but not be limited thereto, GAP, BESTFIT, BLAST, and Clustal Omega.

The herbicide-tolerant PPO protein or its variant may be obtained by extracting from nature and purifying by methods well known in the art. Otherwise, it may be obtained as a recombinant protein using a gene recombination technology. In case of using a gene recombination technology, it may be obtained by a process of collecting herbicide-tolerant PPO protein or its variant from a host cell, after introducing a nucleic acid encoding the herbicide-tolerant PPO protein or its variant into an appropriate expression vector, and transforming a host cell with the vector in order to express a targeted protein. After the protein is expressed in a selected host cell, general biochemical separation techniques, for example, treatment with a protein precipitating agent (salting out), centrifugation, ultrasonic disruption, ultrafiltration, dialysis, chromatography such as molecular sieve chromatography (gel filtration), adsorption chromatography, ion exchange chromatography, affinity chromatography and the like may be used for the isolation and purification thereof, and in order to separate the protein with a high purity, these methods may be used in combination.

The herbicide-tolerant PPO nucleic acid molecule (polynucleotide encoding the PPO protein or its variant) may be isolated or prepared using standard molecular biological techniques, for example, a chemical synthesis or recombination method, or

commercially available one may be used.

In a specific embodiment, the PPO proteins were found to exhibit a broad herbicide tolerance against representative 9 families of PPO inhibiting herbicides classified according to their chemical structures in an herbicide tolerance test system using PPO-deficient *E. coli* BT3(Δ PPO). It was also found that they may be also expressed in the chloroplast of a plant by using a transit peptide (TP). Further, it was found that the PPO proteins may be also expressed in *A. thaliana* ecotype Columbia by a plant expression vector. Even though the transformed plants are treated with PPO inhibiting herbicides, germination and growth of the plants are observed. Furthermore, inheritance of the above herbicide-tolerant traits to the next generation was confirmed by an inheritance study.

Therefore, the PPO protein and its variants provided herein may be introduced into a plant or an alga, thereby being used for enhancement of the herbicide tolerance of the plant or an alga.

The herbicide herein refers to an active ingredient that kills, controls, or otherwise adversely modifies the growth of plants or algae. In addition, the herbicide tolerance or herbicide tolerance means that even after treatment of a herbicide which normally kills a normal or wild-type plant or normally inhibits growth thereof, inhibition of the plant growth is weakened or eliminated, compared to that of the normal or wild-type plant, and therefore, the plant continues to grow. The herbicide includes a herbicide inhibiting protoporphyrinogen oxidase (PPO) of a plant or an alga. Such PPO inhibiting herbicide may be classified into pyrimidinediones, diphenyl-ethers, phenylpyrazoles, N-phenylphthalimides, thiadiazoles, oxadiazoles, triazolinones, oxazolidinediones, and other herbicides according to their chemical structures.

As a specific embodiment, the pyrimidinediones herbicide includes butafenacil, saflufenacil, benzfendizone, and tiafenacil, but is not limited thereto.

The diphenyl-ethers herbicide includes fomesafen, oxyfluorfen, aclonifen, acifluorfen, bifenoxy, ethoxyfen, lactofen, chlormethoxyfen, chlorintofen, fluoroglycofen-ethyl and halosafen, but not limited thereto.

The phenylpyrazoles herbicide includes pyraflufen-ethyl and fluazolate, but not limited thereto.

The phenylphthalimides herbicide includes flumioxazin, cinidon-ethyl and flumiclorac-pentyl, but not limited thereto.

- 5 The phenylesters herbicide includes phenopylate (2,4-dichlorophenyl 1-pyrrolidinecarboxylate) and carbamate analogues of phenopylate (for example, O-phenylpyrrolidino- and piperidinocarbamate analoges (refer to“Ujjana B. Nandihalli, Mary V. Duke, Stephen O. Duke, Relationships between molecular properties and biological activities of O-phenyl pyrrolidino- and piperidinocarbamate herbicides., J. Agric. Food Chem., 1992, 40(10):1993-2000”), etc., but not limited thereto. In one embodiment, the carbamate analogue of phenopylate may be one or more selected from the group consisting of pyrrolidine-1-carboxylic acid phenyl ester (CAS No. 55379-71-0), 1-pyrrolidinecarboxylic acid, 2-chlorophenyl ester (CAS No. 143121-06-6), 4-chlorophenyl pyrrolidine-1-carboxylate (CAS No. 1759-02-0), carbamic acid, diethyl-, 15 2,4-dichloro-5-(2-propynyloxy)phenyl ester (9CI) (CAS No. 143121-07-7), 1-pyrrolidinecarboxylic acid, 2,4-dichloro-5-hydroxyphenyl ester (CAS No. 143121-08-8), 2,4-dichloro-5-(methoxycarbonyl)phenyl pyrrolidine-1-carboxylate (CAS No. 133636-94-9), 2,4-dichloro-5-[(propan-2-yloxy)carbonyl]phenyl pyrrolidine-1-carboxylate (CAS No. 133636-96-1), 1-piperidinecarboxylic acid, 2,4-dichloro-5-(2-propynyloxy)phenyl ester (CAS No. 87374-78-5), 2,4-dichloro-5-(prop-2-yn-1-yloxy)phenyl pyrrolidine-1-carboxylate (CAS No. 87365-63-7), 2,4-dichloro-5-(prop-2-yn-1-yloxy)phenyl 4,4-difluoropiperidine-1-carboxylate (CAS No. 138926-22-4), 1-pyrrolidinecarboxylic acid, 3,3-difluoro-, 2,4-dichloro-5-(2-propyn-1-yloxy)phenyl ester (CAS No. 143121-10-2), 4-chloro-2-fluoro-5-[(propan-2-yloxy)carbonyl]phenyl 25 pyrrolidine-1-carboxylate (CAS No. 133636-98-3), etc.

The thiadiazoles herbicide includes fluthiacet and thidiazimin, but not limited thereto.

The oxadiazoles herbicide includes oxadiargyl and oxadiazon, but not limited thereto.

- 30 The triazolinones herbicide includes carfentrazone, sulfentrazone and

azafenidin, but not limited thereto.

The oxazolidinediones herbicide includes pentoxazone, but not limited thereto.

The other herbicide includes pyraclonil, flufenpyr-ethyl and proflumizone, but not limited thereto.

5 The herbicide-tolerant PPO gene provided herein may be introduced into a plant or an alga by various methods known in the art, and preferably, by using an expression vector for plant or alga transformation.

 In case of plant transformation, an appropriate promoter which may be included in the vector may be any promoter generally used in the art for introduction of the gene
10 into the plant. For example, the promoter may include an SP6 promoter, a T7 promoter, a T3 promoter, a PM promoter, a maize ubiquitin promoter, a cauliflower mosaic virus (CaMV) 35S promoter, a nopaline synthase (nos) promoter, a figwort mosaic virus 35S promoter, a sugarcane bacilliform virus promoter, a commelina yellow mottle virus promoter, a light-inducible promoter from the small subunit of
15 ribulose-1,5-bisphosphate carboxylase (ssRuBisCO), a rice cytosolic triosephosphate isomerase (TPI) promoter, an adenine phosphoribosyltransferase (APRT) promoter of Arabidopsis, an octopine synthase promoter, and a BCB (blue copper binding protein) promoter, but is not limited thereto.

 Further, the vector may include a poly A signal sequence causing
20 polyadenylation of 3'-terminus, and for example, it may include NOS 3'-end derived from a nopaline synthase gene of *Agrobacterium tumefaciens*, an octopine synthase terminator derived from an octopine synthase gene of *Agrobacterium tumefaciens*, 3'-end of protease inhibitor I or II gene of tomato or potato, a CaMV 35S terminator, a rice α -amylase terminator RAmy1 A, and a phaseoline terminator, but is not limited thereto.

25 In addition, chloroplast-specific promoter, nucleus promoter, constitutive promoter, or inducible promoter may be used for introduction of the gene into the algae as a promoter. The herbicide-tolerant PPO gene or its variant provided herein may be designed in order to operationally link to 5' UTR or 3' UTR, thereby expressing function in nucleus of algae. In addition, the vector may further comprise a
30 transcriptional regulatory sequence which is appropriate to transformation of algae. A

recombinant gene conferring herbicide tolerance may be integrated to genome of nucleus or genome of chloroplast in a host alga, but not limited thereto.

In addition, in the vector, a transit peptide required for targeting to chloroplasts may be linked to 5'-end of the PPO gene in order to express the herbicide-tolerant PPO gene in the chloroplasts.

In addition, optionally, the vector may further include a gene encoding selectable marker as a reporter molecule, and example of the selectable marker may include antibiotics (e.g., neomycin, carbenicillin, kanamycin, spectinomycin, hygromycin, bleomycin, chloramphenicol, etc.) or herbicide (glyphosate, glufosinate, phosphinothricin, etc.)-tolerant genes, but is not limited thereto.

Further, the recombinant vector for plant expression may include an *Agrobacterium* binary vector, a cointegration vector, or a general vector which has no T-DNA region but is designed to be expressed in the plant. Of them, the binary vector refers to a vector containing two separate vector systems harboring one plasmid responsible for migration consisting of left border (LB) and right border (RB) in Ti (tumor inducible) plasmid, and the other plasmid for target gene-transferring, and the vector may include a promoter region and a polyadenylation signal sequence for expression in plants.

When the binary vector or cointegration vector is used, a strain for transformation of the recombinant vector into the plant is preferably *Agrobacterium* (*Agrobacterium*-mediated transformation). In this regard, *Agrobacterium tumefaciens* or *Agrobacterium rhizogenes* may be used. In addition, when the vector having no T-DNA region is used, electroporation, particle bombardment, polyethylene glycol-mediated uptake, etc. may be used for introduction of the recombinant plasmid into the plant.

The plant transformed with the gene by the above method may be re-differentiated into a plant through callus induction, rhizogenesis, and soil acclimatization using a standard technique known in the art.

The plant subjected to transformation herein is understood by a meaning including a plant cell (containing a suspension-cultured cell), a protoplast, a callus, a

hypocotyl, a seed, a cotyledon, a shoot as well as a mature plant.

Further, the scope of the transformant includes a transformant introduced with the gene as well as a clone or progeny thereof (T₁ generation, T₂ generation, T₃ generation, T₄ generation, T₅ generation, or any subsequent generations). For example, the transformed plant also includes a plant having the inherited herbicide tolerance traits as sexual and asexual progeny of the plant transformed with the gene provided herein. The scope of the present invention also includes all mutants and variants showing the characteristics of the initial transformed plant, together with all hybridization and fusion products of the plant transformed with the gene provided herein. Furthermore, the scope of the present invention also includes a part of the plant, such as a seed, a flower, a stem, a fruit, a leaf, a root, a tuber, and/or a tuberous root, which is originated from a transformed plant which is transformed in advance by the method of the present invention, or a progeny thereof, and is composed of at least a part of the transformed cells.

The plant, to which the present invention is applied, is not particularly limited to, but includes monocotyledonous or dicotyledonous plants. Further, the plant includes herbaceous plants or woody plants. The monocotyledonous plant may include plants belonging to the family Alismataceae, Hydrocharitaceae, Juncaginaceae, Scheuchzeriaceae, Potamogetonaceae, Najadaceae, Zosteraceae, Liliaceae, Haemodoraceae, Agavaceae, Amaryllidaceae, Dioscoreaceae, Pontederiaceae, Iridaceae, Burmanniaceae, Juncaceae, Commelinaceae, Eriocaulaceae, Gramineae (Poaceae), Araceae, Lemnaceae, Sparganiaceae, Typhaceae, Cyperaceae, Musaceae, Zingiberaceae, Cannaceae, Orchidaceae, but not limited thereto.

The dicotyledonous plant may include plants belonging to the family Diapensiaceae, Clethraceae, Pyrolaceae, Ericaceae, Myrsinaceae, Primulaceae, Plumbaginaceae, Ebenaceae, Styracaceae, Symplocaceae, Symplocaceae, Oleaceae, Loganiaceae, Gentianaceae, Menyanthaceae, Apocynaceae, Asclepiadaceae, Rubiaceae, Polemoniaceae, Convolvulaceae, Boraginaceae, Verbenaceae, Labiatae, Solanaceae, Scrophulariaceae, Bignoniaceae, Acanthaceae, Pedaliaceae, Orobanchaceae, Gesneriaceae, Lentibulariaceae, Phrymaceae, Plantaginaceae, Caprifoliaceae,

- Adoxaceae, Valerianaceae, Dipsacaceae, Campanulaceae, Compositae, Myricaceae, Juglandaceae, Salicaceae, Betulaceae, Fagaceae, Ulmaceae, Moraceae, Urticaceae, Santalaceae, Loranthaceae, Polygonaceae, Phytolaccaceae, Nyctaginaceae, Aizoaceae, Portulacaceae, Caryophyllaceae, Chenopodiaceae, Amaranthaceae, Cactaceae,
- 5 Magnoliaceae, Illiciaceae, Lauraceae, Cercidiphyllaceae, Ranunculaceae, Berberidaceae, Lardizabalaceae, Menispermaceae, Nymphaeaceae, Ceratophyllaceae, Cabombaceae, Saururaceae, Piperaceae, Chloranthaceae, Aristolochiaceae, Actinidiaceae, Theaceae, Guttiferae, Droseraceae, Papaveraceae, Capparidaceae, Cruciferae, Platanaceae, Hamamelidaceae, Crassulaceae, Saxifragaceae, Eucommiaceae, Pittosporaceae,
- 10 Rosaceae, Leguminosae, Oxalidaceae, Geraniaceae, Tropaeolaceae, Zygophyllaceae, Linaceae, Euphorbiaceae, Callitrichaceae, Rutaceae, Simaroubaceae, Meliaceae, Polygalaceae, Anacardiaceae, Aceraceae, Sapindaceae, Hippocastanaceae, Sabiaceae, Balsaminaceae, Aquifoliaceae, Celastraceae, Staphyleaceae, Buxaceae, Empetraceae, Rhamnaceae, Vitaceae, Elaeocarpaceae, Tiliaceae, Malvaceae, Sterculiaceae,
- 15 Thymelaeaceae, Elaeagnaceae, Flacourtiaceae, Violaceae, Passifloraceae, Tamaricaceae, Elatinaceae, Begoniaceae, Cucurbitaceae, Lythraceae, Punicaceae, Onagraceae, Haloragaceae, Alangiaceae, Cornaceae, Araliaceae, Umbelliferae (Apiaceae), but not limited thereto.

- In a specific embodiment, the plant may be one or more selected from the group
- 20 consisting of food crops such as rice, wheat, barley, corn, soybean, potato, red bean, oat, and sorghum; vegetable crops such as Chinese cabbage, radish, red pepper, strawberry, tomato, watermelon, cucumber, cabbage, oriental melon, pumpkin, welsh anion, anion, and carrot; crops for special use such as ginseng, tobacco, cotton, silage, forage, sesame, sugar cane, sugar beet, *Perilla* sp., peanut, rape, grass, and castor-oil plant; fruit
- 25 trees such as apple tree, pear tree, jujube tree, peach tree, kiwi fruit tree, grape tree, citrus fruit tree, persimmon tree, plum tree, apricot tree and banana tree; woody plants such as pine, palm oil, and eucalyptus; flowering crops such as rose, gladiolus, gerbera, carnation, chrysanthemum, lily and tulip; and fodder crops such as ryegrass, red clover, orchardgrass, alfalfa, tall fescue and perennial ryegrass, but is not limited thereto. As a
- 30 specific embodiment, the plant may be one or more selected from the group consisting

of dicotyledonous plants such as *Arabidopsis thaliana*, potato, eggplant, tobacco, red pepper, tomato, burdock, crown daisy, lettuce, balloon flower, spinach, chard, sweet potato, celery, carrot, water dropwort, parsley, Chinese cabbage, cabbage, radish, watermelon, oriental melon, cucumber, pumpkin, gourd, strawberry, soybean, mung
 5 bean, kidney bean, and pea; and monocotyledonous plants such as rice, wheat, barley, corn, sorghum, etc., but are not limited thereto.

The alga, to which the present invention is applied, is not particularly limited to, but includes Prokaryotic algae or Eukaryotic algae. For example, the alga may be cyanobacteria, green algae, red algae, brown algae, macroalgae, or microalgae.

10 The cyanobacteria includes Chroococcales phylum (for example, *Aphanocapsa*, *Aphanothece*, *Chamaesiphon*, *Chondrocystis*, *Chroococcus*, *Chroogloeocystis*, *Crocospaera*, *Cyanobacterium*, *Cyanobium*, *Cyanodictyon*, *Cyanosarcina*, *Cyanothece*, *Dactylococcopsis*, *Gloeocapsa*, *Gloeothece*, *Halothece*, *Johannesbaptistia*, *Merismopedia*, *Microcystis*, *Radiocystis*, *Rhabdoderma*, *Snowella*, *Synechococcus*,
 15 *Synechocystis*, *Thermosynechococcus*, *Woronichinia*), *Gloeobacteria* phylum, *Nostocales* phylum (for example, *Microchaetaceae*, *Nostocaceae*, *Rivulariaceae*, *Scytonemataceae*), *Oscillatoriales* phylum (for example, *Arthronema*, *Arthrospira*, *Blennothrix*, *Crinalium*, *Geitlerinema*, *Halomicronema*, *Halospirulina*, *Hydrocoleum*, *Jaaginema*, *Katagnymene*, *Komvophoron*, *Leptolyngbya*, *Limnothrix*, *Lyngbya*,
 20 *Microcoleus*, *Oscillatoria*, *Phormidium*, *Planktothricoides*, *Planktothrix*, *Plectonema*, *Pseudanabaena*, *Pseudophormidium*, *Schizothrix*, *Spirulina*, *Starria*, *Symploca*, *Trichodesmium*, *Tychonema*), *Pleurocapsales* phylum (for example, *Chroococcidiopsis*, *Dermocarpa*, *Dermocarpella*, *Myxosarcina*, *Pleurocapsa*, *Solentia*, *Stanieria*, *Xenococcus*), *Prochlorales* phylum, or *Stigonematales* phylum (for example, *Capsosira*,
 25 *Chlorogloeopsis*, *Fischerella*, *Hapalosiphon*, *Mastigocladopsis*, *Mastigocladus*, *Nostochopsis*, *Stigonema*, *Symphyonema*, *Symphonemopsis*, *Umezakia*, *Westiellopsis*), etc.

As another example of algae, Chlorophyta, *Chlamydomonas*, Volvocales, *Dunaliella*, *Scenedesmus*, *Chlorella*, or *Hematococcm* may be exemplified.

30 As other example of algae, *Phaeodactylum tricornutum*, *Amphiprora hyaline*,

Amphora spp., Chaetoceros muelleri, Navicula saprophila, Nitzschia communis, Scenedesmus dimorphus, Scenedesmus obliquus, Tetrastelmis suecica, Chlamydomonas reinhardtii, Chlorella vulgaris, Haematococcus pluvialis, Neochloris oleoabundans, Synechococcus elongatus, Botryococcus braunii, Gloeobacter violaceus, Synechocystis, 5 Thermosynechococcus elongatus, Nannochloropsis oculata, Nannochloropsis salina, Nannochloropsis gaditana, Isochrysis galbana, Botryococcus sudeticus, Euglena gracilis, Neochloris oleoabundans, Nitzschia palea, Pleurochrysis carterae, Tetrastelmis chuii, Pavlova spp., Aphanocapsa spp., Synechosystis spp., Nannochloris spp., etc. may be exemplified. However, it is not limited to kinds listed above, and algae belonging to 10 other various genus and family may be comprised.

The plant or alga introduced with the herbicide-tolerant PPO or its variant provided herein may exhibit tolerance against two or more of PPO inhibiting herbicides.

Therefore, the technology provided herein may be used to control weeds or remove undesired aquatic organisms by using two or more kinds of PPO inhibiting 15 herbicides sequentially or simultaneously.

One embodiment provides a method of controlling weeds in a cropland, comprising a step of providing the cropland with a plant comprising the herbicide-tolerant PPO protein, its variant, or a gene encoding thereof described above, and a step of applying an effective dosage of protoporphyrinogen oxidase-inhibiting herbicide to 20 the cropland.

Another embodiment provides a method of removing an undesired aquatic organism from a culture medium, comprising a step of providing a culture medium with algae comprising the herbicide-tolerant PPO protein, its variant, or a gene encoding thereof described above, and a step of applying an effective dosage of 25 protoporphyrinogen oxidase-inhibiting herbicide to the culture medium.

In addition, the herbicide-tolerant PPO protein, its variant, or a gene encoding thereof provided herein may be used in combination of a second herbicide-tolerant polypeptide or a gene encoding thereof.

Therefore, the plant or alga introduced with the herbicide-tolerant PPO 30 provided herein may exhibit tolerance against two or more of herbicides which are

different from each other in mechanism of action. In the present invention, two or more of different herbicides including the PPO inhibiting herbicide, which are different from each other in mechanism of action, may be used sequentially or simultaneously, thereby controlling weeds and/or removing undesired aquatic organisms. Hereinafter, the herbicide which is different from the PPO inhibiting herbicide in the mechanism of action is called "second herbicide".

One embodiment provides a composition for conferring or enhancing herbicide tolerance of plants or algae, comprising the above-described herbicide-tolerant PPO protein, its variant, or a gene encoding thereof; and the second herbicide-tolerant polypeptide or a gene encoding thereof.

Another embodiment provides a transformant having herbicide tolerance of plants or algae, or a clone or progeny thereof, comprising the above-described herbicide-tolerant PPO protein, its variant, or a gene encoding thereof; and the second herbicide-tolerant polypeptide or a gene encoding thereof.

Other embodiment provides a method of preparing plants or algae having herbicide tolerance, comprising a step of transforming algae, or plant cell, protoplast, callus, hypocotyl, seed, cotyledon, shoot, or whole plant with the above-described herbicide-tolerant PPO protein, its variant, or a gene encoding thereof; and the second herbicide-tolerant polypeptide or a gene encoding thereof.

Other embodiment provides a method of controlling weeds in a cropland, comprising a step of providing the cropland with a plant comprising the above-described herbicide-tolerant PPO protein, its variant, or a gene encoding thereof; and the second herbicide-tolerant polypeptide or a gene encoding thereof, and a step of applying an effective dosage of protoporphyrinogen oxidase-inhibiting herbicide to the cropland.

Other embodiment provides a method of removing an undesired aquatic organism from a culture medium, comprising a step of providing a culture medium with algae comprising the herbicide-tolerant PPO protein, its variant, or a gene encoding thereof; and the second herbicide-tolerant polypeptide or a gene encoding thereof, and a step of applying an effective dosage of protoporphyrinogen oxidase-inhibiting herbicide to the culture medium.

For example, the plant or alga further includes the second herbicide-tolerant polypeptide or a gene encoding thereof, thereby having novel and/or enhanced tolerance against the second herbicide.

For example, the second herbicide may include cell division-inhibiting herbicides, photosynthesis-inhibiting herbicides, amino acid synthesis-inhibiting herbicides, plastid-inhibiting herbicides, cell membrane-inhibiting herbicides, and/or any combinations thereof, but is not limited thereto. The second herbicide may be exemplified by glyphosate, glufosinate, dicamba, 2,4-D (2,4-dichlorophenoxyacetic acid), ALS (acetolactate synthase)-inhibiting herbicides (for example, imidazolidinone, sulfonylurea, triazole pyrimidine, sulphonanilide, pyrimidine thiobenzoate, etc.), photosystem II-inhibiting herbicides, phenylurea-based herbicides, plastid-inhibiting herbicides, bromoxynil-based herbicides, and/or any combinations thereof, but is not limited thereto.

For example, the second herbicide-tolerant polypeptide may be exemplified as one or more selected from the group consisting of glyphosate herbicide-tolerant EPSPS (glyphosate tolerant 5-enolpyruvylshikimate-3-phosphate synthase), GOX (glyphosate oxidase), GAT (glyphosate-N-acetyltransferase) or glyphosate decarboxylase; glufosinate herbicide-tolerant PAT (phosphinothricin-N-acetyltransferase); dicamba herbicide-tolerant DMO (dicamba monooxygenase); 2,4-D herbicide-tolerant 2,4-D monooxygenase or AAD (aryloxyalkanoate Dioxygenase); ALS-inhibiting sulfonylurea-based herbicide-tolerant ALS (acetolactate Synthase), AHAS (acetohydroxyacid synthase), or AtAHASL (acetohydroxyacid synthase Large Subunit); photosystem II-inhibiting herbicide-tolerant photosystem II protein D1; phenylurea-based herbicide-tolerant cytochrome P450; plastid-inhibiting herbicide-tolerant HPPD (hydroxylphenylpyruvate dioxygenase); bromoxynil herbicide-tolerant nitrilase; and any combinations thereof, but is not limited thereto.

Further, the gene encoding the second herbicide-tolerant polypeptide may be exemplified as one or more selected from the group consisting of glyphosate herbicide-tolerant cp4 epsps, epsps (AG), mepsps, 2mepsps, goxv247, gat4601 or gat4621 gene; glufosinate herbicide-tolerant bar, pat or pat(SYN) gene; dicamba herbicide-tolerant

dmo gene; 2,4-D herbicide-tolerant AAD-1 or AAD-12 gene; ALS-inhibiting sulfonylurea-based herbicide-tolerant ALS, GM-HRA, S4-HRA, ZM-HRA, Csr1, Csr1-1, Csr1-2, SurA or SurB; photosystem II-inhibiting herbicide-tolerant psba gene; phenylurea herbicide-tolerant CYP76B1 gene; isoxaflutole herbicide-tolerant HPPDPF
 5 W336 gene; bromoxynil herbicide-tolerant bxn gene; and any combinations thereof, but is not limited thereto.

【Advantageous Effects】

A variant of herbicide-tolerant PPO protein or a gene encoding thereof provided
 10 herein is applied to plants or algae, thereby conferring and/or enhancing more excellent herbicide tolerance traits, and the selective control is performed using herbicides, thereby economically controlling weeds or removing aquatic organisms.

【Description of Drawings】

15 FIG. 1 is the map of pACBB vector.

FIG. 2 shows cell growth level after tiafenacil treatment at a concentration of 0 μ M (micromole), 100 μ M, or 400 μ M, of PPO-deficient BT3 *E. coli* transformed with pACBB-eGFP vector control (V), PPO-susceptible *Arabidopsis thaliana* (*A. thaliana*) PPO1 gene (AtPPO1 WT), PPO-tolerant *A. thaliana* PPO1 mutant gene (AtPPO1
 20 SLYM), CyPPO10 gene (Cy10 WT), and CyPPO13 gene (Cy13 WT), respectively.

FIG. 3 is the map of pET303-CT-His vector.

FIG. 4 shows the schematic diagram of a recombinant vector for a fusion protein wherein MBP (maltose binding protein) and PPO protein are fused.

FIG. 5 is the map of pMAL-c2X vector.

25 FIG. 6 is a schematic diagram exemplarily showing the structure of binary vector for plant transformation of CyPPO genes.

FIG. 7 is the result of western blotting showing the expression level of CyPPO variant proteins in T₂ *A. thaliana* transformed with CyPPO10 variant (F360I variant or F360M variant) or CyPPO13 variant (F373M variant) gene.

30 FIG. 8 shows the injury level of *A. thaliana* transformant (T₃) transformed with

CyPPO10 or CyPPO13 wild type gene when treated with 1 μ M of tiafenacil. Col-O means non-transgenic *A. thaliana*.

FIG. 9 shows the injury level of *A. thaliana* transformant (T₂) transformed with a genes encoding a CyPPO10 variant (F360C, F360I, F360L, F360M, F360V, F360T, A167C, A167L, A167L+F360M, or A167C+F360I) when treated with tiafenacil at a concentration of 1 μ M, 5 μ M, or 25 μ M.

FIG. 10 shows the injury level of *A. thaliana* transformant (T₂) transformed with a gene encoding a CyPPO13 variant (A177C, F373C, F373I, F373M, A177L+F373L, or A177L+F373I) when treated with tiafenacil at a concentration of 1 μ M or 10 μ M.

FIG. 11 shows cell growth level of PPO-deficient BT3 *E. coli* (Δ PPO) transformants transformed with CyPPO10 wild type gene (indicated as Cy10 WT), or various CyPPO10 mutant genes, when treated with tiafenacil at a concentration of 0 μ M, 5 μ M, 25 μ M, 50 μ M, 100 μ M, and 200 μ M, respectively.

FIG. 12 shows cell growth level of PPO-deficient BT3 (Δ PPO) transformants transformed with Cy10 WT or various CyPPO10 mutant genes, when treated with saflufenacil at a concentration of 0 μ M, 5 μ M, 25 μ M, 50 μ M, 100 μ M, and 200 μ M, respectively.

FIG. 13 shows cell growth level of PPO-deficient BT3 (Δ PPO) transformants transformed with Cy10 WT or various CyPPO10 mutant genes, when treated with fomesafen at a concentration of 0 μ M, 5 μ M, 25 μ M, 50 μ M, 100 μ M and 200 μ M, respectively.

FIG. 14 shows cell growth level of PPO-deficient BT3 (Δ PPO) transformants transformed with Cy10 WT or various CyPPO10 mutant genes, when treated with acifluorfen at a concentration of 0 μ M, 5 μ M, 25 μ M, 50 μ M, 100 μ M and 200 μ M, respectively.

FIG. 15 shows cell growth level of PPO-deficient BT3 (Δ PPO) transformants transformed with Cy10 WT or various CyPPO10 mutant genes, when treated with flumioxazin at a concentration of 0 μ M, 5 μ M, 25 μ M, 50 μ M, 100 μ M and 200 μ M, respectively.

FIG. 16 shows cell growth level of PPO-deficient BT3 (Δ PPO) transformants transformed with Cy10 WT or various CyPPO10 mutant genes, when treated with sulfentrazone at a concentration of 0 μ M, 5 μ M, 25 μ M, 50 μ M, 100 μ M and 200 μ M, respectively.

5 FIG. 17 shows cell growth level of PPO-deficient BT3 (Δ PPO) transformants transformed with Cy10 WT or various CyPPO10 mutant genes, when treated with pentoxazone at a concentration of 0 μ M, 5 μ M, 25 μ M, 50 μ M, 100 μ M and 200 μ M, respectively.

FIG. 18 shows cell growth level of PPO-deficient BT3 (Δ PPO) transformants
10 transformed with Cy10 WT or various CyPPO10 mutant genes, when treated with pyraflufen-ethyl at a concentration of 0 μ M, 5 μ M, 25 μ M, 50 μ M, 100 μ M and 200 μ M, respectively.

FIG. 19 shows cell growth level of PPO-deficient BT3 (Δ PPO) transformants transformed with Cy10 WT or various CyPPO10 mutant genes, when treated with
15 pyraclozil at a concentration of 0 μ M, 5 μ M, 25 μ M, 50 μ M, 100 μ M and 200 μ M, respectively.

FIG. 20 shows cell growth level of PPO-deficient BT3 (Δ PPO) transformants transformed with CyPPO13 wild type gene (indicated as Cy13 WT), or various CyPPO13 mutant genes, when treated with tiafenacil at a concentration of 0 μ M, 5 μ M,
20 25 μ M, and 50 μ M, respectively.

FIG. 21 shows cell growth level of PPO-deficient BT3 (Δ PPO) transformants transformed with Cy13 WT or various CyPPO13 mutant genes, when treated with saflufenacil at a concentration of 0 μ M, 5 μ M, 25 μ M, and 50 μ M, respectively.

FIG. 22 shows cell growth level of PPO-deficient BT3 (Δ PPO) transformants
25 transformed with Cy13 WT or various CyPPO13 mutant genes, when treated with fomesafen at a concentration of 0 μ M, 5 μ M, 25 μ M, 50 μ M, 100 μ M and 200 μ M, respectively.

FIG. 23 shows cell growth level of PPO-deficient BT3 (Δ PPO) transformants transformed with Cy13 WT or various CyPPO13 mutant genes, when treated with
30 acifluorfen at a concentration of 0 μ M, 5 μ M, 25 μ M, 50 μ M, 100 μ M and 200 μ M,

respectively.

FIG. 24 shows cell growth level of PPO-deficient BT3 (Δ PPO) transformants transformed with Cy13 WT or various CyPPO13 mutant genes, when treated with flumioxazin at a concentration of 0 μ M, 5 μ M, 25 μ M, and 50 μ M, respectively.

5 FIG. 25 shows cell growth level of PPO-deficient BT3 (Δ PPO) transformants transformed with Cy13 WT or various CyPPO13 mutant genes, when treated with sulfentrazone at a concentration of 0 μ M, 5 μ M, 25 μ M, 50 μ M, 100 μ M and 200 μ M, respectively.

10 FIG. 26 shows cell growth level of PPO-deficient BT3 (Δ PPO) transformants transformed with Cy13 WT or various CyPPO13 mutant genes, when treated with pentoxazone at a concentration of 0 μ M, 5 μ M, 25 μ M, 50 μ M, 100 μ M and 200 μ M, respectively.

15 FIG. 27 shows cell growth level of PPO-deficient BT3 (Δ PPO) transformants transformed with Cy13 WT or various CyPPO13 mutant genes, when treated with pyraflufen-ethyl at a concentration of 0 μ M, 5 μ M, 25 μ M, 50 μ M, 100 μ M and 200 μ M, respectively.

20 FIG. 28 shows cell growth level of PPO-deficient BT3 (Δ PPO) transformants transformed with Cy13 WT or various CyPPO13 mutant genes, when treated with pyraclostrobin at a concentration of 0 μ M, 5 μ M, 25 μ M, 50 μ M, 100 μ M and 200 μ M, respectively.

FIG. 29 shows cell growth level of PPO-deficient BT3 (Δ PPO) transformants transformed with Cy13 WT or various CyPPO13 mutant genes, when treated with oxadiazon at a concentration of 0 μ M, 5 μ M, 25 μ M, 50 μ M, 100 μ M and 200 μ M, respectively.

25 FIG. 30 is the map of pET29b vector.

FIGS. 31a to 31c show the results of seed germination of *A. thaliana* transformant transformed with CyPPO10 or CyPPO13 wild type gene or a mutant gene thereof, at 7th days after sowing on 1/2 MS medium containing various herbicides. Col-0 means non-transgenic *A. thaliana*.

30 FIG. 32 shows the injury level of *A. thaliana* transformants (T_3) transformed

with a gene encoding a CyPPO10 variant (F360I, F360L, F360M, A167C+F360I, A167C+F360M, or V305M+F360M) when treated with 25 μ M of tiafenacil or 100 μ M of saflufenacil. Col-0 means non-transgenic *A. thaliana*.

FIG. 33a shows the injury level of *A. thaliana* transformants (T₃) transformed with a gene encoding a CyPPO10 variant (F360I or A167L+F360M), when treated with tiafenacil, saflufenacil, flumioxazin, or sulfentrazone at a concentration of 50 μ M, respectively.

FIG. 33b shows the injury level of *A. thaliana* transformants (T₃) transformed with a gene encoding a CyPPO13 variant (A177L+F373L or A177L+F373I) when treated with saflufenacil, tiafenacil, flumioxazin, sulfentrazone, oxyfluorfen, or pyraclonil at a concentration of 50 μ M, respectively. Col-0 means non-transgenic *A. thaliana*.

FIG. 34 shows the injury level of *A. thaliana* transformants (T₄) transformed with CyPPO10 F360I when treated with 15 μ M of tiafenacil or 150 μ M of saflufenacil.

FIG. 35 shows the injury level of *A. thaliana* transformants (T₅) transformed with CyPPO10 F360I when treated with 15 μ M of tiafenacil or 150 μ M of saflufenacil. Col-0 means non-transgenic *A. thaliana*.

FIG. 36 is a western blot result showing expression of CyPPO10 F360I protein in *A. thaliana* transformants (T₄ or T₅) transformed with CyPPO10 F360I.

FIG. 37 is the map of pB2GW7.0 binary vector.

FIG. 38 shows the injury level in leaves of T₀ soybean transformed with CyPPO10 A167L+F360M mutant gene when treated with 5 μ M or 15 μ M of tiafenacil. Kwangan soybean means non-transgenic soybean (cultivar).

FIG. 39 provides southern blotting results showing the presence of transgene in CyPPO10 A167L+F360M transformed soybean.

FIG. 40 shows herbicide tolerance of the T1 transgenic soybeans (CyPPO10 A167L+F360M) 5 days after spray treatment with 25 μ M tiafenacil or 150 μ M saflufenacil. Kwangan soybean means non-transgenic soybean (cultivar).

FIG. 41 shows cell growth level of BT3 (Δ PPO) *E. coli* transformed with a mutant gene of CyPPO10 when cultured in herbicide-containing media.

【Mode for Invention】

Hereinafter, the present invention will be described in detail by Examples. However, the following Examples are for illustrative purposes only, and the invention is not intended to be limited by the following Examples.

Example 1. Isolation of PPO gene from prokaryote

PPO genes were collected using Genbank data base of *Thermosynechococcus elongatus* BP-1 and *Synechococcus* sp. JA-3-3Ab, and the PPO genes were synthesized with codon-optimized information for efficient herbicide resistance screening in BT3 *E. coli*. The synthesized PPO genes were amplified under the following conditions using primers of Table 1 to clone on pACBB vector.

Fifty microliters (50 μ l) of PCR reaction mixture was prepared by mixing 1 μ l of template (synthetic DNA of each gene), 5 μ l of 10X buffer, 1 μ l of dNTP mixture (each 10 mM), 1 μ l of a forward primer (refer to Table 1; 10 μ M), 1 μ l of a reverse primer (refer to Table 1; 10 μ M), 40 μ l of DDW, and 1 μ l of Pfu-X (Solgent, 2.5 unit/ μ l), and amplification was performed under conditions of at 1 cycle of 94 °C for 4 minutes, 25 cycles of 94 °C for 30 seconds, 56 °C for 30 seconds and 72 °C for 1.5 minutes, and 1 cycle of 72 °C for 5 minutes.

PPO isolated from *Thermosynechococcus elongatus* BP-1 was designated as CyPPO10, and PPO isolated from *Synechococcus* sp. JA-3-3Ab strain was designated as CyPPO13, respectively.

【Table 1】

Strain	Primer	Sequence	SEQ ID NO:
<i>Thermosynechococcus elongatus</i>	CyPPO10_BamHI F	CCCCGGATCCATGATTGAAGTGGATGTG GC	8
	CyPPO10_XhoI R	CCCCCTCGAGTGATTGTCCACCAGCGA GGT	9

<i>Synechococcus</i> sp. JA-3-3Ab	CyPPO13_BamHI F	CCCCGGATCCATGAACCCTGCTACCCCT GA	10
	CyPPO13_XhoI R	CCCCCTCGAG CACCTGTGAT AACAACTGCT	11

Example 2. Herbicide tolerance by CyPPO10 and CyPPO13

The herbicide tolerance by CyPPO10 and CyPPO13 was tested using PPO-deficient *E. coli*.

5 After transforming PPO-deficient BT3 *E. coli* (Δ PPO) with CyPPO10 or CyPPO13, the transformed BT3 (Δ PPO) was cultured on LB agar plates containing PPO-inhibiting herbicide to examine the growth level of the transformed BT3 (Δ PPO). BT3 (Δ PPO) strain was obtained from Hokkaido University (Japan). The BT3 (Δ PPO) strain is deficient in hemG-type PPO and has kanamycin tolerance (refer to "Watanabe
10 et al., Dual targeting of spinach protoporphyrinogen oxidase II to mitochondria and chloroplasts by alternative use of two in-frame inhibition codons, JBC 2001 276(23):20474–20481; Che et al., Molecular Characterization and Subcellular Localization of Protoporphyrinogen Oxidase in Spinach Chloroplasts, Plant Physiol. 2000 Sep;124(1):59-70").

15 The specific test process was as follows:

CyPPO10 and CyPPO13 genes were cloned in pACBB vector (Plasmid #32551; Addgene; refer to FIG. 1).

Specifically, PCR products amplified in the Example 1 were treated with BamHI and XhoI restriction enzymes (New England Biolabs), and ligated with pACBB-
20 eGFP vector which was treated with the same restriction enzymes.

The treatment of restriction enzymes was conducted under the following conditions:

30 μ l (microliter) of PCR product, 0.5 μ l of BamHI and XhoI (New England Biolabs) respectively, 4 μ l of 10X buffer, and 5.5 μ l of water; Restriction enzyme
25 reaction 37 °C, 1hr

Ligation reaction was conducted under the following conditions:

0.5 µl of T4 DNA ligase (RBC), 1 µl of A buffer, 1 µl of B buffer, PCR products and vector which were treated with the restriction enzymes, total 10 µl; 22 °C, 30min.

The cloned plasmid was added to 100 µl of BT3 competent cell (Hokkaido University; Japan) respectively, thereby transforming by a heat shock method. The transformed *E. coli* with each PPO gene was cultured in LB (Luria-Bertani) agar media comprising Chloramphenicol (Duchefa).

For seed culture of *E. coli* transformed with respective genes, each single colony of *E. coli* transformant as provided above was cultured in 3 ml of LB broth containing chloramphenicol overnight (220 rpm, 37 °C), and 50 to 100 µl were subcultured in a new 3 ml of LB broth, and they were cultured until absorbance (OD₆₀₀) became 0.5 to 1, and they were diluted with LB broth to absorbance (OD₆₀₀) of 0.5. The diluted solution was serially diluted again 5 times by a factor of one tenth with LB broth. Thereafter, on the LB agar media (petri dish) containing tiafenacil at the concentration of 0 µM, 100 µM, and 400 µM, 10 µl of each diluted solution was dropped. The LB Agar media were incubated at 37 °C, under light condition, and level of inhibiting growth was observed after 16 to 20 hours of incubation.

For comparison, the same test was conducted using BT3 *E. coli* transformant transformed with pACBB-eGFP vector (Plasmid #32551; Addgene; refer to FIG. 1) (V; pACBB-eGFP vector); BT3 *E. coli* transformant transformed with the wild type *Arabidopsis thaliana* (*A. thaliana*) PPO1 gene (AtPPO1 WT, Wild type AtPPO1; PPO susceptible) (SEQ ID NO: 6); and BT3 *E. coli* transformant transformed with a *A. thaliana* mutant PPO1 gene encoding mutated AtPPO1 (AtPPO1 SLYM, SEQ ID NO: 7) amino acid substitutions of Y426M (the 426th amino acid residue, tyrosine, was substituted with methionine) and S305L (the 305th amino acid residue, serine, was substituted with leucine), based on the amino acid sequence of wild type AtPPO1 (SEQ ID NO: 5) (Li et al. Development of protoporphyrinogen oxidase as an efficient selection marker for agrobacterium tumefaciens-mediated transformation of maize. Plant physiol. 2003 133:736-747).

The obtained result was shown in FIG. 2. As shown in FIG. 2, on a medium

containing no herbicide (tiafenacil 0 μ M), the growth of BT3 transformant (V) transformed with pACBB-eGFP in which PPO gene was not introduced was not recovered, and the growth of BT3 transformants transformed with PPO susceptible *A. thaliana* PPO1 wild type gene (AtPPO1 WT), PPO tolerant *A. thaliana* PPO1 mutant gene (AtPPO1 SLYM), CyPPO10 gene (Cy10 WT), or CyPPO13 gene (Cy13 WT) was recovered, as each introduced gene functioned as the PPO enzyme in BT3. Such results demonstrate that both of CyPPO10 and CyPPO13 exerted normal PPO function.

BT3 transformant (AtPPO1 WT) transformed with *A. thaliana* PPO1 wild type gene that is susceptible to tiafenacil, normally grew in a medium containing no herbicide (0 μ M), but did not grow in a medium containing 100 μ M of tiafenacil. BT3 transformant (AtPPO1 SLYM) transformed with *A. thaliana* PPO1 mutant gene that is tolerant to tiafenacil, gradually started to exhibit growth inhibition from 100 μ M of tiafenacil and hardly grew at 400 μ M. BT3 transformant transformed with CyPPO10 or CyPPO13 gene grew in the medium containing tiafenacil 100 μ M at the similar level to that of the medium containing no tiafenacil, and also grew well even in the medium containing tiafenacil 400 μ M. From such results, it was demonstrated that CyPPO10 and CyPPO13 gene can exhibit significantly higher tiafenacil tolerance compared to *A. thaliana* PPO1 wild type that is susceptible to tiafenacil, and similar or high level of tiafenacil tolerance compared to *A. thaliana* PPO1 mutant type having tiafenacil tolerance.

Example 3. Determination of PPO amino acid residues interacting with PPO-inhibiting herbicides from PPO and PPO-inhibiting herbicide complex

In order to investigate the binding structure information of PPO protein and herbicide, tiafenacil, saflufenacil, flumioxazin, or sulfentrazone were used for test as representative examples of PPO-inhibiting herbicides. A gene encoding CyPPO10 protein was cloned into the pET29b vector (Catalog Number: 69872-3; EMD Biosciences; refer to FIG. 30) and expressed as a CyPPO10 protein using *E. coli* system. The expressed CyPPO10 protein was purified through nickel affinity chromatography, and crystallized with PPO-inhibiting herbicides. Then, using a synchrotron radiation

accelerator, X-ray diffraction data of the 2.4 Å resolution of complexes of CyPPO10 and tiafenacil, saflufenacil, flumioxazin, or sulfentrazone were obtained, to identify the three-dimensional structure of the complex. Through such process, information for amino acid mutation position in CyPPO10 proteins conferring herbicide tolerance was collected.

As a result of analysis of structure of CyPPO10 and tiafenacil complex, it was concluded that amino acids of N59, S60, R89, F161, V165, A167, Q184, P303, V305, F324, L327, I340, F360, and I408 of CyPPO10 protein (SEQ ID NO: 2) were interacted with tiafenacil.

Using the binding information derived from the structure of CyPPO10-tiafenacil complex, amino acid residues that interact with tiafenacil in CyPPO13 (SEQ ID NO: 4) protein were identified by sequence homology analysis (NCBI BLAST, http://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastp&PAGE_TYPE=BlastSearch&LINK_LOC=blasthome) between amino acids of CyPPO10 (SEQ ID NO: 2) and CyPPO13.

As a result, it was comprehended that amino acids of R101, F171, V175, A177, G194, P316, V318, F337, L340, I353, and F373 positions of CyPPO13 protein (SEQ ID NO: 4) interacted with tiafenacil.

Example 4. Preparation of PPO variants

In order to enhance PPO-inhibiting herbicide tolerance of CyPPO10 and CyPPO13, both genes were mutated at the positions of amino acids interacting with herbicides, as identified in the Example 3, thereby preparing the mutated genes for increasing PPO-inhibiting herbicide tolerance.

Mutant PPO genes were isolated and amplified by PCR under the following conditions using primers of Table 3:

Materials

Template (synthetic DNA of CyPPO10 or CyPPO13) 1 µl

10X buffer 5 µl

dNTP mixture (10 mM each) 1 µl

forward primer (10 μ M) 1 μ l
reverse primer (10 μ M) 1 μ l
DDW 40 μ l
Pfu-X (Solgent, 2.5unit/ μ l) 1 μ l
5 Total 50 μ l

【Table 2】

PCR conditions

94 °C	4min	25cycles
94 °C	30sec	
56 °C	30sec	
72 °C	1.5min	
72 °C	5min	
4 °C	5min	

【Table 3】

Strain	Primer	Sequence	SEQ ID NO:
<i>Thermosynechococcus elongatus</i> BP-1	CyPPO10_XbaI F	CCCCTCTAGAATGATTGAAGTGGATG TGGC	12
	CyPPO10_XhoI R	CCCCCTCGAG TGATTGTCCA CCAGCGAGGT	13
<i>Synechococcus</i> sp. JA-3-3Ab	CyPPO13_XbaI F	CCC TCTAGAATG AAC CCT GCT ACC CCT GA	14
	CyPPO13_XhoI R	CCCCCTCGAG CACCTGTGAT AACAACTGCT	15

10 The amplified gene products and pET303-CT His vector (VT0163; Novagen; refer to FIG. 3) were cleaved with XbaI and XhoI, and then, pET303-CyPPO10 and pET303-CyPPO13 plasmids were prepared respectively using T4 DNA ligase (RBC, 3unit/ μ l).

Mutant genes of CyPPO10 and CyPPO13 were prepared by conducting PCR under the following conditions using primers of following Tables 5 and 6, and using the CyPPO10 and CyPPO13 which were cloned to the pET303-CT His vector as a template.

Materials

- 5 Template 1 μ l
 10X buffer 5 μ l
 dNTP mixture (10 mM each) 1 μ l
 forward primer (10 μ M) 1 μ l
 reverse primer (10 μ M) 1 μ l
 10 DDW 40 μ l
 Pfu-X (Solgent, 2.5unit/ μ l) 1 μ l
 Total 50 μ l

【Table 4】

PCR conditions

94 °C	4min	17~25cycles
94 °C	30sec	
56~60 °C	30sec	
72 °C	3min	
72 °C	5min	
4 °C	5min	

15 【Table 5】

List of primers for constructing CyPPO13 mutant gene

Amino acid mutation of CyPPO10	Primer sequence (5'-> 3')
F360M	F: GTT TTT ACC TCT ATG ATA GGA GGT GCT ACT (SEQ ID NO: 16) R: AGC ACC TCC TAT CAT AGA GGT AAA AAC CTG (SEQ ID NO: 17)

F360V	F: GTT TTT ACC TCT GTT ATA GGA GGT GCT ACT (SEQ ID NO: 18) R: AGC ACC TCC TAT AAC AGA GGT AAA AAC CTG (SEQ ID NO: 19)
F360I	F: GTT TTT ACC TCT ATT ATA GGA GGT GCT ACT (SEQ ID NO: 20) R: AGC ACC TCC TAT AAT AGA GGT AAA AAC CTG (SEQ ID NO: 21)
F360T	F: GTT TTT ACC TCT ACT ATA GGA GGT GCT ACT (SEQ ID NO: 22) R: AGC TCC ACC AAT AGT AGA GGT AAA AAC CTG (SEQ ID NO: 23)
F360L	F: GTT TTT ACC TCT CTT ATA GGA GGT GCT ACT (SEQ ID NO: 24) R: AGC TCC ACC AAT AAG AGA GGT AAA AAC CTG (SEQ ID NO: 25)
F360C	F: GTT TTT ACC TCT TGT ATA GGA GGT GCT ACT (SEQ ID NO: 26) R: AGC TCC ACC AAT ACA AGA GGT AAA AAC CTG (SEQ ID NO: 27)
A167C	F: TCAGGAGTGTAC TGT GGAGATCCTCAACAG (SEQ ID NO: 28) R: TTGAGGATCTCC ACA GTACACTCCTGAAAC (SEQ ID NO: 29)
A167L	F: TCAGGAGTGTAC CTT GGAGATCCTCAACAG (SEQ ID NO: 30) R: TTGAGGATCTCC AAG GTACACTCCTGAAAC (SEQ ID NO: 31)
P303L+ V305L	F: ATACCTTAT CTT ACT CTT GCT TGT GTT GTG (SEQ ID NO: 32) R: AACACAAGC AAG AGT AAG ATA AGG TAT (SEQ ID NO: 33)
V305M	F: CCTTATCCAACAT ATG GCTTGTGTTGTGCTT (SEQ ID NO: 34) R: CACAACACAAGC CAT AGTTGGATAAGGTAT (SEQ ID NO: 35)
N59T	F: GAG CTT GGT CCA ACT AGT TTC GCT C (SEQ ID NO: 36) R: AGCGAAACT AGT TGGACCAAGCTCCCA (SEQ ID NO: 37)
R89A	F: CAC CTT CCA GCT TAT ATA TAC TGG AGG GGA (SEQ ID NO: 38) R: GTA TAT ATA AGC TGG AAG GTG CCT ATC TCC (SEQ ID NO: 39)
V165S	F: GTT TCA GGA TCA TAC GCT GGA GAT CCT CAA CAG (SEQ ID NO: 40)

	R: TCC AGC GTA TGA TCC TGA AAC AAA TGG TGC CAC (SEQ ID NO: 41)
V305T	F: CCTTATCCAAC ACT GCTTGTGTTGTGCTT (SEQ ID NO: 42) R: CACAACACAAGC AGT AGTTGGATAAGGTAT (SEQ ID NO: 43)
S60T	F: GGT CCA AAC ACT TTC GCT CCT ACT CCA GCA CTC (SEQ ID NO:44) R: AGG AGC GAA AGT GTT TGG ACC AAG CTC CCA CAC (SEQ ID NO: 45)
I340T	F: CTC GGA ACC ACC TGG TCT TCA TGC TTA TTC CCA (SEQ ID NO: 46) R: TGA AGA CCA GGT GGT TCC GAG TGT CCT TAT ACC (SEQ ID NO: 47)
R89L	F: CAC CTT CCA CTT TAT ATA TAC TGG AGG GGA (SEQ ID NO: 48) R: GTA TAT ATA AAG TGG AAG GTG CCT ATC TCC (SEQ ID NO: 49)
R89V	F: CAC CTT CCA GTT TAT ATA TAC TGG AGG GGA (SEQ ID NO: 50) R: GTA TAT ATA AAC TGG AAG GTG CCT ATC TCC (SEQ ID NO: 51)
F161A	F: AGATTGGTGGCACCAGCAGTTTCAGGAGTGTAC (SEQ ID NO: 52) R: GTACACTCCTGAAACTGCTGGTGCCACCAATCT (SEQ ID NO: 53)
V165C	F: CCATTTGTTTCAGGA TGCTACGCTGGAGATCCT (SEQ ID NO: 54) R: AGGATCTCCAGCGTAGCATCCTGAAACAAATGG (SEQ ID NO: 55)
Q184G	F: TTAGAAGGATTGCTGGACTTGAGAAGTTGGGA (SEQ ID NO: 56) R: TCCCAACTTCTCAAGTCCAGCAATCCTTCTAAA (SEQ ID NO: 57)
F324V	F: TCAGTTAGACCTGGAGTTGGTGTGTTTGGTGCCT (SEQ ID NO: 58) R: AGGCACCAAAACACCAACTCCAGGTCTAACTGA (SEQ ID NO: 59)
L327T	F: CCTGGATTTGGTGTACCGTGCCTAGAGGACAA (SEQ ID NO: 60) R: TTGTCCTCTAGGCACGGTAACACCAAATCCAGG (SEQ ID NO: 61)
A167I	F: TCAGGAGTGTACATTGGAGATCCTCAACAG (SEQ ID NO: 62) R: TTGAGGATCTCCAATGTACACTCCTGAAAC (SEQ ID NO: 63)

I408R	F: AGAAGGGCTCGTCCACAATATATCGTTGGTTAC (SEQ ID NO: 64) R: TATTGTGGACGAGCCCTTCTCCAAACCTTC (SEQ ID NO: 65)
I408W	F: GGTTTGGAGAAGGGCTTGGCCACAATATATCGTTGG (SEQ ID NO: 66) R: CCAACGATATATTGTGGCCAAGCCCTTCTCCAAACC (SEQ ID NO: 67)

【Table 6】

List of primers for constructing CyPPO13 mutant gene

Amino acid mutation of CyPPO13	Primer sequence (5'→3')
F373M	F: TCATTTCTCAGT ATG TTAGGAGGTGCTACA (SEQ ID NO: 68) R: AGCACCTCCTAA CAT ACTGAGAAATGAGTG (SEQ ID NO: 69)
F373V	F: TCATTTCTCAGT GTT TTAGGAGGTGCTACA (SEQ ID NO: 70) R: AGCACCTCCTAA AAC ACTGAGAAATGAGTG (SEQ ID NO: 71)
F373I	F: TCATTTCTCAGT ATT TTAGGAGGTGCTACA (SEQ ID NO: 72) R: AGCACCTCCTAA AAT ACTGAGAAATGAGTG (SEQ ID NO: 73)
F373T	F: TCATTTCTCAGT ACT TTAGGAGGTGCTACA (SEQ ID NO: 74) R: AGCACCTCCTAA AGT ACTGAGAAATGAGTG (SEQ ID NO: 75)
F373L	F: TCATTTCTCAGT CTT TTAGGAGGTGCTACA (SEQ ID NO: 76) R: AGCACCTCCTAA AAG ACTGAGAAATGAGTG (SEQ ID NO: 77)
F373C	F: TCATTTCTCAGT TGT TTAGGAGGTGCTACA (SEQ ID NO: 78) R: AGCACCTCCTAA ACA ACTGAGAAATGAGTG (SEQ ID NO: 79)
R101A	F: AAGTTGCCAGCATATATCTACTGGGAGGGTGC (SEQ ID NO: 80) R: AGTAGATATATGCTGGCAACTTTGCATCAGCC (SEQ ID NO: 81)
A177C	F: TCA GGA GTT TAT TGT GGA GAT CCT GAT CAA (SEQ ID NO: 82)

	R: ATC AGG ATC TCC ACA ATA AAC TCC TGA TGT (SEQ ID NO: 83)
A177L	F: TCAGGAGTTTAT CTT GGAGATCCTGATCAA (SEQ ID NO: 84) R: ATCAGGATCTCC AAG ATAAACTCCTGATGT (SEQ ID NO: 85)
A177I	F: GGAGTTTATATTGGAGATCCTGATCAACTTAG (SEQ ID NO: 86) R: AGGATCTCCAATATAAACTCCTGATGTGAAAG (SEQ ID NO: 87)
P316L+ V318L	F: ATA CTC TAT CTT CCT CTT GCT GTT GTG GCT (SEQ ID NO: 88) R: CAC AAC AGC AAG AGG AAG ATA GAG TAT TTC (SEQ ID NO: 89)
V318L	F: TATCCACCTCTTGCTGTTGTGGCTCTTGCATAC (SEQ ID NO: 90) R: CAACAGCAAGAGGTGGATAGAGTATTCTGCC (SEQ ID NO: 91)
V318M	F: CTC TAT CCA CCT ATG GCT GTT GTG GCT CTT (SEQ ID NO: 92) R: AGC CAC AAC AGC CAT AGG TGG ATA GAG TAT (SEQ ID NO: 93)
P316A+ V318L	F: ATA CTC TAT GCT CCT CTT GCT GTT GTG GCT (SEQ ID NO: 94) R: CAC AAC AGC AGC AGG AAG ATA GAG TAT TTC (SEQ ID NO: 95)
F373N	F: TTTCTCAGTAACTTAGGAGGTGCTACAGATGC (SEQ ID NO: 96) R: CCTCCTAAGTTACTGAGAAATGAGTGATAAC (SEQ ID NO: 97)
F373H	F: TTTCTCAGTCACTTAGGAGGTGCTACAGATGC (SEQ ID NO: 98) R: CCTCCTAAGTGACTGAGAAATGAGTGATAAC (SEQ ID NO: 99)
G194Q	F: GCTTTTCCTAGGGTGGCTCAGCTCGAAGAGAGATACGG (SEQ ID NO: 100) R: CCGTATCTCTCTTCGAGCTGAGCCACCCTAGGAAAAGC (SEQ ID NO: 101)
G194K	F: GCTTTTCCTAGGGTGGCTAAACTCGAAGAGAGATACGG (SEQ ID NO: 102) R: CCGTATCTCTCTTCGAGTTTAGCCACCCTAGGAAAAGC (SEQ ID NO: 103)
G194R	F: GCTTTTCCTAGGGTGGCTCGTCTCGAAGAGAGATACGG (SEQ ID NO: 104) R: CCGTATCTCTCTTCGAGACGAGCCACCCTAGGAAAAGC (SEQ ID NO: 105)

G194E	F: GCTTTTCCTAGGGTGGCTGAACTCGAAGAGAGATACGG (SEQ ID NO: 106) R: CCGTATCTCTCTTCGAGTTCAGCCACCCTAGGAAAAGC (SEQ ID NO: 107)
G194M	F: GCTTTTCCTAGGGTGGCTATGCTCGAAGAGAGATACGG (SEQ ID NO: 108) R: CCGTATCTCTCTTCGAGCATAGCCACCCTAGGAAAAGC (SEQ ID NO: 109)
F337V	F: CAGCCATTAAGAGGAGTGGGTCATCTCATCCC (SEQ ID NO: 110) R: GGGATGAGATGACCCACTCCTCTTAATGGCTG (SEQ ID NO: 111)
L340T	F: GAGGATTTGGTCATACCATCCCTAGGTCTCAAG (SEQ ID NO: 112) R: CTTGAGACCTAGGGATGGTATGACCAAATCCTC (SEQ ID NO: 113)
I353T	F: GAACCTTGGGTACTACCTGGGCTTCATGTTTG (SEQ ID NO: 114) R: CAAACATGAAGCCCAGGTAGTACCCAAGGTC (SEQ ID NO: 115)
F171A	F: AGATTGGTGGAGCCTGCTACATCAGGAGTTTAT (SEQ ID NO: 116) R: ATAAACTCCTGATGTAGCAGGCTCCACCAATCT (SEQ ID NO: 117)
R101A	F: GATGCAAAGTTGCCAGCTTATATCTACTGGGAG (SEQ ID NO: 118) R: CTCCCAGTAGATATAAGCTGGCAACTTTGCATC (SEQ ID NO: 119)
V175C	F: CCTTTCACATCAGGATGTTATGCTGGAGATCCT (SEQ ID NO: 120) R: AGGATCTCCAGCATAACATCCTGATGTGAAAGG (SEQ ID NO: 121)
V175L	F: ACATCAGGATTGTATGCTGGAGATCCTGATC (SEQ ID NO: 122) R: TCCAGCATACAATCCTGATGTGAAAGGCTCCAC (SEQ ID NO: 123)

Example 5. PPO-inhibiting herbicide tolerance of PPO and its variants

In order to enhance PPO-inhibiting herbicide tolerance of CyPPO10 and CyPPO13, the amino acids interacting with herbicide, as identified in the Example 3, were mutated. After PPO-deficient BT3 *E. coli* (Δ PPO) was transformed with a PPO gene having such mutation, and then cultured with PPO-inhibiting herbicide, to observe the growth of transformed *E. coli*, as follows:

The pET303-CyPPO10 or pET303-CyPPO13 plasmids prepared in the Example 4, and plasmids containing each mutant gene, were transformed into BT3 competent cell by a heat shock method, and cultured in a LB agar medium containing ampicillin (100 µg/ml).

- 5 For seed culture of BT3 transformants, a single colony thereof was cultured in 3 ml of LB broth (LPSS) containing ampicillin for 12 hours or more, and 50~100 µl of the cultured solution was further cultured until absorbance (OD₆₀₀) reaches 0.5 to 1. Then, the obtained cultured solution was diluted with LB broth to adjust absorbance (OD₆₀₀) to 0.5, and was diluted again 5 times by a factor of one tenth with LB broth.

- 10 LB (25 g/L), Bacto agar (12 g/L), ampicillin (100 µg/ml) and various herbicides (0~200 µM) were mixed, to prepare herbicide-containing media.

- Ten microliters of the diluted solution were dropped on the herbicide-containing media, and the media were incubated with light for 16-20 hours at 37 °C. The growth level and PPO-inhibiting herbicide tolerance of BT3 transformed with each
15 gene were evaluated.

Herbicides used in the test were listed in following Table 7:

【Table 7】

Family	Herbicide
Pyrimidinedione-based herbicides	Tiafenacil
	Saflufenacil
Diphenyl ether-based herbicides	Fomesafen
	Acifluorfen
N-phenylphthalimides-based herbicides	Flumioxazin
Triazolinones-based herbicides	Sulfentrazone
Oxazolidinediones-based herbicides	Pentoxazone
Phenylpyrazoles-based herbicides	Pyraflufen-ethyl

Other herbicides	Pyraclonil
------------------	------------

The herbicide tolerance was evaluated relatively compared to CyPPO wild type, and shown in following Tables 8 to 11 and FIGs. 11 to 29:

【Table 8】

CyPPO10 mutation	Tiafenacil (up to 200 μ M)	Saflufenacil (up to 200 μ M)	Acifluorfen (up to 200 μ M)	Fomesafen (up to 200 μ M)
CyPPO10 (wild type)	-	-	-	-
F360C	++++	++++	++++	++++
F360I	++++	++++	++++	++++
F360L	++++	++++	++++	++++
F360M	++++	++++	++++	++++
F360V	++++	++++	++++	++++
A167C	+++	+	++++	++++
A167L	++++	+++	++++	++++
P303L+V305L	NT	NT	++	+
V305M	++	+	+++	++++

NT(Not tested)

5 【Table 9】

CyPPO10 mutation	Pentoxazone (up to 200 μ M)	Pyraflufen -ethyl (up to 200 μ M)	Pyraclonil (up to 200 μ M)	Flumioxazin (up to 200 μ M)	Sulfentrazone (up to 200 μ M)
CyPPO10 (wild type)	-	-	-	-	-
F360C	++++	++++	++++	++++	++++
F360I	++++	++++	++++	++++	++++
F360L	++++	++++	++++	++++	++++
F360M	++++	++++	++++	++++	++++
F360V	++++	++++	++++	NT	++++

A167C	++++	++++	++++	+	++
A167L	++++	++++	++++	++++	+++
P303L+V305L	++++	+	+++	NT	NT
V305M	++++	+	+++	NT	NT

NT(Not tested)

【Table 10】

CyPPO13 mutation	Tiafenacil (up to 50 μ M)	Saflufenacil (up to 50 μ M)	Acifluorfen (up to 200 μ M)	Fomesafen (up to 200 μ M)	Pentoxazone (up to 200 μ M)
CyPPO13 (wild type)	-	-	-	-	-
F373C	+++++	+++	+++	+++	++++
F373I	+++++	+++++	+++	+++	+++++
F373L	+++++	+++++	+++	++++	+++++
F373M	+++++	+++	+++	++++	+++++
F373T	+++++	++++	++++	++++	++++
A177C	NT	+	++++	++++	++++
A177L	++	+	++++	++++	++++
V318M	NT	NT	+++	++	+
P316A+V318L	NT	NT	+++	-	NT
P316L+V318L	NT	NT	+++	++	NT

NT(Not tested)

【Table 11】

CyPPO13 mutation	Pyraflufen -ethyl (up to 200 μ M)	Pyraclonil (up to 200 μ M)	Sulfentrazone (up to 200 μ M)	Flumioxazin (up to 50 μ M)
CyPPO13	-	-	-	-
F373C	++	+++++	-	-
F373I	++	+++++	++++	++++

F373L	++	+++++	++++	++++
F373M	++	+++++	++++	+++
F373T	++++	++++	+	++++
A177C	+++++	++++	++++	-
A177L	+++++	+++	++++	++++
V318M	++	-	+	NT
P316A+V318L	+	-	-	NT
P316L+V318L	+	-	+	NT

NT(Not tested)

In the Tables 8 to 11, the level of herbicide tolerance of the wild type was represented by "-", and the level of herbicide tolerance was graduated by representing the equal level of tolerance by "-", and if higher, adding "+" to the max "+++++".

5 FIG. 11 to 19 (wild type and variants of CyPPO10) and FIG. 20 to 29 (wild type and variants of CyPPO13) show the results of culturing *E. coli* transformed with CyPPO genes (wild type and variant type), and the concentration described on the top is concentration of herbicide treated. Six columns of each concentration were sequentially diluted 5 times by a factor of one tenth with the *E. coli* culture solution to the right, and
10 the most left column is the result of *E. coli* culture solution OD600=0.5.

As shown in Tables 8 to 11 and FIG. 11 to 29, it was demonstrated that all the transformants transformed with mutant genes of CyPPO10 and CyPPO13 exhibited equal level or increased level of herbicide tolerance to various kinds of herbicides, compared to the transformant with wild type gene.

15

Example 6: Measurement of enzyme activity and IC₅₀ value by herbicides of PPO

The enzyme activities of PPO protein and PPO protein variants were examined, and inhibition assay by PPO-inhibiting herbicides was conducted. It was confirmed that

the PPO protein has low water-solubility, but in case of being expressed as a fusion protein with MBP (maltose binding protein) (MBP-PPO), the PPO protein is able to be stably expressed as water-soluble form. Therefore, the wild type and variant proteins which were expressed in the form of fusion protein with MBP were used in the present test (refer to FIG. 4).

In order to express wild type genes and mutant genes of CyPPO10 and CyPPO13 (refer to Example 1 and Example 4), those genes were introduced to pMAL-c2X vector (refer to FIG. 5) respectively, and then cloned to BL21 (DE3) *E. coli* (CodonPlus).

The transformed *E. coli* were cultured under the following conditions to express introduced PPO genes:

Induction: OD₆₀₀=0.2, addition of IPTG to 0.3 mM final concentration;

Expression temperature: 23 °C, 200 rpm shaking culture;

Expression time: 16hrs;

Culture scale: 200 ml/1,000 ml flask.

Cell lysis and protein extraction were performed by the following process to the cultured *E. coli* cells:

Extraction buffer: Column buffer (50 mM Tris-Cl, pH8.0, 200 mM NaCl) 5 ml buffer/g cell;

Sonication: SONICS&MATERIALS VCX130 (130 watts);

15 sec ON, 10 sec OFF for 5 min on ice;

Centrifugation under the condition of 4 °C for 20 minutes (20,000 x g); and the supernatant obtained by the centrifugation was diluted at the ratio of 1:6 using column buffer.

The following process for purification of PPO protein was performed in a 4 °C cold room. Amylose resin (New England Biolabs) was packed to 1.5x15 cm column (Bio-Rad Econo Columns 1.5 x 10 cm, glass chromatography column, max. vol), and the obtained protein extracts were loaded to the column at a flow rate of 0.2 ml/min. The column was washed with 3 column volumes of buffer, and the amount of protein in the washing solution was checked. When the protein was no longer detected, the

washing was terminated. Then, the MBP-PPO protein was eluted with approximately 2 column volumes of buffer containing 20 mM maltose. The protein concentration of each eluent was determined and the elution was stopped when the protein was no longer detected. Ten microliter of each fraction was investigated for protein quantification and SDS-PAGE analysis. The highly pure fractions with PPO proteins were taken for enzyme activity assay.

The enzyme activity of the purified wild type protein and variant proteins of CyPPO10 and CyPPO13 was measured by the following process.

At first, a substrate of PPO protein, Protoporphyrinogen IX was synthesized. This process was performed in the space where nitrogen gas is streamed. 6 mg of protoporphyrin IX was dissolved in 20% (v/v) EtOH 20 ml, and stirred under dark condition for 30 minutes. The obtained protoporphyrinogen IX solution was put into a 15 ml screw tube in an amount of 800 μ l, and flushed with nitrogen gas for 5 minutes. To this, 1 g of sodium amalgam was added and vigorous shaking was performed for 2 minutes. The lid was open to exhaust hydrogen gas in the tube. Thereafter, the lid was closed and incubated for 3 minutes. The protoporphyrin IX solution was filtered using syringe and cellulose membrane filter. To 600 μ l of the obtained protoporphyrin IX solution, 2M MOPS [3-(N-morpholino)propanesulfonic acid] was added in an amount of approximately 300 μ l, thereby adjusting pH to 8.0. To determine the enzyme activity of PPO protein, a reaction mixture was prepared with the following composition (based on 10 ml): 50 mM Tris-Cl (pH 8.0); 50 mM NaCl; 0.04% (v/v) Tween 20; 40 mM glucose (0.072 g); 5 units glucose oxidase (16.6 mg); and 10 units catalase (1 μ l).

Two hundred microliters (200 μ l) of reaction mixture containing a purified PPO protein were placed in 96 well plates, and preincubated for 30 min at room temperature to reduce the oxygen concentration by the reaction of glucose oxidase-catalase. The mineral oil was layered and then the reaction was initiated by adding the substrate, protoporphyrin IX solution, to a final concentration of 50 μ M. The reaction proceeded at room temperature for 30 min and the fluorescence of protoporphyrin IX was measured using Microplate reader (Sense, Hidex) (excitation: 405 nm; emission: 633 nm). To calculate the PPO enzyme activity, protoporphyrinogen IX solution was kept

open in the air to oxidize the solution (overnight). To this, 2.7N HCl was added, and the absorbance at 408nm was measured. A standard curve was generated using standard protoporphyrin IX, and the PPO activity was measured by calibration of protoporphyrin IX using the standard curve of protoporphyrin IX.

5 The enzyme activity of the obtained PPO wildtype and variants was shown in Table 12.

Meanwhile, Michaelis-Menten constant (K_m) and the maximal velocity (V_{max}) values of each enzyme were calculated in order to evaluate the kinetic parameters of PPO proteins (CyPPO10 and CyPPO13). The initial reaction velocity was measured where the reaction velocity was proportional to substrate concentration, and the amount of produced protoporphyrin IX which is an enzymatic reaction product was measured by time course at room temperature for 20 minutes. K_m and V_{max} values were calculated with the enzyme kinetics analysis program by Michaelis-Menten equation, and the plant PPO was used as a control group. The obtained result was shown in Table 12:

15 **【Table 12】**

Classification	CyPPO10	CyPPO13	AtPPO1	<i>Amaranthus</i> PPO1
V_{max} ($\mu\text{M mg protein}^{-1} \text{ min}^{-1}$)	949.1 $\pm$ 64	341.4 $\pm$ 14	134.4 $\pm$ 19	57 $\pm$ 7

As shown in Table 12, CyPPO10 and CyPPO13 have superior ability as a PPO enzyme than *A. thaliana* PPO1 (AtPPO1) and *Amaranthus* PPO1.

The concentration of the PPO-inhibiting herbicides that inhibits the PPO enzyme activity by 50% (IC_{50}) was measured for each herbicide. The final concentration of each herbicide was as follows:

0, 10, 50, 100, 250, 500, 1,000, 2,500, 5,000 nM

The IC_{50} value was calculated as the concentration of the herbicide inhibiting the PPO enzyme activity to 50% before adding the herbicide at the above concentration to the above enzyme activity measurement process.

The IC_{50} values of different herbicides were shown in the following Table 13.

【Table 13】

CyPP	Mutatio	Acti	IC_{50} (nM)
------	---------	------	----------------

O10	n	vity						
No.		(%)	Tiafenacil	Saflufenacil	Fomesafen	Butafenacil	Flumioxazin	Sulfentrazone
1	WT	100	21	9	15	8	NT	NT
2	F360M	93	115	1,500	114	24	NT	NT
3	F360I	67	799	3,916	191	268	3,323	NT
4	F360L	59	172	NT	NT	NT	NT	NT
5	F360V	56	307	NT	NT	NT	NT	NT
6	N59T + F360V	62	543	NT	NT	NT	NT	NT
7	R89A + F360M	67	931	5,000	5,000	674	1,216	5,000
8	R89A + F360I	38	2,153	5,000	5,000	1,323	5,000	5,000
9	R89A + F360L	30	1,000	NT	NT	NT	1,025	NT
10	V165S + F360M	78	435	NT	NT	NT	119	NT
11	V165S + F360I	63	818	NT	NT	NT	NT	NT
12	V165S + F360L	59	470	NT	NT	NT	NT	NT
13	V165S + F360V	52	929	NT	NT	NT	NT	NT
14	A167L + F360M	80	5,000	5,000	3,000	4,000	5,000	5,000

15	A167L + F360I	32	5,000	NT	NT	NT	NT	NT
16	A167C + F360M	90	4,500	5,000	1,900	2,500	4,000	5,000
17	A167C + F360I	48	4,500	NT	NT	NT	NT	NT
18	V305M + F360M	87	356	5,000	675	121	544	2,057
19	V305T + F360I	10	276	NT	NT	NT	NT	NT
20	R89A + V305T + F360M	5	741	NT	NT	NT	NT	NT
21	S60T + V165S + F360M	17	2,720	NT	NT	NT	NT	NT
22	S60T + V165S + F360I	12	3,580	NT	NT	NT	NT	NT
23	S60T + I340T + F360I	5	2,000	NT	NT	NT	NT	NT
24	R89V + F360I	57	242	NT	NT	NT	NT	NT
25	R89L + F360I	51	184	NT	NT	NT	NT	NT

26	A167I + F360M	85	5,000	5,000	5,000	5,000	5,000	5,000
27	V165C + F360M	93	2,169	NT	NT	NT	NT	NT
28	V305L + F360M	82	262	NT	NT	NT	NT	NT
29	V165C + A167C + F360M	91	5,000	5,000	3,034	2,810	5,000	5,000
30	V165C + A167I + F360M	75	5,000	5,000	3,741	5,000	5,000	5,000
31	V165C + A167L + F360M	83	5,000	5,000	4,277	4,820	5,000	5,000
32	R89A + A167L + F360M	7	5,000	NT	NT	NT	NT	NT
33	I408R +	5	5,000	NT	NT	NT	NT	NT

	F360M							
34	I408W + F360M	5	5,000	NT	NT	NT	NT	NT
35	R89A	83	104	NT	NT	NT	NT	NT
36	F161A	92	203	NT	NT	NT	NT	NT
37	V165C	99	97	NT	NT	NT	NT	NT
38	A167C	98	86	NT	NT	NT	NT	NT
39	A167L	95	792	NT	NT	NT	NT	NT
40	Q184G	97	79	NT	NT	NT	NT	NT
41	V305M	100	186	NT	NT	NT	NT	NT
42	F324V	59	140	NT	NT	NT	NT	NT
43	L327T	84	214	NT	NT	NT	NT	NT
44	I340T	19	216	NT	NT	NT	NT	NT
45	F360T	85	5,000	NT	NT	NT	NT	NT
CyPP								
O13								
1	WT	100	28	36	30	37	NT	NT
2	F373M	98	56	481	77	18	NT	NT
3	F373I	83	135	1,480	NT	NT	NT	NT
4	F373L	82	141	1,470	NT	NT	NT	NT
5	F373C	86	212	NT	NT	NT	NT	NT
6	F373V	83	339	NT	NT	NT	NT	NT
7	F373T	81	818	NT	NT	NT	NT	NT
8	F373H	26	114	NT	NT	NT	NT	NT
9	F373N	40	40	NT	NT	NT	NT	NT
10	R101A + F373M	55	615	5,000	NT	NT	573	NT

11	A177C + F373M	77	336	4,500	NT	NT	NT	NT
12	A177I + F373M	75	261	4,700	NT	NT	NT	NT
13	A177L + F373M	75	1,122	5,000	690	2,500	5,000	5,000
14	A177L + F373I	66	1,630	5,000	315	5,000	5,000	5,000
15	A177L + F373L	68	5,000	5,000	464	5,000	5,000	5,000
16	V175L + F373M	93	203	1,375	NT	NT	NT	NT
17	V318M + F373M	72	386	1,924	NT	NT	NT	NT
18	A177L + F373T	62	4,700	5,000	3,000	4,000	5,000	5,000
19	A177L + F373V	49	5,000	5,000	1,229	5,000	5,000	5,000
20	A177C + F373T	80	3,900	NT	NT	NT	NT	NT
21	A177C	56	3,200	NT	NT	NT	NT	NT

	+							
	F373V							
22	G194E + F373M	32	64	261	NT	NT	66	NT
23	G194Q + F373M	37	24	265	NT	NT	5.2	NT
24	G194M + F373M	43	20	475	NT	NT	53	NT
25	G194K + F373M	41	95	224	NT	NT	128	NT
26	G194R + F373M	35	67	218	NT	NT	81	NT
27	R101A	87	139	NT	NT	NT	NT	NT
28	F171A	70	70	NT	NT	NT	NT	NT
29	V175C	94	57	NT	NT	NT	NT	NT
30	A177C	98	113	NT	NT	NT	NT	NT
31	A177L	97	211	NT	NT	NT	NT	NT
32	V318M	81	211	NT	NT	NT	NT	NT
33	F337V	88	158	NT	NT	NT	NT	NT
34	L340T	83	443	NT	NT	NT	NT	NT
35	I353T	62	280	NT	NT	NT	NT	NT

NT(Not Tested)

As shown in Table 13, CyPPO protein variants exhibit more increased IC₅₀ values, compared to wild type CyPPO protein. Such results demonstrate that the amino acid mutations at certain positions of PPO protein can lead to increase in herbicide

tolerance. Although the present data showed that CyPPO protein variants have reduced enzyme activity compared to the wild type, it might be caused by the different conditions of the protein folding, and/or hydrophobicity of recombinants PPOs compared to the native PPOs. While the native PPOs are hydrophobic and localize to the membranes of chloroplasts in plants, the recombinant PPOs produced in *E.coli* are hydrophilic containing a MBP as a fusion partner. Thus, when PPO variants are properly assembled and localized in chloroplasts membrane of plants, the enzyme activity would not be affected drastically.

10 **Example 7. Generation of *A. thaliana* transformants using CyPPO and its variants and PPO-inhibiting herbicide tolerance test**

7-1. Construction of *A. thaliana* transformation vectors and transformation of *A. thaliana*

A. thaliana was transformed with a binary vector having ORF of a selectable marker, bar gene (glufosinate-tolerant), and that of each encoding gene of CyPPO10 or CyPPO13 variants. The transgenic plant was examined for cross-tolerance towards glufosinate and PPO-inhibiting herbicides. The bar gene was also used to examine whether the transgene was stably inherited during generations. NOS promoter and E9 terminator were used for bar gene expression.

20 In order to express CyPPO10, CyPPO10 variants, CyPPO13 and CyPPO13 variants, respectively in a plant, CaMV35S promoter and NOS terminator were used. Encoding genes of CyPPO10, CyPPO10 variants, CyPPO13 and CyPPO13 variants were cloned using XhoI and BamHI restriction enzymes. For identification of expressed protein, hemagglutinin (HA) tag was fused to the 3'-terminal region using BamHI and
25 SacI restriction enzymes. NOS terminator was inserted after HA tag, thereby terminating transcription of PPO gene. In addition, in order to transit proteins to chloroplast, transit peptide (TP) of AtPPO1 gene (SEQ ID NO: 10) was inserted in front of 5' of the inserted gene using XbaI and XhoI restriction enzymes. The transit peptide region inserted in the vector was represented by SEQ ID NO: 27 and the inserted HA
30 tag sequence was represented by SEQ ID NO: 28. A schematic diagram of the plant

transformation binary vector is shown in FIG. 6.

Each constructed vector above was introduced to *Agrobacterium tumefaciens* GV3101 competent cell by a freeze-thaw method. To prepare *Agrobacterium* GV3101 competent cell, *Agrobacterium* GV3101 strain was seed-cultured in 5 ml LB media under the condition of 30 °C and 200 rpm for 12 hrs. The culture medium was inoculated to 200 ml LB media, and then cultured at 200 rpm for 3~4 hrs at 30 °C, and centrifuged at 3000 xg for 20 minutes at 4 °C. The pellet was washed with sterile distilled water, and resuspended in 20 ml LB media. Snap frozen 200 µl aliquots with liquid nitrogen were stored in a deep freezer.

Each transformed *Agrobacterium* was cultured in an antibiotic medium (LB agar containing spectinomycin) and screened. The screened colony was liquid cultured in LB broth. After *Agrobacterium* was harvested from the culture medium, it was resuspended in 5% (w/v) sucrose, 0.05% (v/v) Silwet L-77 solution (Momentive performance materials company) at an absorbance (OD₆₀₀) of 0.8. By Floral dipping method, Col-0 ecotype *A. thaliana* wild type was transformed, and then the seed (T₁) was harvested 1~2 months later.

Bar gene in the binary vector was used for screening of individual transformants. The obtained T₁ seeds were sown in 1/2 MS media (2.25 g/L MS salt, 10 g/L sucrose, 7 g/L Agar) supplemented with 25 µM glufosinate, and the surviving plants were selected after 7 days of sowing, and transplanted into soil.

In order to examine PPO-inhibiting herbicide tolerance of the transgenic plants, 4-week-old plants were evenly sprayed with 100 ml of 1 µM tiafenacil solution (0.05% Silwet L-77) per 40 x 60 cm area (0.24 m²). While wild type *A. thaliana* (Col-0 ecotype; Columbia-0 ecotype) completely died within 7 days after treatment, each transformant showed no damage to PPO-inhibiting herbicide treatment.

The T₂ seeds harvested from surviving plants were sown to 1/2 MS media (2.25 g/L MS salt, 10 g/L sucrose, 7 g/L Agar) supplemented with 25 µM glufosinate, and after 1 week, surviving plants were transplanted into soil.

To confirm the copy number of each line, the segregation ratios were investigated with T₂ seeds.

Tiafenacil tolerance of 4-week-old transformants was confirmed by spraying 100 ml of tiafenacil solution (1 μ M, 5 μ M, 10 μ M or 25 μ M tiafenacil + 0.05% Silwet L-77) per 40 x 60 cm area (0.24 m²). T₃ seeds were harvested from tiafenacil-tolerant T₂ plants.

- 5 The seeds were selected in a 1/2 MS medium containing 25 μ M glufosinate, and the lines in which all individuals were glufosinate-tolerant were judged as homolines.

7-2. Seed germination

- Herbicide tolerance of *A. thaliana* transformants introduced with wild type or
10 variant genes of CyPPO10 and CyPPO13 was confirmed.

T₃ generation seeds of each transformant were sown in 1/2 MS media containing herbicides. Col-0 ecotype (wild type Arabidopsis) seeds were used as a control. The kinds of herbicides and concentration are as follows:

- FIG. 31a: 25 μ M gufosinate (PPT), 70 nM tiafenacil, 100 nM saflufenacil, 25
15 μ M glufosinate + 70 nM tiafenacil, or 25 μ M glufosinate + 30 nM tiafenacil + 40 nM saflufenacil;

FIGs. 31b and 31c: 25 μ M glufosinate (PPT), 0.1 μ M or 1 μ M tiafenacil, 0.3 μ M or 3 μ M saflufenacil, 0.1 μ M or 1 μ M flumioxazin, 0.5 μ M or 5 μ M pyraclonil, or 1 μ M or 10 μ M sulfentrazone.

- 20 The results of seed germination in 7 days after sowing were shown in FIGs. 31a, 31b, and 31c. In FIGs. 31a to 31c, 10-3 refers to CyPPO10 wild type, 10FM-4-7 to the CyPPO10 F360M transgenic line, 10FL-1-9 to the CyPPO10 F360L transgenic line, 10FC-3-5 to the CyPPO10 F360C transgenic line, 10AC-5-4 to the CyPPO10 A167C transgenic line, 13-1 to CyPPO13 wild type, 13FM-3-1 to the CyPPO13 F373M
25 transgenic line, 13FC-1-1 to the CyPPO13 F373C transgenic line, 13FI-2-1 to the CyPPO13 F373I transgenic line, 13AC-1-3 to the CyPPO13 A177C transgenic line, CyPPO13_ALFL to the CyPPO13 A177L+F373L transgenic line, and CyPPO13_ALFI to the CyPPO13 A177L+F373I transgenic line, respectively.

- As shown in FIGs. 31a to 31c, while the wild type *A. thaliana* (Col-0 ecotype)
30 germinated in the 1/2 MS medium containing no herbicide, it did not germinate in the

1/2 MS medium containing herbicides. Therefore, germination test on the medium containing herbicides is useful to evaluate herbicide tolerance.

Meanwhile, transformed *A. thaliana* T₃ lines in which CyPPO10 wild type, CyPPO10 mutant genes (F360M, F360I, F360L, F360C, A167C), CyPPO13 wild type
 5 or CyPPO13 mutant genes (F373M, F373C, F373I, A177C, A177L+F373L, A177L+F373I) germinated in the media containing herbicides (containing 25 µM glufosinate, 25 µM glufosinate + 70 nM tiafenacil, or 25 µM glufosinate + 30 nM tiafenacil + 40 nM saflufenacil). These results indicate that bar gene (glufosinate-tolerant gene) and CyPPO genes (PPO-inhibiting herbicide-tolerant gene) functioned as
 10 herbicide tolerant traits simultaneously and independently in the transgenic plants.

As shown in 31a to 31c, in the media containing various kinds and various concentrations of PPO-inhibiting herbicides, the transformed *A. thaliana* normally germinated and survived, while Col-0 did not normally germinate. Such result showed that transformed *A. thaliana* was conferred tolerance or retained enhanced tolerance to
 15 various PPO-inhibiting herbicides by the inserted genes of transformants.

7-3. Investigation of CyPPO protein expression in CyPPO genes-introduced *A. thaliana* (T₂)

Each protein expression was investigated in *A. thaliana* transformants (T₂) in
 20 which genes encoding CyPPO10, CyPPO10 variants (F360I or F360M), CyPPO13, or CyPPO13 variant (F373M) were inserted, respectively.

Four-week-old *A. thaliana* transformant leaves were ground with liquid nitrogen, and the protein was extracted by adding protein extraction buffer (0.05 M Tris-Cl pH7.5, 0.1 M NaCl, 0.01 M EDTA, 1% Triton X-100, 1 mM DTT). Then,
 25 western blotting was conducted using anti-HA antibody (Santa cruz). The expressed proteins in the transformants were detected using HA tag. To compare the amount of proteins loaded, the amount of RuBisCO large subunit was confirmed by Coomassie blue staining. Two independent lines per each variant were tested, and Col-0 was used as a control.

30 The result was shown in FIG. 7. All the *A. thaliana* transformants introduced

with CyPPO10 variant (F360I variant or F360M variant) or CyPPO13 variant (F373M variant) genes exhibited successful expression of the PPO proteins.

7-4. Verification of herbicide tolerance of transformed *A. thaliana* (T₂ or T₃)

Herbicide tolerance was tested with *A. thaliana* transformants (T₂ or T₃) in which genes encoding CyPPO10, CyPPO10 variant (F360C, F360I, F360L, F360M, F360V, F360T, A167C, A167L, A167L+F360M, A167C+F360M, A167C+F360I, or V305M+F360M), CyPPO13, or CyPPO13 variant (A177C, F373C, F373I, F373M, A177L+F373I, or A177L+F373L) were introduced respectively.

After treatment with tiafenacil solution (1 μ M tiafenacil + 0.05% (v/v) Silwet L-77) to CyPPO10 or CyPPO13 transformants (T₃) in the amount of 100 ml per 40 X 60 cm area (0.24 m²), injury level of the plant was judged at the 7th day. For comparison, the same test was conducted using the wild type *A. thaliana* (Col-0 ecotype).

The result was shown in FIG. 8.

In addition, after treatment with 100 ml of tiafenacil solution (1 μ M, 5 μ M, 10 μ M, or 25 μ M tiafenacil + 0.05% (v/v) Silwet L-77) per 40 X 60 cm area (0.24 m²) to transformants (T₂) with genes encoding CyPPO10 variant (F360C, F360I, F360L, F360M, F360V, F360T, A167C, A167L, A167L+F360M, or A167C+F360I) or CyPPO13 variant (A177C, F373C, F373I, F373M, A177L+F373I, or A177L+F373L), injury level of the plant was judged at the 7th day.

The result was shown in FIG. 9 (CyPPO10 variant gene-introduced T₂ transformants) and FIG. 10 (CyPPO13 variant gene-introduced T₂ transformants).

In addition, the injury level (Injury index) of each line after tiafenacil treatment in FIG. 8 to 10 was shown in the following Table 14 as numerical index.

Table 14

T₂ Injury Index (injury level)

	Line No.	Tiafenacil	Average injury index
Col-0		1 μ M	5
CyPPO10			
Wild type		1 μ M	0.5

F360C	3	1 μ M	0.3
		5 μ M	0.9
F360I	7	1 μ M	0
		5 μ M	0.1
F360L	3	1 μ M	0
		5 μ M	0.3
F360M	4	1 μ M	0.1
		5 μ M	0.3
F360V	4	1 μ M	0
		5 μ M	0.3
F360T	3	1 μ M	2.6
A167C	3	1 μ M	0
A167L	3	1 μ M	0.2
A167L+F360M	12	25 μ M	2
A167C+F360I	19	25 μ M	2
CyPPO13			
Wild type		1 μ M	0.5
A177C	1	1 μ M	0
F373C	2	1 μ M	0.1
F373I	2	1 μ M	0.1
F373M	2	1 μ M	0
A177L+F373I	9	10 μ M	1.5
A177L+F373L	7	10 μ M	0

After treatment with tiafenacil solution (25 μ M tiafenacil + 0.05% (v/v) Silwet L-77) or saflufenacil solution (100 μ M saflufenacil + 0.05% (v/v) Silwet L-77) in the amount of 100 ml per 40 X 60 cm area (0.24 m²) to transformants (T₃) in which genes encoding CyPPO10 variant (F360I, F360L, F360M, A167C+F360I, A167C+F360M, or V305M+F360M) were introduced, injury level of the plants was judged at the 7th day.

The result of T₃ transformants introduced with CyPPO10 variant encoding

genes was shown in FIG. 32.

In addition, the injury level (Injury index) by tiafenacil or saflufenacil treatment of CyPPO10 mutant gene-introduced *A. thaliana* transformants was shown in the following Table 15 as numerical index.

5 **【Table 15】**

T₃ Injury Index (injury level)

		Line No.	Tiafenacil	Average injury index	Saflufenacil	Average injury index
Col-0			25 μ M	5	100 μ M	5
CyPPO10	F360I	7-2	25 μ M	1	100 μ M	1.1
		10-2			100 μ M	0
	F360M	4-7	25 μ M	2		
	F360L	3-2	25 μ M	1		
	A167C+F360I	1-4	25 μ M	2		
	A167C+F360M	4-5	25 μ M	2		
	V305M+F360M	6-5	25 μ M	2		

The Table 14 and 15 showed the average of injury levels of tested individuals (10 to 20 individuals) according to the criteria of the following Table 16.

10 **【Table 16】**

Definition of injury level

Injury index	Symptom
0	No damage
1	Dried leaf end or less than 20% scorched
2	Over 20% and less than 30% of the plant was scorched
2.5	Over 30% and less than 50% of the plant was scorched
3	Over 50% and less than 70% of the plant was scorched

4	Over 70% of the plant was scorched
5	The whole plant was dried and died

The tolerance level of *A. thaliana* transformants (T₃) introduced with CyPPO10 mutant genes (F360I or A167L+F360M) or CyPPO13 mutant genes (A177L+F373L or A177L+F373I) was confirmed at the 7th day after treating tiafenacil, saflufenacil, flumioxazin, or sulfentrazone (50 μ M each). For comparison, *A. thaliana* wild type or *A.*
 5 *thaliana* PPO1 SLYM (AtPPO1 SLYM, S305L+Y426M) transformants (T₃) known for PPO-inhibiting herbicide tolerance was tested as the same condition.

In the tolerance experiment with various herbicides, 100 ml of 50 μ M concentration of each herbicide was evenly sprayed per a 40 x 60 cm area (0.24 m²). The molecular weight (MW) of tiafenacil, saflufenacil, flumioxazin and sulfentrazone is
 10 511.87, 500.85, 354.34 and 387.18, respectively. The converted treatment dosages correspond to 106.7 g ai/ha of tiafenacil, 104.4 g ai/ha of saflufenacil, 73.8 g ai/ha of flumioxazin and 80.7 g ai/ha of sulfentrazone.

The result was shown in FIGs. 33a and 33b.

In addition, the injury level (Injury index) of transformants was shown in FIG.
 15 33 and Table 17 as numerical index.

【Table 17】

T3 Injury Index (injury level)

	Cy10 FI	AtPPO1 SLYM	Cy10 ALFM
Tiafenacil	1	4	1
Saflufenacil	0	0-1	0-1
Flumioxazin	0-1	4-5	1
Sulfentrazone	0-1	0-1	1

In FIG. 33a and Table 17, Cy10 FI, AtPPO1 SLYM, Cy10 ALFM represented the transformants of CyPPO10 F360I, S305L+Y426M of AtPPO1 (control), and
 20 CyPPO10 A167L+F360M, respectively.

In FIG. 33b, Col-0, Cy13 ALFL and Cy13 ALFI represented the wild type,

transformants of CyPPO13 A177L+F373L and CyPPO13 A177L+F373I, respectively.

As shown in FIG. 33a, transformants of mutant gene have equal or more tolerance than AtPPO1 SLYM. It was demonstrated that all of CyPPO10 FI and CyPPO10 ALFM conferred higher level of tolerance to various herbicides compared to the AtPPO1 SLYM.

As shown in Table 14 and FIG 8, almost all of the transformants with CyPPO10 wild type, its variant genes, CyPPO13 wild type, or its variant genes grew after 1 μ M tiafenacil treatment while wild type *A. thaliana* (Col-0) died.

In addition, as shown in Table 15 and 17, FIGs 9 to 10, and FIGs 32 to 33, CyPPO10 or CyPPO13 variant gene-introduced *A. thaliana* transformants exhibited no or weak level of damage after over 5 μ M of tiafenacil treatment. The result showed that herbicide tolerance of *A. thaliana* was conferred and/or enhanced by introduction of CyPPO10, CyPPO13, or their mutant gene.

It was demonstrated that herbicide tolerance was maintained T₂ to T₃ generations, which indicates that herbicide tolerance was stably transferred even if generation progresses.

From this result, the CyPPO variants are expected to give various PPO-inhibition herbicide tolerances to other plants as well as *A. thaliana*.

7-5. Confirmation of transgene stability during generation passage

In this Example, whether introduced genes in *A. thaliana* were stably inherited during generations was confirmed.

T₃ lines 7-2, 10-2, and 10-5 transformant transformed with CyPPO10 F360I were further developed to T₄, T₅ generation, and thereby tiafenacil or saflufenacil tolerance and the expression of introduced genes in T₄ and T₅ generations of each line were confirmed.

Protein extraction

Proteins were extracted from plants of each generation. After grinding seedling using liquid nitrogen, protein extraction buffer (0.05 M Tris-Cl pH7.5, 0.1 M NaCl, 0.01 M EDTA, 1% Triton X-100, 1 mM DTT) was added and the total protein was

extracted. After the extracted protein was transferred to PVDF membrane following electrophoresis, western blotting was conducted using anti-HA antibody (Santacruz).

Confirmation of herbicide tolerance

One hundred milliliters of herbicide solution containing 15 μ M of tiafenacil or 150 μ M of saflufenacil were evenly sprayed in the 40 x 60 cm area (0.24 m²) to *A. thaliana* 4 weeks after transplanting. The herbicide injury level was observed at the 7th day after the treatment.

The result of herbicide tolerance was shown in FIG. 34 (T₄) and FIG. 35 (T₅), and the injury level (Injury index) of transformants by herbicides was shown in Table 18.

【Table 18】

T ₄ and T ₅ Injury Index (injury level)		
	CyPPO10 F360I	
	T ₄	T ₅
Tiafenacil	0.5	0.5
Saflufenacil	0	1

While the negative control (Col-0; *A. thaliana* wild type) was susceptible to the herbicides treatment, T₄ and T₅ *A. thaliana* transformants of CyPPO10 F360I were tolerant.

In addition, the western blotting analysis for transgene expression was shown in FIG. 36. The CyPPO10 F360I protein was detected only in all T₄ and T₅ generations of transformants.

Therefore it was demonstrated that herbicide tolerance by introduction of CyPPO10 variants was stably inherited and maintained through T₄ and T₅ generations.

Example 8. Construction of soybean transformants using CyPPO and its variants and PPO-inhibiting herbicide tolerance test

8-1. A recombinant vector for soybean transformation and construction of soybean transformants using the same

A vector for soybean plant transformation to confer tiafenacil tolerance by expressing CyPPO10 A167L+F360M gene was constructed.

Specifically, the CyPPO10 A167L+F360M gene combined with the transit peptide of *A. thaliana* PPO1 gene was amplified by PCR using the vector used for *A. thaliana* transformation (refer to FIG. 6) as a template. The amplified product was cloned using pENTR Directional TOPO cloning kits (Invitrogen), and transformed to DH5 alpha competent cell (Invitrogen). Then, the cloned gene was moved to a vector, pB2GW7.0 binary vector (FIG. 37) for plant transformation, using Gateway LR Clonase II Enzyme Mix (Invitrogen) kit. After mixing pENTR/D-TOPO vector in which CyPPO10 A167L+F360M gene was cloned, TE buffer, and LR Clonase II enzyme mix, it was incubated at 25 °C for 1 hr. After Proteinase K solution (Invitrogen) was added to the reaction mixture, it was incubated for 10 minutes at 37 °C, and transformed to DH5 alpha competent cell.

Agrobacterium EHA105 was electro-transformed with the binary vector constructed as above.

Kwangan soybean plants were used for the construction of soybean transformants.

After removing seed coat from soybean seed, hypocotyl was cut and wounded 7-8 times by surgical scalpel (#11 blade). Approximately 50 pieces of explants were mixed with transformed *A. tumefaciens* EHA105 (Hood et al., New Agrobacterium helper plasmids for gene transfer to plants (EHA105). Trans Res. 1993 2:208-218), and the mixture was sonicated for 20 seconds and then incubated for 30 minutes for inoculation. It was placed on CCM (Co-cultivation media; 0.32 g/L Gamborg B5, 4.26 g/L MES, 30 g/L sucrose, 0.7% agar). Then, it was co-cultured in a growth chamber (25 °C, 18 h light / 6 h dark) for 5 days.

After that, it was washed for 10 minutes in liquid 1/2 SIM (shoot induction media; 3.2 g/L Gamborg B5, 1.67 mg/L BA, 3 mM MES, 0.8% (w/v) agar, 3% (w/v) sucrose, 250 mg/L cefotaxime, 50 mg/L vancomycin, 100 mg/L ticarcillin, pH 5.6) and was placed on SIM without antibiotics and cultured in the growth chamber (25 °C, 18 h light / 6 h dark) for 2 weeks.

The shoot-induced explants were transplanted on SIM-1 (SIM media supplemented with 10 mg/L DL-phosphinothricin, pH 5.6).

The browned shoots were transplanted on SEM (shoot elongation media; 4.4 g/L MS salt, 3 mM MES, 0.5 mg/L GA₃, 50 mg/L Asparagine, 100 mg/L pyroglutamic acid, 0.1 mg/L IAA, 1 mg/L zeatin, 3% (w/v) sucrose, 0.8% (w/v) agar, 250 mg/L cefotaxime, 50 mg/L vancomycin, 100 mg/L ticarcillin, 5 mg/L DL-phosphinothricin, pH 5.6). The elongated shoots over height 4 cm were transferred on RIM (root induction medium; 4.4 g/L MS salt, 3 mM MES, 3% sucrose, 0.8% Agar, 50 mg/L cefotaxime, 50 mg/L vancomycin, 50 mg/L ticarcillin, 25 mg/L asparagine, 25 mg/L pyroglutamic acid, pH 5.6).

When the roots grew sufficiently, the plants were moved to bed soil (Bioplug No. 2, Farmhannong) mixed with vermiculite in 2:1 (v/v). After 10 days, leaves were painted with 100 mg/L DL-phosphinothricin.

8-2. Verification of herbicide tolerance of transformed soybeans

Five micromolar or 15 μ M of tiafenacil was painted to the leaves of lines No. 2 of CyPPO10 A167L+F360M transformed soybean (T₀ generation) and non-transformed soybean (Kwangan; wild type soybean, control) 2~3 times with a brush. tiafenacil solution contains 0.05% (v/v) Silwet L-77 as a surfactant.

As shown in FIG. 38, Kwangan (non-transformed soybean) exhibited severe damage 7 days after 5 μ M tiafenacil treatment, but CyPPO10 A167L+F360M transformed soybean showed no damage even after the treatment of 15 μ M tiafenacil.

Meanwhile, tiafenacil or saflufenacil was treated to T₁ generation of CyPPO10 A167L+F360M transformant line No. 2 at the stage of V2~3. The 100 ml of 25 μ M tiafenacil or 150 μ M saflufenacil was evenly sprayed on the area of 40 X 60 cm (0.24 m²), and the damage level was evaluated 5 days after spray.

In FIG. 40, Kwangan soybean was used as a control. Compared to control, CyPPO10 A167L+F360M (10ALFM) transformant soybean showed no damage even after the treatment of a relatively high concentration of tiafenacil or saflufenacil.

8-3. Confirmation of the number of inserted genes in transformed soybeans

The genomic DNA was extracted in 250 mg of leaf tissues of CyPPO10 A167L+F360M transformed lines No. 2 or No. 23, to analyze the copy number of the transgene.

- 5 The genomic DNA was extracted using CTAB buffer method. After grinding leaf tissues using a pestle and a mortar in liquid nitrogen, 1.25 ml of DNA isolation buffer (2% (w/v) CTAB, 1.5 M NaCl, 25 mM EDTA, 0.2% (v/v) beta-mercaptoethanol, 100 mM Tris-Cl (pH 8.0)) was added and vortexed. After heating at 60 °C for 1 hour, 1 volume of chloroform:isoamyl alcohol (24:1) was added and mixed by inverting. After
- 10 centrifugation at 7000 xg for 10 minutes at 4 °C, supernatant was transferred to a new tube, and 2.5 volume of ethanol was mixed. After centrifugation at 5000 xg for 5 minutes at 4 °C, supernatant was discarded and the pellet was dissolved with TE buffer (LPSS). After adding 20 µg/ml RNase A (Bioneer), it was incubated at 37 °C for 30 minutes. After adding 1 volume of phenol:chloroform (1:1), it was mixed and
- 15 centrifuged at 10,000 xg for 10 minutes at 4 °C. Supernatant was transferred to a new tube, and then 1 volume chloroform:isoamyl alcohol(24:1) was added and mixed. After centrifugation at 10,000 xg for 10 minutes at 4 °C, supernatant was transferred to a new tube and 0.1 volume of NaOAc (pH 5.2) and 2 volume of ethanol were added and mixed. After centrifugation at 5,000 xg for 5 minutes at 4 °C, it was washed with 70% ethanol.
- 20 After air dry, genomic DNA was dissolved with an appropriate amount of TE buffer.

The 10~40 µg of extracted DNA was digested overnight using EcoRI (Enzymonics).

Then, after 0.8% (w/v) Agarose gel electrophoresis (50 V), gel was treated as follows:

- 25 1) depurination: 0.25 N HCl, 15min shaking
- 2) denaturation: 0.5 M NaOH, 1.5 M NaCl, 30min shaking
- 3) neutralization: 0.5 M Tris(pH 7.5), 1.5 M NaCl, 20min shaking

- Thereafter, DNA fragments were moved to nitrocellulose membrane using a capillary transfer method, cross linking was performed using UV Crosslinker (UVC-508;
- 30 ULTRA LUM Inc.).

Hybridization was performed by the following method: The nitrocellulose membrane was dipped in DIG Easyhybridization solution (Roche), and incubated at 42 °C for 3 hrs. Then, the solution was discarded, substituted with a fresh DIG Easyhybridization solution with DIG-labelled probe, and incubated for 16-18 hours at 42 °C.

The probe (DIG-labeled CyPPO8-M probe) was labelled by PCR reaction as follows:

Probe PCR

The DIG-labeled bar gene was amplified using DIG dUTP (Jena bioscience), and the primers used then were as follows:

Forward primer for bar probe: 5'- TTC CGT ACC GAG CCG CAG GA-3' (SEQ ID NO: 124)

Reverse primer for bar probe: 5'- CGT TGG GCA GCC CGA TGA CA-3' (SEQ ID NO: 125)

PCR: using Solgent e-Taq kit

Conditions: 95 °C for 5 min, 35 cycles of 94 °C for 30 sec, 60 °C for 30 sec, and 72 °C for 30 sec, and 72 °C for 2 min

After hybridization, membrane was washed in low stringency washing buffer (2X SSC, 0.1% SDS) and high stringency washing buffer (0.5X SSC, 0.1% SDS).

Southern blotting signal was detected as follows:

1) shaking for 30 minutes after adding blocking buffer (Roche) to the membrane

2) shaking for 30 minutes after adding DIG antibody (anti-digoxigenin-AP Fab fragments, Roche)

3) shaking for 15 minutes in washing buffer (Roche)

4) shaking for 3 minutes after adding detection buffer (Roche)

5) After applying CDP-Star (Roche) on the membrane, developing the blot on x-ray film.

For a negative control, the genomic DNA of non-transformed Kwangan soybean plants was used for southern blotting.

In FIG. 39, the number of bands shown on the film means the number of transgenes. Since one band was observed in CyPPO10 A167L+F360M transformant line No. 2 or No. 23 lines, it was determined that each transgenic plant had a single copy transgene.

5

Example 9: Activity test of mutated genes having sequence homology to PPO variant

Error-prone PCR was conducted under the following conditions using CyPPO plasmid (pACBB vector) as a template, thereby inducing random mutations in CyPPO:

10	Template	0.5 μ l
	10X buffer	5 μ l
	10 mM MnCl ₂	1.5 μ l
	dNTP	5 μ l
	e-Taq(Solgent Inc.)	1 μ l
15	forward primer (100 μ M)	0.5 μ l
	reverse primer (100 μ M)	0.5 μ l
	DDW	36 μ l

total 50 μ l

10X buffer: 100 mM Tris-Cl, pH8.3; 500 mM KCl, 70 mM MgCl₂, 0.1% (w/v)

20 gelatin

dNTP: 10 mM dATP, 10 mM dGTP, 100 mM dCTP, 100 mM dTTP

94 °C 3 min; (94 °C 30 sec, 57 °C 30 sec, 72 °C 1.5 min, 72 °C 5 min) 35

cycles

Primer sequences:

25

CyPPO10_BamHI F

ccccgcatccATGATTGAAGTGGATGTGGCTA (SEQ ID NO: 126)

CyPPO10_XhoI R

cccctcgagTGATTGTCCACCAGCGAGGTAAG (SEQ ID NO: 127)

CyPPO13_BamHI F

30

ccccgcatccATGAACCCTGCTACCCCTGAAC (SEQ ID NO: 128)

CyPPO13_XhoI R

ccccctcgagCACCTGTGATAACAACCTGCTGAG (SEQ ID NO: 129)

The obtained error-prone PCR product was electrophoresed in agarose gel and then cleaned up from gel, and pACBB vector and PCR product were digested by BamHI and XhoI restriction enzymes. The digested vector and PCR product electrophoresed in agarose gel were cleaned up, and ligation was conducted. Ligation product was transformed into BT3 competent cell, and mutated CyPPO genes from growing BT3 colonies were sequenced. BT3 confirmed to have mutated CyPPO genes were spotted on LB plate comprising various concentrations (0 μ M, 50 μ M, 100 μ M, and 200 μ M) of tiafenacil or saflufenacil, thereby investigating the growth of *E. coli*, and testing the level of herbicide tolerance.

Among the mutated clones, a clone having the following mutations was used for this herbicide tolerance test:

CyPPO10m-6: comprising 9 amino acid mutations (E225G, G258S, Q266L, T336I, V356F, F360M, A364D, R406G, W419R); nucleic acid sequence – SEQ ID NO: 130, amino acid sequence – SEQ ID NO: 131 (98% sequence homology to the amino acid sequence of wild type CyPPO10)

BT3 cells transformed with the mutant genes of CyPPO10 were cultured in herbicide-contained medium, and cell growth inhibition was measured. In FIG. 41, 'AtPPO1 WT' refers to wild type PPO1 of *A. thaliana*, 'AtPPO1 SLYM' to mutant PPO1 (Y426M+S305L) of *A. thaliana*, 'CyPPO10 WT' to wild type CyPPO10, and 'CyPPO10m-6' to mutated CyPPO10 as described above, respectively.

As shown in FIG. 41, the cells transformed with the CyPPO10 mutants having the sequence homology of 98% or higher to that of the wild type CyPPO10 display cell viability similar to that of cells with wild type CyPPO10, even the case in the medium containing high concentration (up to 200 μ M) of tiafenacil or saflufenacil. This result demonstrates that the CyPPO10 mutants having the sequence homology of 98% or higher can retain herbicide tolerance (viability in herbicide containing media) of the wild type.

【Claims】**【Claim 1】**

A polypeptide selected from the followings:

a polypeptide comprising an amino acid sequence wherein at least one selected
5 from the group consisting of N59, S60, R89, F161, V165, A167, Q184, P303, V305,
F324, L327, I340, F360, and I408 of the amino acid sequence of SEQ ID NO: 2 is
independently deleted or substituted with an amino acid which is selected from the
group consisting of M(Met), V(Val), I(Ile), T(Thr), L(Leu), C(Cys), A(Ala), S(Ser),
F(Phe), P(Pro), W(Trp), N(Asn), Q(Gln), G(Gly), Y(Tyr), D(Asp), E(Glu), R(Arg),
10 H(His), and K(Lys), and is different from the original amino acid at the corresponding
position;

a polypeptide comprising an amino acid sequence wherein at least one selected
from the group consisting of R101, F171, V175, A177, G194, P316, V318, F337, L340,
I353, and F373 of the amino acid sequence of SEQ ID NO: 4 is independently deleted
15 or substituted with an amino acid which is selected from the group consisting of M(Met),
V(Val), I(Ile), T(Thr), L(Leu), C(Cys), A(Ala), S(Ser), F(Phe), P(Pro), W(Trp), N(Asn),
Q(Gln), G(Gly), Y(Tyr), D(Asp), E(Glu), R(Arg), H(His), and K(Lys), and is different
from the amino acid at the corresponding position in the wild type; and

a polypeptide consisting of an amino acid sequence having 95% or higher
20 homology with the amino acid sequence of said polypeptides.

【Claim 2】

The polypeptide of claim 1, wherein the polypeptide is selected from the group
consisting of,

a polypeptide comprising of an amino acid sequence wherein at least one
25 selected from the group consisting of N59, S60, R89, F161, V165, A167, Q184, P303,
V305, F324, L327, I340, F360, and I408 of the amino acid sequence of SEQ ID NO: 2
is independently substituted with an amino acid which is selected from the group
consisting of M(Met), V(Val), I(Ile), T(Thr), L(Leu), C(Cys), A(Ala), S(Ser), R(Arg),
W(Trp), and G(Gly);

30 a polypeptide comprising an amino acid sequence wherein at least one selected

from the group consisting of R101, F171, V175, A177, G194, P316, V318, F337, L340, I353, and F373 of the amino acid sequence of SEQ ID NO: 4 is independently substituted with an amino acid which is selected from the group consisting of M(Met), V(Val), I(Ile), T(Thr), L(Leu), C(Cys), A(Ala), E(Glu), Q(Gln), K(Lys), R(Arg), H(His),
 5 and N(Asn); and

a polypeptide consisting of an amino acid sequence having 95% or higher homology with the amino acid sequence of said polypeptides.

【Claim 3】

The polypeptide of claim 1, wherein the polypeptide is selected from the group
 10 consisting of,

a polypeptide comprising an amino acid sequence comprising at least one amino acid mutation selected from the group consisting of F360M, F360V, F360I, F360T, F360L, F360C, A167C, A167L, A167I, P303L, V305L, V305M, V305T, N59T, S60T, R89A, R89L, R89V, F161A, V165S, V165C, Q184G, F324V, L327T, I340T,
 15 I408R, and I408W in the amino acid sequence of SEQ ID NO: 2;

a polypeptide comprising an amino acid sequence comprising at least one amino acid mutation selected from the group consisting of F373M, F373V, F373I, F373T, F373L, F373C, F373N, F373H, A177C, A177L, A177I, P316A, P316L, V318L, V318M, R101A, F171A, V175C, V175L, G194E, G194Q, G194M, G194K, G194R,
 20 F337V, L340T, and I353T in the amino acid sequence of SEQ ID NO: 4; and

a polypeptide consisting of an amino acid sequence having 95% or higher homology with the amino acid sequence of said polypeptides.

【Claim 4】

The polypeptide of claim 3, wherein the polypeptide is selected from the group
 25 consisting of,

a polypeptide comprising an amino acid sequence comprising amino acid mutation of F360M, F360V, F360I, F360T, F360L, F360C, A167C, A167L, P303L, N59T, S60T, R89A, R89L, R89V, F161A, V165S, V165C, A167I, Q184G, V305L, V305M, V305T, F324V, L327T, I340T, I408R, I408W, P303L+V305L, N59T+F360V,
 30 S60T+V165S+F360M, S60T+V165S+F360I, S60T+I340T+F360I, R89A+F360M,

R89A+F360I, R89A+F360L, R89L+F360I, R89V+F360I, R89A+A167L+F360M, R89A+V305T+F360M, V165S+F360M, V165S+F360I, V165S+F360L, V165S+F360V, V165C+F360M, V165C+A167C+F360M, V165C+A167I+F360M, V165C+A167L+F360M, A167L+F360M, A167L+F360I, A167C+F360M, A167C+F360I, A167I+F360M, V305M+F360M, V305T+F360I, V305L+F360M, I408R+F360M, or I408W+F360M in the amino acid sequence of SEQ ID NO: 2;

a polypeptide comprising an amino acid sequence comprising amino acid mutation of F373M, F373V, F373I, F373T, F373L, F373C, F373N, F373H, A177C, A177L, A177I, P316A, P316L, V318L, V318M, R101A, F171A, V175C, V175L, G194E, G194Q, G194M, G194K, G194R, F337V, L340T, I353T, P316L+V318L, P316A+V318L, R101A+F373M, A177C+F373M, A177I+F373M, A177L+F373M, A177L+F373I, A177L+F373L, A177L+F373T, A177L+F373V, A177C+F373T, A177C+F373V, V175L+F373M, G194E+F373M, G194Q+F373M, G194M+F373M, G194K+F373M, G194R+F373M, or V318M+F373M in the amino acid sequence of SEQ ID NO: 4; and

a polypeptide consisting of an amino acid sequence having 95% or higher homology with the amino acid sequence of said polypeptides.

【Claim 5】

A polynucleotide encoding the polypeptide of any one of claims 1 to 4.

20 【Claim 6】

A recombinant vector comprising the polynucleotide of claim 5.

【Claim 7】

A recombinant cell comprising the recombinant vector of claim 6.

【Claim 8】

25 A composition for conferring or enhancing herbicide tolerance of a plant or algae, comprising at least one selected from the group consisting of the polypeptide of SEQ ID NO: 2; the polypeptide of SEQ ID NO: 4; the polypeptide of any one of claims 1 to 4; a polynucleotide encoding the polypeptide; a recombinant vector comprising the polynucleotide; and a recombinant cell comprising the recombinant vector.

30 【Claim 9】

The composition of claim 8, wherein the herbicide is an herbicide inhibiting protoporphyrinogen oxidase.

【Claim 10】

The composition of claim 9, wherein the herbicide is at least one selected from
 5 the group consisting of pyrimidinediones, diphenyl-ethers, phenylpyrazoles, N-phenylphthalimides, phenylesters, thiadiazoles, oxadiazoles, triazolinones, oxazolidinediones, pyraclonil, flufenpyr-ethyl and proflumazone.

【Claim 11】

The composition of claim 10, wherein the herbicide is at least one selected from
 10 the group consisting of butafenacil, saflufenacil, benzofenazone, tifenacil, fomesafen, oxyfluorfen, acifluorfen, bifenox, ethoxyfen, lactofen, chlomefenox, chlorintofen, fluoroglycofen-ethyl, halosafen, pyraflufen-ethyl, flumioxazin, cinidon-ethyl, flumiclorac-pentyl, fluthiacet, thidiazimin, oxadiargyl, oxadiazon, carfentrazone, sulfentrazone, azafenidin, pentoxazone, pyraclonil, flufenpyr-ethyl,
 15 proflumazone, phenoprylate, carbamate analogues of phenoprylate, and agriculturally acceptable salt thereof.

【Claim 12】

The composition of claim 8, wherein the plant or algae further comprise a second herbicide-tolerant polypeptide or a gene encoding thereof, and tolerance to the
 20 second herbicide is conferred or enhanced.

【Claim 13】

The composition of claim 12, wherein the second herbicide is selected from the group consisting of glyphosate, glufosinate, dicamba, 2,4-D (2,4-dichlorophenoxyacetic acid), isoxaflutole, ALS(acetolactate synthase)-inhibiting herbicide, photosystem II-
 25 inhibiting herbicide, phenylurea-based herbicide, bromoxynil-based herbicide, and combinations thereof.

【Claim 14】

The composition of claim 12, wherein the second herbicide is at least one selected from the group consisting of,
 30 glyphosate herbicide-tolerant EPSPS (glyphosate tolerant 5-

enolpyruvylshikimate-3-phosphate synthase), GOX (glyphosate oxidase), GAT (glyphosate-N-acetyltransferase) or glyphosate decarboxylase;

glufosinate herbicide-tolerant PAT (phosphinothricin-N-acetyltransferase);

dicamba herbicide-tolerant DMO (Dicamba monooxygenase);

5 2,4-D (2,4-dichlorophenoxyacetic acid) herbicide-tolerant 2,4-D monooxygenase or AAD (aryloxyalkanoate Dioxygenase);

ALS (acetolactate synthase)-inhibiting sulfonylurea-based herbicide-tolerant AHAS (acetohydroxyacid synthase), AHAS (acetohydroxyacid synthase) or Atahas1 (acetohydroxyacid synthase large subunit);

10 photosystem II-inhibiting herbicide-tolerant photosystem II protein D1;

phenylurea herbicide-tolerant Cytochrome P450;

plastid-inhibiting herbicide-tolerant HPPD (Hydroxylphenylpyruvate dioxygenase);

bromoxynil herbicide-tolerant Nitrilase; and

15 combinations thereof.

【Claim 15】

The composition of claim 12, wherein the gene encoding the second herbicide-tolerant polypeptide is at least one selected from the group consisting of,

glyphosate herbicide-tolerant cp4 epsps, epsps (AG), mepsps, 2mepsps, goxv247, gat4601 or gat4621 gene;

glufosinate herbicide-tolerant bar or pat gene;

dicamba herbicide-tolerant dmo gene;

2,4-D (2,4-Dichlorophenoxyacetic acid) herbicide-tolerant AAD-1 or AAD-12 gene;

25 isoxaflutole herbicide-tolerant HPPDPF W336 gene;

sulfonylurea herbicide-tolerant ALS, Csr1, Csr1-1, Csr1-2, GM-HRA, S4-HRA, Zm-HRA, SurA or SurB gene;

photosystem II-inhibiting herbicide-tolerant psbA gene;

phenylurea herbicide-tolerant CYP76B1 gene;

30 bromoxynil herbicide-tolerant bxn gene; and

combinations thereof.

【Claim 16】

A transformant of a plant or algae having herbicide tolerance, or a clone or progeny thereof, comprising the polypeptide of SEQ ID NO: 2, the polypeptide of SEQ ID NO: 4, the polypeptide of any one of claims 1 to 4, or a polynucleotide encoding thereof.

【Claim 17】

The transformant, clone or progeny thereof of claim 16, wherein the transformant is plant cell, protoplast, callus, hypocotyl, seed, cotyledon, shoot, or whole plant.

【Claim 18】

A method of preparing plants or algae having herbicide tolerance, the method comprising transforming algae, or plant cell, protoplast, callus, hypocotyl, seed, cotyledon, shoot, or whole plant, with the polypeptide of SEQ ID NO: 2, the polypeptide of SEQ ID NO: 4, the polypeptide of any one of claims 1 to 4, or a polynucleotide encoding thereof.

【Claim 19】

A method of conferring or enhancing herbicide tolerance of plants or algae, the method comprising transforming algae, or plant cell, protoplast, callus, hypocotyl, seed, cotyledon, shoot, or whole plant, with the polypeptide of SEQ ID NO: 2, the polypeptide of SEQ ID NO: 4, the polypeptide of any one of claims 1 to 4, or a polynucleotide encoding thereof.

【Claim 20】

A method of controlling weeds in a cropland, the method comprising, providing the cropland with a plant comprising the polypeptide of SEQ ID NO: 2, the polypeptide of SEQ ID NO: 4, the polypeptide of any one of claims 1 to 4, or a polynucleotide encoding thereof, and

applying an effective dosage of protoporphyrinogen oxidase-inhibiting herbicide to the cropland.

【Claim 21】

The method of claim 20, wherein the step of applying an effective dosage of protoporphyrinogen oxidase-inhibiting herbicide to the cropland is performed by applying an effective dosage of two or more kinds of protoporphyrinogen oxidase-inhibiting herbicides sequentially or simultaneously.

5 **【Claim 22】**

The method of claim 20,

wherein the plant further comprises the second herbicide-tolerant polypeptide or a gene encoding thereof, and

10 the step of applying an effective dosage of protoporphyrinogen oxidase-inhibiting herbicide to the cropland is performed by applying an effective dosage of the protoporphyrinogen oxidase-inhibiting herbicide and a second herbicide are applied sequentially or simultaneously.


【Claim 23】

15 A method of removing an undesired aquatic organism from a culture medium, the method comprising,


providing a culture medium with algae comprising the polypeptide of SEQ ID NO: 2, the polypeptide of SEQ ID NO: 4, the polypeptide of any one of claims 1 to 4 or a polynucleotide encoding thereof, and

20 applying an effective dosage of protoporphyrinogen oxidase-inhibiting herbicide to the culture medium.


【Fig. 1】



【Fig. 2】



【Fig. 3】



**Comments for pET303 CT-His
5369 nucleotides**

T7 promoter: bases 20-36

T7 promoter priming site: bases 20-39

lac operator (*lacO*): bases 39-63

Ribosome binding site (RBS): bases 95-100

6X His Tag: bases 119-136

T7 reverse priming site: bases 186-206

T7 transcription termination region: bases 147-277

F1 origin: bases 287-742

bla promoter: bases 775-879

Ampicillin (*bla*) resistance gene: bases 874-1734


pBR322 origin: bases 1945-2678 (c)

ROP ORF: bases 2920-3011 (c)


lacI ORF: bases 3914-5032 (c)

【Fig. 4】


Vector for Fusion Protein of PPO and MBP(Maltose binding protein)




【Fig. 5】




【Fig. 6】




【Fig. 7】




【Fig. 8】




【Fig. 9】




【Fig. 10】




【Fig. 11】




【Fig. 12】




【Fig. 13】




【Fig. 14】




【Fig. 15】




【Fig. 16】




【Fig. 17】




【Fig. 18】




【Fig. 19】




【Fig. 20】




【Fig. 21】




【Fig. 22】




【Fig. 23】




【Fig. 24】




【Fig. 25】




【Fig. 26】




【Fig. 27】




【Fig. 28】




【Fig. 29】




【Fig. 30】




【Fig. 31a】




【Fig. 31b】




【Fig. 31c】




【Fig. 32】



【Fig. 33a】




【Fig. 33b】




【Fig. 34】

CyPPO10 F360I(T₄)

Tiafenacil 15 μ M




Saflufenacil 150 μ M




【Fig. 35】


CyPPO10 F360I(T₅)



【Fig. 36】




【Fig. 37】




【Fig. 38】


Kwangan soybean
(Wild type)




CyPPO10 A167L+F360M #2




【Fig. 39】



【Fig. 40】



【Fig. 41】



A. CLASSIFICATION OF SUBJECT MATTER**C07K 14/195(2006.01)i, C12N 1/12(2006.01)i, C12N 15/63(2006.01)i, C12N 15/82(2006.01)i**

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07K 14/195; A01N 63/00; C12N 5/10; C12N 15/82; C12N 9/02; C12N 1/12; C12N 15/63

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Korean utility models and applications for utility models

Japanese utility models and applications for utility models

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

eKOMPASS(KIPO internal) & Keywords: herbicide tolerance, protoporphyrinogen oxidase, mutation, substitution, transformant

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2015-092706 A1 (BASF AGRO B.V.) 25 June 2015 See abstract; pages 6, 8, 11, 13, 77, 188; claims 1, 4-5, 9; and table 2a.	1-23
A	HAO, GE-FEI et al., 'Understanding resistance mechanism of protoporphyrinogen oxidase-inhibiting herbicides: insights from computational mutation scanning and site-directed mutagenesis', Journal of Agricultural and Food Chemistry, 01 July 2014, vol. 62, pp. 7209-7215 See abstract; and table 2.	1-23
A	US 2015-0252379 A1 (HUTZLER, JOHANNES et al.) 10 September 2015 See abstract; and claim 53.	1-23
A	BRUGGEMAN, ANDREW J. et al., 'Evaluation of three herbicide resistance genes for use in genetic transformations and for potential crop protection in algae production', Plant Biotechnology Journal, 2014, vol. 12, pp. 894-902 See pages 894-895.	1-23
A	US 7586023 B1 (BOYNTON, JOHN E. et al.) 08 September 2009 See abstract; and claim 1.	1-23



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

18 September 2017 (18.09.2017)

Date of mailing of the international search report

20 September 2017 (20.09.2017)

Name and mailing address of the ISA/KR

International Application Division

Korean Intellectual Property Office

189 Cheongsa-ro, Seo-gu, Daejeon, 35208, Republic of Korea

Facsimile No. +82-42-481-8578

Authorized officer

LEE GYONG CHEOL

Telephone No. +82-42-481-8611



INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR2017/006275

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2015-092706 A1	25/06/2015	AR 099371 A1 AU 2014-369229 A1 CA 2933002 A1 CN 106029890 A EA 201691198 A1 EP 3083968 A1 MD 20160080 A2 PH 12016501133 A1 US 2016-0374339 A1 UY 35891 A	20/07/2016 09/06/2016 25/06/2015 12/10/2016 30/11/2016 26/10/2016 28/02/2017 18/07/2016 29/12/2016 30/06/2015
US 2015-0252379 A1	10/09/2015	AU 2011-342759 A1 AU 2011-342759 B2 BR 112013014778 A2 CA 2818917 A1 CN 103261424 A CR 20130296 A DE 112011104396 T5 EA 201390842 A1 EP 2652139 A1 JP 2014-504855 A KR 10-2014-0033330 A MX 2013005975 A WO 2012-080975 A1 ZA 201305262 B	13/06/2013 27/04/2017 06/06/2017 21/06/2012 21/08/2013 09/08/2013 10/10/2013 30/12/2013 23/10/2013 27/02/2014 18/03/2014 15/07/2013 21/06/2012 23/12/2014
US 7586023 B1	08/09/2009	AU 1429897 A AU 739948 B2 CA 2276053 A1 CA 2276053 C EP 1007703 A1 EP 1017846 A1 EP 1017846 B1 JP 2002-528036 A JP 2002-528037 A JP 4451933 B2 WO 98-29554 A1 WO 98-54365 A1	31/07/1998 25/10/2001 09/07/1998 23/10/2007 14/06/2000 12/07/2000 22/08/2007 27/08/2002 27/08/2002 14/04/2010 09/07/1998 03/12/1998